Periodontal Soft Tissue Root Coverage Procedures: A Systematic Review From the AAP Regeneration Workshop

Leandro Chambrone* and Dimitris N. Tatakis[†]

Background: This paper aims to create a "bridge" between research and practice by developing a practical, extensive, and clinically relevant study that translates evidence-based findings on soft tissue root coverage (RC) of recession-type defects to daily clinical practice.

Methods: This review is prepared in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement based on the proposed focused questions. A literature search with no restrictions regarding status or the language of publication was performed for MEDLINE and EMBASE databases up to and including June 2013. Systematic reviews (SRs), randomized clinical trials, controlled clinical trials, case series, and case reports evaluating recession areas that were treated by means of RC procedures were considered eligible for inclusion through the three parts of the study (part I, an overview of the base of SRs; part II, an alternative random-effects meta-analyses on mean percentage of RC and sites exhibiting complete RC; and part III, an SR of non-randomized trials exploring other conditions not extensively evaluated by previous SRs). Data on Class I, II, III, and IV recessions, type of histologic attachment achieved with treatment, recipient- and donor-site anatomic characteristics, smoking-related outcomes, root surface conditions, tooth type and location, long-term effectiveness outcomes, unusual conditions that may be reported during conventional daily practice, and patient-centered outcomes were assessed as well.

Results: Of the 2,456 potentially eligible trials, 234 were included. Data on Class I, II, III, and IV gingival recessions, histologic attachment achieved after treatment, recipient- and donor-site anatomic characteristics, smoking-related outcomes, root surface conditions/biomodification, tooth type and location, long-term effectiveness outcomes and unusual conditions that may be reported during conventional daily practice, and patient-centered outcomes (i.e., esthetic, visual analog scale, complications, hypersensitivity, patients perceptions) were assessed. Subepithelial connective tissue (CT)-based procedures and coronally advanced flap plus acellular dermal matrix grafts, enamel matrix derivative, or collagen matrix led to the best improvements of recession depth, clinical attachment level (CAL) gain, and keratinized tissue (KT). Some conditions, such as smoking and use of magnification, may affect RC outcomes.

Conclusions: All RC procedures can provide significant reduction in recession depth and CAL gain for Miller Class I and II recession-type defects. Subepithelial CT graft-based procedures provided the best outcomes for clinical practice because of their superior percentages of mean and complete RC, as well as significant increase of KT. *J Periodontol 2015;86(Suppl.):S8-S51.*

KEY WORDS

Connective tissue; evidence-based dentistry; gingival recession; gingival recession, surgery; gingival recession, therapy; tooth root, surgery.

^{*} UIBO (Unit of Basic Oral Investigation), Faculty of Dentistry, El Bosque University, Bogotá, Colombia.

[†] Division of Periodontology, College of Dentistry, The Ohio State University, Columbus, OH.

See related practical applications paper in Clinical Advances in Periodontics (February 2015, Vol. 5, No. 1) at www.clinicalperio.org.

Root coverage (RC) periodontal plastic surgery procedures have long been used for the treatment of gingival recession (GR). Esthetics, dental hypersensitivity, and the prevention of caries and non-carious cervical lesions (NCCLs) are considered the main indications reported in the literature.¹⁻¹¹

Concomitant to the development of flap and graftbased surgical techniques, more refined and judicious research protocols have also been developed and applied to establish the predictability and best clinical scenarios for each group of procedures.¹²⁻¹⁴

Described in the literature as part of "mucogingival surgery" or "periodontal plastic surgery (PPS),"¹⁵ much information from efficacy trials (i.e., studies performed under ideal conditions)¹⁶ suggest that GR classified as Miller Class I and II¹⁷ may lead to mean RC (MRC) of 80.9% (50% to 97.3%) and complete RC (CRC) of 46.6% (7.7% to 91.6%) \geq 6 months after treatment.^{4,5} Furthermore, data from other systematic reviews (SRs), including effectiveness trials (i.e., studies performed in clinical practice or in "real-world situations"),¹⁶ support these findings as well.^{2,3,6,8}

Evidence is clear that CRC is certainly the definitive clinical outcome expected when an RC procedure is performed.¹⁻¹¹ It can also be argued that there are few high-quality studies available for many soft tissue RC PPS procedures that have been in clinical use for many years and that some patientcentered outcomes, such as esthetics, patients' preferences, and function, may play an equally important part in the implementation of novel surgical techniques in the future. Additionally, SRs per se may not be clearly designed to translate the current evidence into practical decision guidance for common daily clinical scenarios.¹⁸

As part of the efforts advanced and highlighted by the 2014 American Academy of Periodontology *Regeneration Workshop*, it is of paramount importance "to build on existing knowledge to determine the best, practical way to treat patients with periodontal regeneration, as well as to prepare solid guidelines and treatment rationale to support decisionmaking for specific clinical scenarios."

CLINICAL SCENARIOS AND CONSIDERATION OF TREATMENT OPTIONS

During daily practice, clinicians are required to deal with diverse clinical scenarios and to provide the most adequate treatment options for each particular condition based on the best evidence available, the clinician's skills, and the patients' desires. For instance, which treatment options are available for the management of the following conditions? And why are they important?

Clinical Scenario 1: A Complex Case Involving

Multiple Recession-Type Defects in Esthetic Areas Is there sufficient donor tissue to be removed from the palatal vault? Is it safe to use a flap procedure alone, or should other biomaterial be used? What factors will lead to the best choice?

Clinical Scenario 2: Treatment of Miller¹⁷ Class III and IV Recession

How can the odds of achieving a satisfactory result be improved? Is it possible to use a flap procedure alone, or should a graft/biomaterial be used with it? Will a restorative/prosthetic approach be required?

Clinical Scenario 3: Treatment of GRs Not

Surgically Treated But Restored With Composites What is the best technique/material to graft over these previously restored root surfaces? Should the restoration be removed or changed? Is it safe and predictable to surgically treat these areas?

Clinical Scenario 4: Treatment of NCCL Root Surfaces

Should the presence of NCCLs alter the treatment approach? Do these areas need to be restored? If yes, before, during, or after the surgical procedure?

Clinical Scenario 5: Treatment of Carious Root Surfaces

Is it possible to cover carious root surfaces? After removing the caries, it is obvious a restoration will be necessary. How does that change the treatment plan? Similarly to abraded surfaces, do these areas need to be restored before, during, or after the surgical procedure?

Clinical Scenario 6: Lack of Adequate Donor Site (e.g., Small and Shallow Palatal Vault)

What are the risks and benefits associated with the use of allogenic or xenogenic graft substitutes? Do they provide evidence of long-term stability?

Clinical Scenario 7: Most Patients Are Interested Not Only in RC But in Achieving the Best Color and Texture Match

What technique should be used to achieve these goals?

Clinical Scenario 8: Best Treatment Options for the Treatment of Class I and II Recessions

Are the results of therapy stable? What is known about the attachment of the graft/flap to the root and is it important? Is it possible to estimate the outcomes and propose treatment options (i.e., establish a decision tree)? Is it possible to obtain satisfactory results when treating patients who smoke?

Clinical Scenario 9: Other Defect Risk Factors for RC Are the geometry and the degree of recession important (e.g., narrow and deep versus wide and shallow)?

Is the amount of available keratinized attached gingiva important in the decision-making process? Does the degree of keratinized gingiva in the final outcome affect the long-term stability of cases?

BASIC QUESTIONS TO BE ADDRESSED IN THIS STUDY

Additionally, definitive answers to other important questions remain unclear. For instance, what is the amount of RC that might be anticipated for Class III and IV GR defects? Is it similar to the one achieved by Class I and II defects? What are the longterm (i.e., ≥ 24 months of follow-up) outcomes of these treatment procedures in clinical practice? Do RC procedures regenerate part of the lost periodontium? Is it important to change the periodontal biotype adjacent to a GR? Does the condition of the exposed root surface play a role in the amount of RC achieved? What are the potential risks associated with RC procedures? Are there safe substitutes for subepithelial connective tissue grafts (SCTGs), and how should the SCTG be used? The exclusion of the aforementioned "effectiveness studies" may not allow a better interpretation (translation) of important findings to daily periodontal practice. Consequently, this paper aims to create a "bridge" between research and practice by developing practical, extensive, and clinically applicable guidance that translates evidence-based findings on soft tissue RC of recession-type defects to daily clinical practice (i.e., translation of efficacy/effectiveness to "manageable" outcomes).

SUMMARY OF WHAT OTHER SRs HAVE EVALUATED

Focused Questions

The following focused questions were addressed. 1) What is the efficacy/effectiveness of RC procedures by the degree of recession?: a) Miller Class I and II;¹⁷ b) Miller Class III or IV.¹⁷ 2) Which factors may influence the expected outcomes (i.e., smoking status and root-surface conditions)? For instance, is it possible to accomplish RC for teeth with NCCL, root caries, or cervical root resorption? 3) What is the anticipated success and attachment apparatus of RC enhancements with autogenous grafts compared with alternative methods and materials? 4) What are the long-term and shortterm advantages of root-surface biomodification? 5) What are the relative risks from a patient's viewpoint with the different approaches to RC procedures? 6) Should connective tissue (CT) grafts contain epithelium and/or periosteum? 7) Is there evidence for innovation when treating thin and thick biotypes with existing treatment modalities?

Inclusion and Exclusion Criteria for Papers and/or SRs

The protocol of this study is designed to translate the findings of research to daily practice. It was based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses),¹⁹ Cochrane Collaboration,¹² and Check Review⁶ checklists. Detailed descriptions of parts of the study protocol (i.e., electronic searching and methodology) used in this review have been published previously.^{1-5,7} The subsequent sections give a brief explanation of the detailed protocol of the present study.

To satisfactorily answer the research-focused questions proposed for the present review project, an overview of SRs,⁶ an updated set of metaanalysis of randomized clinical trials (RCTs), and an SR review of effectiveness/non-RCTs (i.e., assessment of other conditions not addressed by previous reviews or RCTs) was prepared. For the first part of this work, only SRs evaluating the effect of treatment of patients with a clinical diagnosis of single or multiple recession-type defects (MRTDs) that were surgically treated by means of RC procedures are analyzed. In the second part, the base of RCTs that assessed non-restored, Miller Class I and II recessions¹⁷ with a duration ≥ 6 months were retrieved and considered eligible for inclusion into the meta-analyses. For the third part, non-randomized studies (controlled clinical trials, case series, and case reports) in which the effectiveness of RC procedures was assessed for conditions that could not be addressed by previous SRs (i.e., Class III and IV, long-term outcomes, histologic findings, etc.) were incorporated into the analyses. Editorials and non-SRs were excluded from this study.

Type of Interventions

The interventions of interest were as follows: 1) free gingival grafts (FGGs); 2) coronally advanced flaps (CAFs) alone or in combination with guided tissue regeneration (GTR), acellular dermal matrix grafts (ADMGs), enamel matrix derivative protein (EMD), xenogenic collagen matrix (CM) grafts, or other biomaterials (e.g., bone substitutes, platelet-rich plasma); 3) laterally positioned flaps (LPFs); and 4) SCTGs alone or in combination with CAFs.

Types of Outcome Measures

The primary outcome measures included CRC and esthetic condition change based on the patient's opinion. The secondary outcome measures included the following: 1) clinical attachment level (CAL) change; 2) keratinized tissue (KT) change; 3) MRC; 4) preference of a patient for a specific PPS procedure; 5) type of histologic healing; 6) occurrence of adverse effects; and/or 7) postoperative complications.

Search Methods for Identification of Studies

The identification of publications included in or considered for this overview study has been based on a comprehensive search strategy reported previously.^{1-5,7} Concisely, it was performed via detailed search strategies developed for MEDLINE (for Medical Literature Analysis and Retrieval System Online) and EMBASE (Excerpta Medica Database) without language restriction. Databases were searched up to and including June 30, 2013 using MeSH (Medical Subject Headings) terms, key words, and other free terms, and Boolean operators (OR, AND) were used to combine searches. Detailed search strategies were developed for each database searched based on the search strategy presented in supplementary Figure 1 in online Journal of Periodontology. Additionally, reference lists of any potential studies and the databases of four periodontal journals (i.e., Journal of Periodontology, Journal of Clinical Periodontology, International Journal of Periodontics and Restorative Dentistry, and Journal of Periodontal Research) were hand searched.

Selection of Studies, Data Extraction, and Assessment of Risk of Bias in Included RCTs

Identification of studies was conducted by one of the authors (LC), who screened the titles, abstracts, and full texts of the articles identified by searching. Data on the following issues were extracted and recorded: 1) citation, publication status, and year of publication; 2) main characteristics of participants; 3) type of interventions; and 4) outcome measures.

As detailed in previous publications,^{1,4,5,7} the methodologic quality of the RCTs potentially eligible for inclusion in the meta-analyses (part II) was assessed by focusing on the points described in the Cochrane Collaboration tool for assessing risk of bias and detailed in the *Cochrane Handbook for Systematic Reviews of Interventions* version 5.0.1:¹² The risk of bias in the included studies was categorized as low, unclear, or high (see supplementary Fig. 2 in the online *Journal of Periodontology*).

Data Synthesis

Data were organized into evidence tables describing the characteristics of the publications and results according to the type of study (e.g., SRs or RCTs). Mean percentages of RC (i.e., recession change) and their respective standard deviations from RCTs eligible for inclusion into "head-to-head" (pairwise) meta-analyses were considered for evaluation to balance potential influences of studies reporting exclusively data from GR depth \geq 3 mm. After that, random-effects meta-analyses were used for the calculation of pooled estimates for continuous data (expressed as weighted mean differences [MDs] of percentage gain with their corresponding 95% confidence intervals [CIs]) and for dichotomous data (expressed as pooled risk ratios [RRs] and corresponding 95% CIs). For continuous outcomes, these were conducted using the generic inverse variance statistical method in which the MDs and standard errors were entered for all studies to allow the combination of parallel and split-mouth group studies. Variance imputation methods were conducted to estimate appropriate variance values in some studies in which the appropriate standard deviations of the differences were not reported.²⁰ Also, for dichotomous data, risk difference (RD) and the number needed to treat (NNT) for sites exhibiting CRC were calculated, for which the pooled estimates reached a level of P < 0.05. The significance of discrepancies in the estimates of the treatment effects from the different trials was assessed by means of the Cochrane test for heterogeneity and the l^2 statistic.¹² Analyses were performed using a statistical software package.[‡]

Articles Found and Eliminated

The flowchart of manuscripts, screened through the review process, is depicted in supplementary Figure 3 in online *Journal of Periodontology*. The search methods for identification of studies yielded 2,456 potentially eligible publications, and of them 2,223 were excluded after the title and/or the abstract were evaluated. In total, 19 papers were appraised in part I,^{1-5,7-11,21-29} and 215 were evaluated in parts II and III.³⁰⁻²⁴⁶

Part I: Overview of SRs

Nineteen publications described as SRs and/or meta-analyses that reported clinical- and/or patientcentered outcomes on the surgical treatment of GR were published between 2002 and 2013.^{1-5,7-11,21-29} Two studies were reported in two publications each, and thus a total of 17 different SRs were included. The majority of reviews specified the type of defects of interest as Miller Class I and II (Table 1), and two were not specifically designed to assess differences between surgical techniques: 1) one assessed the influence of flap thickness,²³ and 2) one assessed the use of RC procedures for the treatment of cervical dentin hypersensitivity.²⁹

The authors of these SRs reached a consensus that all RC procedures promote concomitant significant recession depth reduction and CAL gain.^{1-5,7-11,21-29} With respect to the KT width, SCTG-, ADMG-, and CM-based procedures led to the most significant gains (Table 1). Another common conclusion reported by these publications relates to the indication of SCTG as the gold standard, irrespective

Review Manager (RevMan) statistical analysis software v.5.2.1, Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark.

S	1	2

Reference	Type of Study and Participants Included	Interventions of Interest	Outcomes Included	Comparisons (as described in the reviews)	Authors' Main Conclusions
Roccuzzo et al. ⁹	RCTs, CCTs, and CSs of ≥6 months duration limited to patients with Class I or II ¹⁷ GR ≥2 mm	CAF, FGG, GTR, LPF, and SCTG	CAL, CRC, GR, MRC, PBA, and Stab	GTR versus SCTG, GTR with versus CAF, and GTR with RS versus GTR with non-RS (ΔGR/ΔCAL)	"Overall, PPS was effective in reducing GRs with a concomitant improvement in attachment levels. Even though no single treatment can be considered superior to all the others, SCTG was statistically significantly more effective than GTR in recession reduction."
Al-Hamdan et al. ²¹	All levels of evidence (excluding reviews) of ≥6 months duration limited to patients with GRs	GTR versus any other mucogingival surgery (not specified)	CAL, CRC, GR, MRC, and PD	, All	"Both conventional mucogingival surgery and GTR-based root coverage can be used to repair GR defects with good success."
Pagliaro et al., ²⁶ Clauser et al. ²⁵	RCTs, CCTs, and CSs limited to patients with GRs	CAF, FGG, FGG + CAF, GTR, LPF, and SCTG	CAL, CRC, GR, MRC, and PBA	SCTG versus GTR and individual data meta-analysis	"The meta-analysis of summarized data confirms the fact that surgical root coverage is an effective treatment approach. SCTG appeared to perform better than GTR in terms of CRC."
Oates et al. ⁸	RCTs limited to patients with GRs	Not specified	CAL, CRC, GR, KT, PD, MRC, and PBA	GTR/ADMG versus SCTG (AGR/AKT)	"Soft tissue augmentation procedures are effective means of obtaining root coverage; SCTG techniques appear to have an advantage over GTR."
Gapski et al. ²²	RCTs of ≥3 months duration limited to patients with GRs	ADMG versus CAF or SCTG	CAL, GR, KT, and PD	SCTG versus ADMG (AGR/ APD/AKT) and CAF versus ADMG (AGR/APD/ACAL/ AKT)	"ADMG-based mucogingival surgery can be used successfully to repair GR defects and to increase keratinized gingiva."

Characteristics of SRs and/or Meta-Analyses on RC Procedures

Authors' Main Conclusions	A critical threshold thickness for root coverage success may exist, as suggested by a limited number of investigations, but studies vary significantly in treatment, measurement, and statistical methodology, rendering concrete evidence difficult."	CAF and CAF + chemical root surface conditioning procedures were unpredictable but became more predictable when the CAF procedure was improved by the modification of adding EMD"	SCTG provided significant root coverage, CAL and KT tissue gain."	SCTG or EMD in conjunction with CAF enhances the probability of obtaining CRC in Miller Class I and II single gingival recessions."
Comparisons (as described in the reviews)	Regression analyses for weighted means (CRC/GT/ MRC)	Υ.Υ.Υ.	ADMG versus SCTG, CAF versus SCTG, and GTR with non-RS versus SCTG (AGR/ACAL/AKT); GTR with RS versus SCTG; and (AGR/ACAL/AKT/CRC) GTR with RS + BS versus SCTG (AGR/AKT)	CAF + SCTG versus CAF, CAF + EMD versus CAF, CAF + ADMG versus CAF, CAF + GTR with RS versus CAF + SCTG, and CAF + ADMG versus CAF + SCTG (AGR/ACAL/AKT/CRC); CAF + GTR with RS versus CAF + GTR with RS versus CAF (AGR/ACAL/AKT)
Outcomes Included	CRC, GT, and MRC	CAL, GR, KT, MRC, and PD	CAL, CRC, GR, KT, MRC, and PBA	CAL, CRC GR, KT, and PBA
Interventions of Interest	CAF, CAF + ADMG, CAF + SCTG, GTR with RS, GTR with RS + BS, and EMD associations	CAF, CAF + EMD, and CAF + RC	SCTG versus any RC procedure	CAF alone or combined with ADMG, EMD, HF-DDS, GTR, platelet-rich plasma, or SCTG
Type of Study and Participants Included	RCTs, cohort/case control studies, and case reports of ≥3 months duration	RCTs, CCTs, or CSs of 6 to 12 months duration limited to patients with Class I or II ¹⁷ GR ≥2 mm	RCTs of ≥ 6 months duration limited to patients with Class I or II ¹⁷ GR ≥ 2 mm; ≥ 10 patients per group at the final examination	RCTs of ≥6 months duration limited to patients with Class I or II ¹⁷ localized GR
Reference	Hwang and Wang ²³	Cheng et al. ²⁴	Chambrone et al.'	Cairo et al ¹⁰

Characteristics of SRs and/or Meta-Analyses on RC Procedures

Authors' Main Conclusions	"The results of this review show that smoking may negatively influence GR reduction and CAL gain, especially for SCTG. Additionally, smokers may exhibit fewer sites with CRC."	"SCTG, CAF alone or associated with other biomaterial and GTR may be used as root coverage procedures for the treatment of localized recession-type defects. In cases where both root coverage and gain in the KT are expected, the use of SCTG seems to be more adequate."	"Analysis of the limited information available in the dental literature showed improvements in clinical parameters with all of the PPS procedures."	"SCTGs, MGs, and EMD procedures were superior in achieving CRC when compared with CAF alone. Overall, SCTGs showed the best outcomes. The use of RMA did not affect CRC."
Comparisons (as described in the reviews)	CAF (smokers) versus CAF (non-smokers) and SCTG (smokers) versus SCTG (non-smokers) (ΔGR/ ΔCAL/ΔKT/CRC)	ADMG versus CAF, ADMG versus SCTG and EMD + CAF versus CAF (ΔGR/ ΔCAL/ΔKT); GTR with RS versus GTR with non-RS, GTR with RS + BS versus GTR with RS, and GTR with RS versus SCTG (ΔGR/ ΔCAL/ΔKT/CRC); and GTR with RS +BS versus SCTG (ΔGR/ΔKT)	N/A	Individual data meta-analyses (CRC)
Outcomes Included	CAL, CRC, GR, KT, MRC, and Stab	CAL, CRC, GR, KT, MRC, PBA, and Stab	CAL, CRC GR, KT, and MRC	CRC
Interventions of Interest	ADMG, CAF, FGG, GTR, and SCTG	ADMG, CAF, EMD, FGG, GTR, LPF, and SCTG alone or in combination with LPF or CAF	CAF, FGG, GTR, LPF, and SCTG	ADMG, CAF, EMD, FGG, GTR, LPF, and SCTG alone or in combination with LPF or CAF
Type of Study and Participants Included	RCTs, CCTs, and CSs of ≥6 months duration limited to patients with Class I or II ¹⁷ GR; ≥10 patients per group at the final examination and data from smokers (≥10 cigarettes/d) and non- smokers, recorded separately	RCTs of ≥6 months' duration limited to patients with Class I or II ¹⁷ GR ≥3 mm; ≥10 patients per group at the final examination	RCTs, CCTs, and CSs of 26 months duration limited to patients with Class I or II ¹⁷ multiple GR 22 mm	RCTs of 26 months duration limited to patients with Class I or II ¹⁷ GR
Reference	Chambrone et al. ²	Chambrone et al. ^{4.5}	Chambrone et al. ³	Chambrone et al. ⁷

Characteristics of SRs and/or Meta-Analyses on RC Procedures

	Interventions of Interest
Ň	lot specified
8	lot specified
0	lot specified
CA	AF alone or combined with ADMG, EMD, HF-DDS, GTR, platelet-rich plasma, or SCTG

change from baseline. = mean long-term stability; Δ Stab membranes; resorbable modification agent; KS root RMA nes; outcon -based patient-1 NA N available not Ш MG = matrix grafts; IN/A of the flap procedure approach performed (Table 1), not only because of the better aforementioned outcomes but also because of the significant number of sites exhibiting CRC, better cost-effectiveness, and superior long-term stability when compared with CAF, CAF + GTR, LPF, and FGG. The association of EMD to CAF appears also as an interesting and safe approach superior to the use of CAF alone, despite the additional costs related to biomaterial.^{1,4,5,7,10,11}

Two reviews reporting data exclusively on multiple recessions^{3,27} suggested that both CAF + SCTG and CAF alone may promote an adequate reestablishment of aesthetics with concomitant decrease in dental hypersensitivity. However, none of them could combine in pooled estimates the outcomes of included individuals because of the lack of adequate data, and thus the effects of treatment of these defects clearly seem to remain partially explored.

Moreover, some specific factors influencing RC gain were also discussed, such as the effect of root modification agents (RMAs),^{5,6,9,28} baseline recession characteristics and potential confounders,⁷ and smoking.² Regarding the use of RMAs, there was also a consensus that these agents did not modify the response rate of any surgical procedure.^{5,6,9,28} For tobacco smoking, smokers may benefit from treatment of GR via PPS, but the use of SCTGs seems to be less effective in smokers than in non-smokers in terms of recession reduction and CAL gain, whereas no significant differences were found for smokers treated with CAFs.²

It could be seen that most comparisons between procedures were conducted using pairwise models (i.e., direct comparisons between only two procedures); however, many direct comparisons are not available.^{7,11} Three SRs used Bayesian network or individual data approaches to assess indirect comparisons.^{7,11,25,26} These statistical models, applied when there were no "head-to-head" trials and to improve the power of analysis (to detect any authentic difference between treatments), also give support to the achievement of improved results when SCTGs were used.^{7,11,25,26}

Part II: Random-Effects Meta-Analyses of RCTs: Mean Percentage of RC and Sites Exhibiting CRC

A total of 101 articles³⁰⁻¹³¹ with 94 RCTs potentially eligible for inclusion into the pooled estimates were identified in the base of evidence, and their main characteristics (i.e., number and age of participants, interventions, follow-up period, number of sites exhibiting CRC, MRC [percentage], use of RMAs, randomization, allocation concealment, masking of examiners, completeness of the follow-up period, and risk of bias) are depicted in Table 2.³⁰⁻¹³¹ Seven studies were reported in two articles each, and their data were reported under one study name.^{37,38,57,58,65,66,83,84,90,91,110,111,115,116}

Of the 94 trials included in Table 2, 52 were included in the following sets of meta-analyses: 1) ADMG/CM + CAF versus SCTG-based procedures;^{31,66,76,97,102,114} 2) ADMG/CM + CAF versus CAF;^{57,58,86,125} 3) BS + GTR with resorbable membranes (RS) + CAF versus GTR with RS + CAF;^{62,63,78,101} 4) EMD + CAF versus CAF,^{51,53,59,71,94,103,115,116} 5) EMD + CAF versus SCTG + CAF: 30,32,90,91 6) GTR with RS + CAF versus CAF;^{36,83,84} 7) GTR (all types of membrane) + CAF versus SCTG-based procedures: 35,43,55,74,96,101,107,109,117,122,123,126 8) SCTGbased procedures versus CAF;^{40,41,54,56,80} 9) SCTG + CAF versus SCTG (epithelial collar);^{44,47} 10) SCTG-based procedures, micro versus macro procedures;^{42,46} and 11) SCTG-based procedures versus FGG.70,100 All of the comparisons were performed using studies reporting data on single defects, except for one comparison on EMD + CAF versus CAF^{53,71} that could also be conducted using data on multiple recessions. Primary analyses were performed based on the follow-up evaluation at 6 months (or the minimum one available), but secondary analyses were also performed using longerterm data when these were reported by the individual studies. The full report of all analyses is depicted in Figures 1 and 2 and supplementary Figures 4 through 13 in online Journal of Periodontology.

With respect to GR change (MRC), there was a statistically significantly greater MRC for ADMG + CAF compared with CAF (P = 0.04), EMD + CAF compared with CAF (shorter-term [P = 0.001] and longer-term [P < 0.001] comparisons), SCTG-based procedures compared with GTR + CAF (Fig. 1A [P <0.001]), SCTG + CAF compared with CM + CAF (P = 0.002), SCTG + CAF compared with EMD + CAF (longer-term comparisons [P = 0.03]), SCTGbased procedures compared with CAF (Figs. 2A [P = 0.006] and 2B and 2C [P = 0.004]), for SCTGbased micro procedures compared with macro procedures (P = 0.01), and for SCTG-based procedures compared with FGG (P < 0.001). Additionally, the unique meta-analysis on multiple recessions failed to demonstrate significant differences in mean percentage of RC (5.01, 95% CI = -0.38 to 10.39; $P = 0.07; I^2 = 0\%$).

Regarding the sites with CRC, significant differences were found for EMD + CAF compared with CAF (see supplementary Figs. 7E [P = 0.02] and 7F [P = 0.01] in online *Journal of Periodontology*), for GTR + CAF compared with SCTG-based procedures (Fig. 1B [P = 0.009]), for SCTG-based procedures compared with CAF (Figs. 2D [P = 0.004], 2E [P < 0.001], and 2F [P < 0.001]), for SCTG-based micro procedures compared with macro procedures

ч.	
Ð	
P	
Ъ	

Alone
Procedures
RC
With
Treated
GR
and
Class I
Evaluating
RCTs

Study	Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	ЯR	AC	BE	Ч	RB
Abolfazli et al. ³⁰	12 (NS)/28 to 51	EMD + CAF SCTG + CAF	12 mo 24 mo 12 mo 24 mo	NR/12 3/12 (25.0) NR/12 8/12 (66.6)	77.7 76.9 83.4 93.1	Yes No	\supset	\supset	Yes	Yes	\supset
Aichelmann-Reidy et al. ³¹	22 (NS)/24 to 67	ADMG + CAF SCTG + CAF	6 mo 6 mo	7/22 (31.8) 11/22 (50.0)	65.9 74.1	°Z 2	∢	\supset	Yes	Yes	\supset
Alkan and Parlar ³²	12 (NS)/23 to 42	EMD + CAF SCTG + CAF	6 mo 12 mo 6 mo 12 mo	NR/12 9/12 (75.0) NR/12 7/12 (58.3)	90.6 90.6 88.5 88.5	Yes Yes	<	\supset	\supset	Yes	\supset
Aroca et al. ³³	20/22 to 47 MGR	PRF + CAF CAF	6 mo 6 mo	35/67 (52.2) 50/67 (74.6)	80.7 91.5	°Z Z	∢	\supset	°Z	Yes	I
Aroca et al. ³⁴	22 (NS)/≥18 MGR	CM + CAF (tunnel) SCTG + CAF (tunnel)	2 mo 2 mo	5/22s (22.7) I 3/22s (59.1)	0.06 90.0	² ²	∢	\supset	Yes	Yes	\supset
Babu et al. ³⁵	10/NR	GTR with RS + CAF SCTG + CAF	6 mo 6 mo	NR/10p NR/10p	84.0 84.8	°Z Z	\supset	\supset	\supset	Yes	\supset
Banihashemrad et al. ³⁶	7 (NS)/35 to 65	GTR with RS + CAF CAF	6 mo 6 mo	2/11 (18.2) 2/11 (18.2)	67.9 57.8	°Z °Z	∢	\supset	Yes	Yes	\supset
Barros el al. ^{37,38}	14 (NS)/22 to 46	ADMG mod + CAF ADMG + CAF	6 mo 12 mo 6 mo 12 mo	3/16 (18.7) 3/16 (18.7) 1/16 (6.2) 1/16 (6.2)	79.0 82.5 63.9 62.3	Yes Yes	\triangleleft	\supset	\supset	Yes	\supset
Berlucchi et al. ³⁹	14 (NS)/20 to 45	EMD + SCTG + CAF EMD + CAF	6 mo 6 mo	11/13 (84.6) 10/13 (76.9)	93.6 94.0	Yes Yes	∢	\supset	\supset	Yes	\supset
Bittencourt et al. ^{40.41}	17 (NS)/21 to 52	SCTG CAF (semilunar)	6 mo 30 mo 6 mo 30 mo	13/17 (76.5) 15/17 (88.2) 9/17 (52.9) 10/17 (58.8)	96.1 96.8 90.0 89.2	°Z Z	\triangleleft	\supset	Yes	Yes	С
Bittencourt et al. ⁴²	24 (NS)/18 to 55	SCTG + CAF (micro) SCTG + CAF (macro)	2 mo 2 mo	21/24 (87.5) 14/24 (58.3)	98.0 88.3	₽ Z	\triangleleft	\supset	Yes	Yes	\supset

Alone
Procedures
S
With F
Treated
GR
Π
and
Class I
Evaluating
RCTs

Study	Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	MR	AC	BE	CF	RB
Borghetti et al. ⁴³	14/20 to 55	GTR with RS + CAF SCTG + CAF	6 mo 6 mo	4/14 (28.5) 4/14 (28.5)	70.2 76.0	° Z	\supset	\supset	No	Yes	Т
Bouchard et al. ⁴⁴	30/21 to 62	SCTG + CAF SCTG (epithelial collar) + CAF	6 mo 6 mo	3/15 (20.0) 5/15 (33.2)	69.7 64.7	Yes No	\supset	\supset	Ž	Yes	Г
Bouchard et al. ⁴⁵	30/21 to 70	sctg + caf (TH) sctg + caf + (CA)	6 mo 6 mo	6/15 (40.0) 8/15 (53.3)	79.3 84.0	Yes Yes	\supset	\supset	Š	Yes	Г
Burkhardt and Lang ⁴⁶	10 (NS)/32 to 44	SCTG + DPF (micro) SCTG + DPF (macro)	6 mo 12 mo 6 mo 12 mo	6/8 (75.0) 5/8 (62.5) 2/8 (25.0) 2/8 (25.0)	98.0 98.0 89.7 89.9	oz oz	\triangleleft	\supset	Ž	Yes	Т
Byun et al. ⁴⁷	20 (NS)/20 to 60	SCTG + CAF SCTG (epithelial collar) + CAF	6 mo 6 mo	9/10 (90.0) 7/10 (70.0)	89.1 97.5	°Z 2	_	_	Yes	Yes	Т
Caffesse et al. ⁴⁸	36/18 to 65	SCTG + CAF SCTG + CAF	6 mo 6 mo	NR RR	94.6 85.3	Yes No	∢	\supset	\supset	Yes	\supset
Cardaropoli and Cardaropoli ⁴⁹	16 (NS)/18 to 54	BS + GTR with RS + CAF CAF	6 mo 6 mo	7/10 (70.0) 6/10 (60.0)	93.3 92.5	°Z 2	∢	\supset	\supset	Yes	\supset
Cardaropoli et al. ⁵⁰	18 (NS)/21 to 59	CM + CAF SCTG + CAF	12 mo 12 mo	8/11 (72.7) 9/11 (81.8)	94.2 96.9	°Z 2	∢	\supset	Yes	Yes	\supset
Castellanos et al. ⁵¹	22 (NS)/28 to 71	EMD + CAF CAF	6 mo 12 mo 6 mo 12 mo	NR/I I NR/I I NR/I I NR/I I	89.9 88.6 62.7 62.2	Yes No	-	\supset	\supset	Yes	Т
Cheung and Griffin ⁵²	18/NR	PCG + CAF SCTG + CAF	8 mo 8 mo	NR (60.0) NR (65.5)	80.0 95.0	°Z 2	∢	\supset	\supset	Yes	\supset
Cordaro et al. ⁵³	10/18 to 60 MGR	EMD + CAF CAF	6 mo 24 mo 6 mo 24 mo	9/29 (31.0) 13/29 (44.8) 5/29 (17.2) 7/29 (24.1)	82.8 74.8 80.7 71.0	Yes No	\supset	\supset	Yes	Yes	\supset
Cortellini et al. ⁵⁴	85/218	SCTG + CAF CAF	6 mo 6 mo	25/42 (59.5) 16/43 (37.2)	83.3 77.7	² ²	∢	∢	Yes	Yes	_

tinued	
(con	
ч.	
ble	
<u></u>	

RCTs Evaluating Class I and II GR Treated With RC Procedures Alone

Study	Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	MR	AC	BE	СF	SB
Çetiner et al. ⁵⁵	22 (NS)/22 to 58	GTR with RS (collagen) + CAF GTR with RS (dura mater) + CAF SCTG + CAF	12 mo 12 mo 12 mo	NR/20 NR/20 NR/20	74.3 69.6 86.3	°Z °Z °Z	\triangleleft	\supset	\supset	Yes	\supset
da Silva et al. ⁵⁶	II (NS)/18 to 43	SCTG + CAF CAF	6 mo 6 mo	2/11 (18.1) 1/11 (9.0)	75.3 68.8	°Z	\triangleleft	\supset	°Z	Yes	I
de Queiroz Côrtes et al. ^{57,58}	I 3 (NS)/32.8	ADMG + CAF CAF	6 mo 12 mo 24 m 6 mo 12 mo 24 mo	3/13 (23.0) 2/13 (15.3) 01/13 (7.7) 03/13 (23.0) 02/13 (15.3) 01/13 (7.7)	76.0 71.0 68.4 71.0 66.7 55.9	°Z °Z	∢	\supset	\supset	Yes	\supset
Del Pizzo et al. ⁵⁹	15 (NS)/18 to 56	EMD + CAF CAF	6 mo 12 mo 24 mo 6 mo 12 mo 24 mo	11/15 (73.3) 12/15 (80.0) 11/15 (73.3) 11/15 (73.3) 11/15 (73.3) 11/15 (73.3) 11/15 (73.3) 11/15 (66.7) 9/15 (60.0)	94.0 93.7 90.7 88.3 86.7	Yes Yes	∢	5	Yes	Yes	5
Dilsiz et al. ⁶⁰	17 (NS)/21 to 49	SCTG + CAF (Nd:YAG) SCTG + CAG	6 mo 6 mo	3/17 (17.6) 11/17 (64.7)	31.6 75.7	Yes No	\supset	\supset	\supset	Yes	\supset
Dilsiz et al. ⁶¹	12 (NS)/18 to 42	SCTG + CAF (Er:YAG) SCTG + CAF	6 mo 6 mo	9/12 (75.0) 8/12 (66.7)	79.8 85.9	Yes No	\supset	\supset	\supset	Yes	\supset
Dodge et al. ⁶²	12/23 to 51	BS + GTR with RS + CAF GTR with RS + CAF	2 mo 2 mo	6/12 (50.0) 4/12 (33.3)	89.9 73.7	Yes Yes	∢	\supset	Yes	Yes	\supset
Duval et al. ⁶³	14/NR	BS + GTR with RS + CAF GTR with RS + CAF	6 mo 6 mo	NR/8 NR/9	81.6 90.1	°Z Z	_	\supset	\supset	Yes	I
Felipe et al. ⁶⁴	15 (NS)/22 to 54	ADMG +CAF extend ADMG + CAF extend + VRI	6 mo 6 mo	5/15 (33.3) 9/15 (60.0)	69.0 84.8	Yes Yes	∢	\supset	\supset	Yes	\supset
Haghighati et al. ⁶⁵ /Moslemi et al. ⁶⁶	16 (NS)/24 to 45	ADMG + CAF SCTG + CAF	6 mo 60 mo 6 mo 60 mo	11/16 (68.7) 3/15 (20.0) 5/16 (31.2) 2/15 (13.3)	85.4 54.6 69.0 39.8	oz oz	K	A	Yes	Yes	_

	XC Procedures Alone
	With F
	Treated
	GR
	and II
	Class I
. (continued)	Evaluating
Table 2	RCTs

Study	Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	MR	AC	BE	CF	RB
Henderson et al. ⁶⁷	10 (NS)/24 to 68	ADMG mod + CAF ADMG + CAF	12 mo 12 mo	7/10 (70.0) 8/10 (80.0)	94.9 95.5	°Z °Z	\supset	\supset	Yes	Yes	\supset
Huang et al. ⁶⁸	24 (NS)/24 to 63	PRP + CAF CAF	6 mo 6 mo	7/11 (63.6) 7/12 (58.3)	81.0 83.5	oz oz	∢	\supset	Yes	Yes	\supset
lto et al. ⁶⁹	6/22 to 58 MGR	GTR with non-RS + CAF FGG	6 mo 12 mo 6 mo 12 mo	X X X X X X X X	81.3 73.9 76.3 86.2	Yes Yes	\supset	\supset	\supset	Yes	\supset
Jahnke et al. ⁷⁰	10/16 to 51	SCTG (envelope) FGG	6 mo 6 mo	5/9 (55.5) 1/9 (11.1)	78.6 37.9	Yes Yes	∢	\supset	2 Z	Yes	Т
Jaiswal et al. ⁷¹	20/25 to 46 MGR	EMD + CAF CAF	6 mo	NR/22 NR/24	86.3 79.6	Yes Yes	∢	\supset	\supset	Yes	\supset
Jankovic et al. ⁷²	20 (NS)/21 to 48	PRF + CAF EMD + CAF	12 mo 12 mo	12/20 (60.0) 13/20 (65.0)	72.1 70.5	No Yes	∢	\supset	Yes	Yes	\supset
Jankovic et al. ⁷³	15/19 to 47	PRF + CAF SCTG + CAF	6 mo 6 mo	NR (75.8) NR (79.6)	88.7 91.9	°Z °Z	∢	\supset	Yes	Yes	\supset
Jepsen et al. ⁷⁴	15/20 to 62	GTR with non-RS + CAF SCTG	12 mo 12 mo	7/15 (46.6) 7/15 (46.6)	87.I 86.9	Yes Yes	\supset	\supset	\supset	Yes	\supset
Jepsen et al. ⁷⁵	45/20 to 73	CM + CAF CAF	6 mo 6 mo	16/45 (35.5) 14/45 (31.1)	75.3 72.7	Yes Yes	∢	∢	Yes	Yes	_
Joly et al. ⁷⁶	10/20 to 68	ADMG + CAF SCTG + CAF	6 mo 6 mo	NR RR	50.0 79.5	°Z °Z	∢	\supset	2 Z	Yes	Г
Keceli et al. ⁷⁷	40/16 to 60	PRF + SCTG SCTG	12 mo 12 mo	06/17 (35.3) 08/19 (42.1)	86.4 86.4	°Z °Z	_	\supset	Yes	Yes	Т
Kimble et al. ⁷⁸	20/21 to 69	BS + GTR with RS + CAF GTR with RS + CAF	6 mo 6 mo	NR/8 NR/10	74.3 68.4	°Z 2	_	\supset	Sol	Yes	I

Study	Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	MR	AC	BE	CF	SB
Koudale et al. ⁷⁹	10 (NS)/18 to 40 MGR	ADMG + CAF SCTG + CAF	6 mo 6 mo	4/5s (80.0) 4/5s (80.0)	94.3 96.6	o N N	∢	\supset	\supset	Yes	\supset
Kuis et al. ⁸⁰	37 (NS)/20 to 52	SCTG + CAF CAF	6 mo 12 mo 24 mo 60 mo 6 mo 24 mo 21 mo 60 mo	53/57 (93.0) 53/57 (93.0) 51/57 (93.0) 47/57 (89.5) 47/57 (82.5) 42/57 (73.7) 38/57 (66.7) 38/57 (66.7)	97.2 97.2 94.6 92.3 91.9 86.5 86.5	Z Z	<	5	Yes	Les (\supset
Kuru and Yildirim ⁸¹	21 (NS)/15 to 50	FGG (marginal to tooth) FGG	8 mo 8 mo	4/8 (50.0) 0/9 (0.0)	91.6 67.0	°Z °Z	∢	\supset	\supset	Yes	\supset
Köseoglu et al. ⁸²	11 (NS)/19 to 41	GTR with RS + GF + CAF GTR with RS + CAF	6 mo 12 mo 6 mo 12 mo	NR/II NR/II NR/II NR/II	72.4 69.6 51.3 38.3	o o z	∢	\supset	\supset	Yes	\supset
Leknes et al ^{.83} /Amarante et al. ⁸⁴	20/38.4	GTR with RS + CAF CAF	6 mo 12 mo 72 mo 6 mo 72 mo	5/20 (25.0) 4/20 (20.0) 2/11 (18.2) 10/20 (50.0) 6/20 (30.0) 1/11 (9.1)	51.2 51.2 35.0 63.8 61.2 34.2	°Z °Z	<	\supset	Yes	Ťes	\supset
Lins et al. ⁸⁵	10 (NS)/25 to 55	GTR with non-RS + CAF CAF	6 mo 6 mo	(0:01) 01/1 (0:01) 01/1	60.0 45.5	Yes Yes	\supset	\supset	\supset	Yes	\supset
Mahajan et al ^{.86}	14 (NS)/16 to 40	ADMG + CAF CAF	6 mo 6 mo	NR/7 NR/7	97.I 77.4	o y	∢	\supset	\supset	Yes	\supset
Mahajan et al. ⁸⁷	20 (NS)/16 to 40	Periosteal graft + CAF SCTG + CAF	2 mo 2 mo	8/10 (80.0) 7/10 (70.0)	92.6 88.5	°Z °Z	∢	\supset	Yes	Yes	\supset
Matarasso et al. ⁸⁸	20/18 to 42	GTR with RS + DPF GTR with RS + CAF	2 mo 2 mo	(0:01) 01/1 (10.0)	73.0 62.5	°Z °Z	\supset	\supset	°Z	Yes	Т
Mazzocco et al. ⁸⁹	20 (NS)/21 to 57	SCTG + CAF mod SCTG + CAF	6 mo 6 mo	20/25 (80.0) 17/27 (62.9)	97.0 95.0	o N N	∢	\supset	° N	Yes	Т

RCTs Evaluating Class I and II GR Treated With RC Procedures Alone Table 2. (continued)

J Periodontol • February 2015 (Suppl.)

Chambrone, Tatakis

S22

Alone
Procedures
RC
With
Treated
GR
Ξ
and
Class I
Evaluating
RCTs

ticipants (n)/Age (y) Interventions Follow-Up
20/23 to 62 EMD + CAF 12.1 10 SCTG + CAF 12.7 10
25 (NS)/18 to 70 CM + CAF 6 12 SCTG + CAF 6 12
30 (NS)/18 to 70 B-TCP + CD with hPDGF-BB + CAF 6 SGTG + CAF 6
12 (NS)/20 to 50 EMD + CAF 6 CAF 6
15 (NS)/22 to 47 BS + CAF CAF
16/18 to 60 GTR with RS + CAF SCTG (envelope)
9 (NS)/23 to 53 ADMG + CAF SCTG + CAF
43/22 to 48 CAF + orthodontic button MGR CAF
10 (NS)/34 CAF + LILT I: CAF CAF
70/25 to 48 SCTG + DPF 6(FGG 6(
45/27 to 51 GTR with RS + CAF 12 BS + GTR with RS + CAF 12 SCTG + DPF 12
30/29 to 51 ADMG + CAF SCTG + CAF

RCTs Evaluating Class I and II GR Treated With RC Procedures Alone

Study	Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	MR	AC	BE	СF	RB
Pilloni et al. ¹⁰³	30 (NS)/19 to 67	EMD + CAF CAF	18 mo 18 mo	13/15 (86.6) 5/15 (33.3)	93.8 66.5	Yes No	\supset	\supset	Yes	Yes	\supset
Pini Prato et al. ¹⁰⁴	IO/NR	CAF + polishing CAF + SRP	+	5/9 (55.5) 3/9 (33.3)	N N N N	2 Z	\supset	\supset	Ž	Yes	I
Pourabbas et al. ¹⁰⁵	15 (NS)/26 to 63	EMD + ADMG + CAF ADMG + CAF	6 mo 6 mo	NR R	84.9 89.5	Yes Yes	\triangleleft	\supset	Yes	Yes	\supset
Rasperini et al. ¹⁰⁶	56 (NS)/35.5	EMD + SCTG + CAF SCTG + CAF	2 mo 2 mo	16/26 (61.5) 14/30 (46.6)	90.7 76.6	Yes Yes	\triangleleft	∢	\supset	Yes	\supset
Ricci et al. ¹⁰⁷	R	GTR with non-RS + CAF SCTG + CAF	2 mo 2 mo	NR/18 NR/18	80.8 77.1	°Z °Z	\supset	\supset	\supset	Yes	\supset
Roccuzzo et al. ¹⁰⁸	12 (NS)/21 to 31	GTR with RS + CAF GTR with non-RS + CAF	6 mo 6 mo	5/12 (41.6) 5/12 (41.6)	82.4 82.4	°Z °Z	∢	\supset	Yes	Yes	\supset
Romagna-Genon ¹⁰⁹	21/21 to 54	GTR with RS + CAF SCTG	6 mo 6 mo	NR/21 NR/21	74.6 84.8	°Z °Z	\triangleleft	\supset	\supset	Yes	\supset
Rossetti et al ^{110,111}	12 (NS)/25 to 60	BS + GTR with RS + CAF SCTG + CAF	6 mo 30 mo 6 mo 18 mo 30 mo	2/12 (25.0) 3/12 (25.0) 8/12 (66.7) 8/12 (66.7)	76.4 84.2 87.0 95.0 95.7 95.7	Yes Yes	\supset	\supset	Yes	Yes	5
Santana et al. ¹¹²	22 (NS)/18 to 47	CAF (semilunar) CAF	6 mo 6 mo	2/22 (9.0) 14/22 (63.6)	41.8 82.8	2 2	∢	\supset	Yes	Yes	\supset
Santana et al. ¹¹³	36 (NS)/34.0	LPF CAF	6 mo 6 mo	15/18 (83.3) 16/18 (88.8)	95.5 96.6	2 2	∢	\supset	Yes	Yes	\supset
Shori et al. ¹¹⁴	20/29.7	ADMG + CAF SCTG + CAF	6 mo 6 mo	NR/10 NR/10	86.9 84.7	°Z S	∢	\supset	\supset	Yes	\supset
Spahr et al. ^{I 15} /Hägewald et al. ^{I 16}	37/22 to 62	EMD + CAF Placebo + CAF	6 mo 12 mo 24 mo 6 mo 24 mo 24 mo	NR/30 NR/30 NR/30 NR/30 NR/30 NR/30 NR/30 NR/30	80.0 80.0 84.0 79.0 67.0	Yes Yes	<	\supset	Yes	Yes	\supset

Alone
Procedures
RC
With
Treated
GR
Π
and
Class 1
Evaluating
RCTs

Study	Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	MR	AC	BE	СF	RB
Tatakis and Trombelli ¹¹⁷	12 (NS)/22 to 48	GTR with RS + CAF SCTG + CAF	6 mo 6 mo	7/12 (58.3) 10/12 (83.3)	81.0 96.0	Yes Yes	\triangleleft	\supset	Yes	Yes	\supset
Tözüm et al. ¹¹⁹	31/16 to 59	SCTG + MTP SCTG + CAF	6 mo 6 mo	NR NR	96.4 77.1	o y	∢	\supset	°Z	Yes	Т
Trabulsi et al. ¹¹⁸	26 (NS)/20 to 65	EMD + GTR with RS + CAF GTR with RS + CAF	6 mo 6 mo	NR/13 NR/13	63.0 75.0	Yes Yes	∢	\supset	\supset	Yes	\supset
Trombelli et al. ¹²⁰	15/25 to 51	Fibrin glue + CAF CAF	6 mo 6 mo	1/11 (9.1) 2/11 (18.2)	63.1 52.9	Yes Yes	\supset	\supset	Yes	Yes	\supset
Trombelli et al. ¹²¹	8/25 to 57	GTR with non-RS + CAF GTR with non-RS + fibrin + CAF	6 mo 6 mo	1/8 (12.5) NR/8	66.6 61.4	No Yes	\supset	\supset	Yes	Yes	\supset
Trombelli et al. ¹²²	12/23 to 58	GTR with RS + CAF SCTG + CAF	6 mo 6 mo	1/12 (8.3) 6/12 (50.0)	51.6 83.3	Yes Yes	∢	\supset	\supset	Yes	\supset
Wang et al. ¹²³	16/30 to 54	GTR with RS + CAF SCTG + CAF	6 mo 6 mo	7/16 (43.8) 7/16 (43.8)	73.0 84.0	o y	∢	\supset	Yes	Yes	\supset
Wilson et al. ¹²⁴	13/38 to 60	TEHG + CAF SCTG + CAF	6 mo 6 mo	1/10 (10.0) 1/10 (10.0)	56.7 64.5	o y	∢	\triangleleft	Yes	Yes	_
Woodyard et al. ¹²⁵	24 (NS)/34.6	ADMG + CAF CAF	6 mo 6 mo	11/12 (91.6) 4/12 (33.3)	96.0 67.0	Yes Yes	∢	\supset	Yes	Yes	\supset
Zucchelli et al. ¹²⁶	54/23 to 33	GTR with RS + CAF GTR with non-RS + CAF SCTG + CAF	2 mo 2 mo 2 mo	7/18 (39.0) 5/18 (28.0) 12/18 (66.0)	85.7 80.5 93.5	°Z °Z °Z	\supset	\supset	Yes	Yes	\supset
Zucchelli et al. ¹²⁷	15/18 to 35	SCTG (Redgraft) + CAF SCTG + CAF	12 mo 12 mo	13/15 (86.7) 12/15 (80.0)	97.3 94.7	o S S	∢	\supset	Yes	Yes	\supset
Zucchelli et al. ¹²⁸	32/22 to 46 MGR	CAF without VRI CAF	12 mo 12 mo	42/47 (89.3) 35/45 (77.7)	97.3 92.6	Yes Yes	∢	∢	Yes	Yes	

τ	3
٩)
-	5
2	
Ŧ	5
Ż	
C)
<u> </u>)
-	-
0	i
6	;
ر مار	
c alde	
Table 2	

CTs Evaluating Class I and II GR Treated With RC Procedures Alone ž

$ tal^{129} = 11^{129} = 11/18 to 40 = 11/1$		Participants (n)/Age (y)	Interventions	Follow-Up	SCRC (%)	MRC (%)	RMA	ЯЯ	AC	BE	Ч	с Д
$a^{1/30} = \frac{50/21 \text{ to } 50}{\text{SCTG + CAF}} = \frac{\text{CAF}(\text{FGG dep})}{\text{SCTG + CAF}} = \frac{12 \text{ mo}}{12 \text{ mo}} = \frac{21/25}{18/20} = \frac{9.2}{92.3} = \frac{\text{No}}{\text{No}} = \frac{\text{A}}{\text{No}} = \frac{\text{Ves}}{\text{No}} = \frac{\text{Ves}}{100} = \frac{1}{100} = 1$	al. 129	11/18 to 40	CAF + ultrasonic CAF + curets	6 mo 6 mo	6/11(54.5) 9/11 (81.8)	84.2 95.4	°Z Z	∢	\supset	Yes	Yes (
al. ¹³¹ 50/20 to 45 LMCAF 12 mo 1/24 (4.0) 74.2 No A A Yes Yes Molar teeth SCTG + CAF 12 mo 12/25 (48.0) 88.8 No	al. 130	50/21 to 50	SCTG + CAF (FGG dep) SCTG + CAF	2 mo 2 mo	21/25 (84.0) 18/25 (72.0)	96.2 92.3	°Z 2℃	∢	∢	Yes	Yes	
SCTG + CAF 12 mo 12/25 (48.0) 88.8 No	al. ¹³¹	50/20 to 45 Molar teeth	LMCAF	12 mo	1/24 (4.0)	74.2	°Z	\triangleleft	\triangleleft	Yes	Yes	
			SCTG + CAF	I2 mo	12/25 (48.0)	88.8	Рo					

deepithelialized graft; DPT = double papilla flap; Er:YAG = erblum:yttrium-aluminum-garnet; extend = extended incision; GT = autologous gingival incrobiasts; n = nign; 1 = inadequate; L = iow; LiL 1 = iow; Intensity laser therapy; LMCAF = laterally moved coronally advanced flap; mod = modified; macro = macrosurgery; micro = microsurgery; MGR = multiple gingival recession; MR = method of randomization; MTP = modified tunnel procedure; Nd:YAG = neodymium:yttrium-aluminum-garnet; NR = not reported; NS = non-smokers; p = patients; PCG = platelet-concentrate graft; PRF = platelet-rich fibrin; PRP = MTP = modified tunnel procedure; Nd:YAG = neodymium:yttrium-aluminum-garnet; NR = not reported; NS = non-smokers; p = patients; PCG = platelet-concentrate graft; PRF = platelet-rich fibrin; PRP = MTP = modified tunnel procedure; Nd:YAG = neodymium:yttrium-aluminum-garnet; NR = not reported; NS = non-smokers; p = patients; PCG = platelet-concentrate graft; PRF = platelet-rich fibrin; PRP = MTP = modified tunnel procedure; Nd:YAG = neodymium:yttrium-aluminum-garnet; NR = not reported; NS = non-smokers; p = platelet-concentrate graft; PRF = platelet-rich fibrin; PRP = MTP = modified tunnel procedure; Nd:YAG = neodymium:yttrium-aluminum-garnet; NR = not reported; NS = non-smokers; p = platelet-concentrate graft; PRF = platelet-rich fibrin; PRP = MTP = modified tunnel procedure; Nd:YAG = neodymium:yttrium-aluminum-garnet; Nd = neodymium:yttrium-aluminum-garnet; Nd = neodymium supersected supersected supersected; NS = non-smokers; p = platelet-concentrate graft; PRF = platelet-rich fibrin; PRF = neodymium:yttrium-aluminum-garnet; Nd = neodymium; Nd = neodymium; PRF = neodymium; PRF = neodymium; Nd = neodymium; PRF = neodymium; Nd platelet-rich plasma; RB = risk of bias; Redgraft = graft size equal to the size of bone dehiscence; RS = resorbable membranes; s = sites (more than one GR per site); SCRC = sites with CRC; TEHG = tissue incisions releasing U = unclear; VRI = vertical hydrochloride; human graft; TH = tetracycline engineered (P = 0.01), and for SCTG-based procedures compared with FGG (P < 0.001).

In addition, the RD (that is, the difference between the proportions of sites exhibiting CRC in the two groups) and NNT for comparisons that reached significant RR were calculated; the results were as follows: 1) EMD + CAF compared with CAF: see supplementary Figures 7E (RD = 0.29; 95% CI = 0.12 to 0.47; P = 0.001; NNT = 4) and 7F (RD = 0.30; 95% CI = 0.12 to 0.47; P = 0.001; NNT = 4) in online Journal of Periodontology; 2) SCTG-based procedures compared with GTR: RD = -0.19; 95% CI = -0.31 to -0.07; P = 0.002; NNT = 6; 3) SCTGbased procedures compared with CAF: see Figures 2D (RD = 0.16; 95% CI = 0.07 to 0.16; P < 0.001; NNT = 7), 2E (RD = 0.22; 95% CI = 0.12 to 0.32; *P* <0.001; NNT = 5), and 2F (RD = 0.22; 95% CI = 0.11 to 0.32; P < 0.001; NNT = 5); 4) SCTG-based micro procedures compared with macro procedures: RD = 0.31; 95% CI = 0.10 to 0.52; P = 0.004; NNT = 4); and 5) SCTG-based procedures compared with FGG: RD = 0.41; 95% CI = 0.24 to 0.58; P <0.001; NNT = 3).

Part III: SR of Efficacy Trials and Conditions Not Judgmentally Explored by Previous SRs

Effect of treatment of Miller¹⁷ Class III GRs. A group of studies that mainly assessed the treatment of Class I or II GR has already included Class III defects. Regarding exclusively these defects, their reported outcomes can be found as follows. 1) For Miller,¹³² of the 21 Class III mandibular defects treated with FGG (recession depth range, 4 to 9 mm), 19 (90.5%) reached CRC (an outcome inferior to those reported for Class I defects [100% CRC or 13 of 13] and superior to Class II ones [87.9% CRC or 58 of 66). Overall, an MRC of 98.1% was reported for Class III defects. 2) For Barker et al., 133 eight Class III defects were assigned to one of the groups testing two types of ADMG + CAF; the MRC for the four defects included in the conventional ADMG were 62.5% and 61.3% for the "alternative" ADMG. 3) For Boltchi et al.,134 seven (50.0%) of 14 Class III defects treated with GTR with RS achieved CRC. 4) For Carney et al.,¹³⁵ 16 Class III defects were treated with ADMG + CAF (n = 8) or recombinant human platelet-derived growth factor (rhPDGF) + ADMG + CAF (n = 8) in this RCT, and MRCs of 60.8% and 51.5% were found for these GRs 6 months after treatment, respectively. 5) For Cueva et al.,¹³⁶ in their RCT that assessed EMD + CAF (test) versus CAF (control), CRC was achieved in three (42.8%) of the seven Class III GRs (2 of 3 [test] and 1 of 4 [control]). 6) For Jepsen et al.,¹³⁷ in none of the eight Class III defects was CRC accomplished after the use of RS. 7) For Nart

Study or Subgroup	Mean	Difference	SE	Weight	N. Ran	dom, 95% Cl	N, Random, 95% Cl
1.1.1 GTR/s + CAF vs	SCIG-b	ased proce	odures (6 months	3		1011 annual () 2217 51
Babu et al ³⁵		-0.8	7.18	10.2%	-0.801-1	4 83 13 231	
Borohetti et al 43		-58	11.34	4.1%	-5.801.3	8 03 16 43	
Nickles et al ⁹⁶		-25.3	14.93	2 3%	-25 301	54 56 3 96	
Paolantonio ⁹⁰¹		.9	6.87	11.0%	-9.001	22 46 4 46	
Romagna-Genon ¹⁰⁹		-10.2	9.26	61%	-10.201	28 35 7 95	
Tatakis & Trombelli ¹¹	17.	-15	10.69	4.6%	-15.00	35.95 5.95	
Trombelli et al. 122		-31.7	14.05	2.8%	-31.701	59.24 -4 181	
Mang et al 120		-11	7.54	9.2%	-11.001	25.78.3.78	
Cettiner et al. ⁵⁵ Subtotal (95% CI)		-12	6.12	13.9% 64.0%	-12.00	23.99, -0.01] 16.10, -4.91]	•
Heterogeneity: Tau ^a = Test for overall effect	0.00; C	h#= 5.56, d I (P = 0.000	#=8(P 2)	= 0.70);./*	= 0%		
1.1.2 GTRors + CAFv	s SCTG	based prov	cedures	(6 month	s)		-
Jeosen et al 74		0.2	10.95	4.3%	0.201-2	21 26. 21 66	
Ricci et al. 107		3.7	10.35	4.9%	3.70 51	6.61, 24.011	
Subtotal (95% CI)		Sec. St.		9.2%	2.051-1	[2.70, 16.80]	+
Heterogeneity: Tau ^a = Test for overall effect	0.00, C	hi* = 0.05, d (P = 0.79)	#=1 (P	= 0.82);/*	= 0%	1996-1995	
1.1.3 GTR/s/GTR/rs	s SCTG	-based pro	cedures	(6 mont	15)		
Zucchelli et al. ¹²⁸ Subtotal (95% CI)		-10.4	4.41	26.8%	-10.40 -	19.04, -1.76]	-
Heterogeneity: Not ap Test for overall effect	Z = 2.36	(P = 0.02)			10193	391.350.65	1923
							2.4
Total (95% CI) Heterogeneity: Tau* = Test for overall effect	0.00; C	h/* = 8.13, c	f= 11 (F 1) 1. df= 2	100.0% P= 0.70);/	-9.32[- *= 0%	13.80, -4.85] -100 SCTO-base	-50 0 50 of procedures GTR + CAF
Total (95% CI) Heterogeneity: Tau* = Test for overall effect Test for subcroup dif	0.00; C z = 4.08 ferences STR + CAF	h/* = 8.13, d 1 (P < 0.000 : Chi* = 2.5 SCTG-b	ff = 11 (F 1) 1, df = 2 ased pro	100.0% P = 0.70);; 0P = 0.20 cedures	-9.32[- *= 0%)./*= 20.5	13.80, -4.85] -100 SCTO-base Risk Rate	-50 0 50 ed procedures GTR + CAF Resk Ratio
Total (95% CI) Heterogeneity: Tau [#] = Test for overall effect Test for sub-proup dif Gudy ar Sub-proup E	0.00; C z = 4.01 ferences otik + CAF vents To	h/* = 8.13, d 1 (P < 0.000 1 Ch/* = 2.5 SCTG-b stal Ev	ff = 11 (F 1) 1, df = 2 ased pro-	100.0% P = 0.70);i (P = 0.20 cestures Total	-9.32 [- "= 0%)./"= 20.5 Weight 1	13.80, -4.85] -100 SCTO-base Risk Ratio A.H. Randoon, 15% CI	-50 0 50 of procedures GTR + CAF Resk Ratio M.H. Random, 95% CI
Iotal (95% CI) Heterogeneity: Tau" = Test for overall effect Test for suberoup dif Gudy or Subgroup () (2.1 GTRrs = CH vs SC	0.00; Ci z = 4.01 ferences otra + CAP vents To TG based	hi [#] = 8.13, c 1 (P < 0.000 : Chi [#] = 2.5 sc10-b dal Ev I procedures	ff = 11 (F 1) 1, df = 2 assed pro- reats 1 (6 month	100.0% P = 0.70); (P = 0.20) cestures to or minin	-9.32 [- "= 0%), /" = 20.5 Weight 1	13.80, -4.85] -100 % SCT0-base Risk Ratio A.H. Randow, 85% CI ble)	-50 0 50 ed procedures GTR + CAF Risk Ratie M.H. Random, 95% CI
Total (95% CI) Heterogeneity: Tau* = Test for overall effect Test for subgroup of Cody or Subgroup (12.1 GTR:s - CAF vs SC Sorghett et al. ⁴⁵	= 0.00; Ci z = 4.01 ferences otra + CAP vents To TG based 4	hi [#] = 8.13, c 0 (P < 0.000 : Chi [#] = 2.5 sctG-b dat Ev iprocedures	fr = 11 (F 1) 1, dr = 2 assed pro- reads (6 month 4	100.0% P = 0.70); 0 ^p = 0.20 cestures <u>Total</u> 14 2	-9.32 [- "= 0%), /" = 20.5 Weight 1 warn availa	13.80, -4.85] -100 % SCT0-base Risk Ratio 4.16, Randow, 95% CI blo) 1.00 (5.37, 3.23) 1.00 (5.37, 3.23) 1.00 (5.37, 3.23)	-50 0 50 of procedures GTR + CAF Risk Ratio M.H. Random, 95% CI
Total (95% CI) Hoterogeneity: Tau* = Test for overall effect Test for subcroup dif Coudy or Subgroup C.2.1 GTRrs = CAF vs SC longheth et al. ⁴⁰ Notaetenoi ¹⁰⁰	= 0.00; Cl z = 4.01 ferences otra + CAP vents To TG based 4 1	h/#= 8.13, d 10 ^p < 0.000 : Chi ^p = 2.5 : SCTG-b tal Ev fprocedures 14 0 15	ff = 11 (F 1) 1, df = 2 assed pro- eets 4 2 9	100.0% P = 0.70);; 0 ^p = 0.28 cedures <u>Total</u> 16 r	-9.32[- "= 0%),/" = 20.5 Weight 1 sam avails 5.7% 1.6%	13.80, -4.85] -100 % SCTO-base Risk Ratio 4.58, Random, 95% CI biol 1.00 (8.31, 3.23) 0.39 (8.64, 3.47) 0.57 (8.21, 4.85)	Pisk Ratio
Iotal (95% CI) Heterogeneity: Tau* = Test for overall effect Test for subcroup dif <u>Dudy or Subgroup</u> <u>B</u> 2.21 GTRrs = CAF vs SC longhett et al. ⁴⁵ Hickles et al. ⁴⁶ "actantionio ¹⁰⁷ Tatalos & Trombelli ¹¹⁷	0.00; C z = 4.01 ferences OTR + CAF Wests To Danse 4 1 8 7	h/*= 8.13, d 10 ^o < 0.000 : Chi*= 2.5 : SCTG-b tal Ev Iprocedures 14 0 15 12	ff = 11 (/ 1) 1, df = 2 assed pro- reats (6 month 4 2 9 10	100.0% P = 0.70);; 0 ^p = 0.20 cedures Total 14 7 15 12	-9.32[- "= 0%),/" = 20.5 Weight 1 sam avails 5.7% 14.0% 26.5%	13.80, -4.85] -100 SCTO-base Risk Ratio 4.14, Random, 19%-CI blog 1.00 (8.31, 3.23) 0.39 (8.64, 3.47) 0.47 (9.32, 1.40) 0.70 (9.41, 1.20)	Risk Ratio
Total (95% CI) Heterogeneity: Tau* = Test for overall effect Test for sub-group dif Caudy or Sub-group E L2.1 GTRrs = CAF vs SC Jorghett et al. ⁴⁰ "actaste at al. ⁹⁰ "actastenio" ¹⁰¹ Tatakis & Trombelliu ¹¹⁷ Tombelliu et al. ¹²²	0.00; C z = 4.05 Ferences UTR + CAP wests Tr TG based 4 1 5 7 1	h/* = 8.13, c 1 (P × 0.000 : Chi* = 2.5 sctic-b tal Ev procedures 14 9 15 12	ff = 11 (/ 1) 1, df = 2 assed pro- reads 10 month 4 2 8 10 5	100.0% P = 0.70);; 0 ^p = 0.28 cedures Total is or minis 14 7 15 12 12 12	-9.32 [- " = 0% 1,/" = 20.5 Weight 3 16% 16% 26.5% 20%	13.80, -4.85] -100 SCTO-base Risk Ratio <u>4.16, Random, 95% CI</u> Dial 1.00 (0.31, 3.23) 0.39 (0.04, 3.47) 0.67 (0.32, 1.40) 0.77 (0.2, 1.10) 0.77 (0.2, 1.10)	Fisk Ratio
Total (95% CI) Heterogeneity: Tau* = Test for overall effect Test for suberoup dif Coudy or Subgroup (12.1 GTPrs = CAF vs SC Jorghett et al. ⁴⁵ Vactaritonio ¹⁰⁰ Tatakio, 6. Trombelli vt 1 ¹⁰⁰ Trombelli et al. ¹⁰⁰ Vang et al. ¹⁰⁰	= 0.00; C z = 4.05 Ferences GTR + CAP wests To TG based 4 5 7 5 7 5 7	h/* = 8.13, c 1 (P × 0.000 : Chi* = 2.5 sct6-b tal Ev procedures 14 9 15 12 12 16	ff = 11 (/ 1) 1, df = 2 ased pro- eds 10 month 2 9 10 5 7	100.0% P = 0.70); (P = 0.28 Total to or minim 14 7 15 12 12 16	-9.32 [- "= 0% Weight 3 sen availa 5.7% 1.6% 1.6% 26.5% 20% 12.6%	13.80, -4.85] -100 SCTO-base Risk Ratio 4.H, Randow, 16% CI biti 1.00 (0.31, 3.23) 0.39 (0.04, 3.47) 0.67 (0.32, 1.40) 0.77 (0.41, 1.30) 1.00 (0.44, 2.19)	-50 0 50 ed procedures GTR + CAF Risk Ratio MH, Random, 95% CI
Total (95% CI) Heterogeneity: Tau# = Test for overall effect Test for subgroup dif Catady or Subgroup (Catady or Subgroup (C	= 0.00; Cl z = 4.01 Ferences Strik + CAF wests Ts TG based 4 1 5 7	hi [#] = 8.13, d 0.0° < 0.000 C Chi [#] = 2.5 SCTG-b far SCTG-b far SC	ff = 11 (f 1) 1, df = 2 assed pro- reads 1 (6 month 4 2 10 5 7	100.0% *= 0.70); 0 ^p = 0.20 <u>Total</u> is or minim 14 7 15 12 16 76 76	-9.32 [- "= 0% k,i ^a = 20.5 weight 1 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 62.4%	13.80, -4.85] -100 % SCTO-bass Risk Ratio 4.50, Ration 4.50, Ration 4.50, Ration 1.00 (0.31, 3.23) 0.59 (0.04, 3.47) 0.67 (0.32, 1.40) 0.77 (0.02, 1.10) 1.00 (0.44, 2.10) 0.72 (0.55, 1.03)	Pisk Ratio
Total (95% CI) Heterogeneity: Tau" = Test for overall effect Test for subcroup dif Cady or Subgroup L2.1 GTRns - CAF vs SC Sorghett et al. ⁴³ Wickes et al. ⁴⁵ Wickes et al. ⁴⁵ Variation ¹⁵⁰ Tatakis & Trombelli Variation ¹⁵¹ Tombelli et al. ¹²² Variation ¹⁵¹ Cold events Feteropeneity: Tau" = 0. Test for overall effect 2 ×	= 0.00, C z = 4.05 ferences OTR + CAP TG based 4 1 2 26 20, Ch/F = 1.01 (P =	ht [#] = 8.13, c 10 ^P < 0.000 Chi [#] = 2.5 SC10-b tal <u>Ev</u> Iprocedures 14 9 15 12 12 16 78 2.60, df = 5.6 0.07)	8" = 11 (F 1) 1, dt = 2 assed pro- ends (6 month 4 2 9 10 6 7 38 P = 0.01%	100.0% ⁵ = 0.70); / (P = 0.28 costures <u>Total</u> 14 15 12 16 16 76 17 18 19 10 10 10 10 10 10 10 10 10 10	-9.32 [- *= 0%), /* = 20.5 Weight 3 5.7% 1.6% 1.6% 1.6% 1.2.6% 5.2% 5.2% 5.2%	13.80, -4.85] -100 SCTO-bass Risk Ratio 4.50, Random, 95% CI 0.09 (0.31, 3.23) 0.39 (0.04, 3.47) 0.47 (0.32, 1.40) 0.70 (0.44, 1.20) 0.70 (0.44, 1.20) 0.70 (0.44, 1.20) 0.72 (0.51, 1.63)	Pisk Ratio
Total (95% CI) Heterogeneity: Tau" = Test for overall effect Test for suberoup dif Cataly or Subgroup (12.1 GTPrs = CAF vs SC borghett et al. ⁴⁵ vactantonio ¹⁰⁰ Tatakio & Trombelli et al. ¹⁰⁰ Vang	= 0.00, C z = 4.08 ferences OTR + CAP vents To TG bases 4 1 5 7 26 20, Ch ² = 1.81 (P ²)	ht [#] = 8.13, c (P < 0.000 Chi [#] = 2.5 SCTG-b dat <u>Ev</u> procedures 16 15 12 16 78 3.60, dr = 5 (0.07) rd procedure	87 = 11 (7 1) 1, d7 = 2 assed pro- wd5 4 2 10 5 7 38 P = 0.61); rs (6 mont	100.0% = 0.70); / (P = 0.28 Total so or minin 14 15 12 16 76 76 16 76 76 16 76 16 76 16 76 12 16 76 16 16 16 16 16 16 16 16 16 1	-9.32 [- *= 0%), /* = 20.5 Weight _1 sam avails 5.7% 1.6% 26.5% 12.6% 62.4%	13.80, -4.85] 	Pisk Ratio
Total (95% CI) Heterogeneity: Tau" = Test for overall effect Test for subcroup dif Cady or Subgroup L2.1 GTPrs = CAF vs SC Sorghett et al. ⁴⁰ Wickes et al. ⁴⁰ Wickes et al. ⁴⁰ Vang et al. ¹²² Vang et al. ¹²³ Vang et al. ¹²⁴ Nang et al. ¹²⁵ Vang et al. ¹²⁵ Vang et al. ¹²⁶ Vang et al. ¹²⁷ Vang et al. ¹²⁸ Vang et al. ¹²⁸ Vang et al. ¹²⁹ Vang et al. ¹²⁹ Vang et al. ¹²⁹ Vang et al. ¹²⁹ Vang et al. ¹²⁰ Vang et al. ¹²⁰ Van	0.00; Ci z = 4.08 Ferences 0TR + CAF wests Tr TG based 4 1 8 7 26 00; ChF = 1.01 0° = CTG-base 7	ht [#] = 8.13, c 10 ^P < 0.000 C Ch [#] = 2.5 SC10-b tal <u>Ev</u> Iprocedures 14 9 15 12 12 12 16 78 2.60, df = 5.6 2.60, df = 5.6 2.60, df = 5.6 2.60, df = 5.6 2.60, df = 5.6 2.60, df = 5.6 2	87 = 11 (7 1) 1, dY = 2 assed pro- wats 0 6 mont 4 2 9 10 6 7 38 7 38 P = 0.61% 7	100.0% ^p = 0.70); (P = 0.28 <u>Total</u> is or million 14 7 15 12 16 76 76 76 76 76 76 76 76 76 7	-9.32 [- *= 0% h,/*= 20.5 h,/*= 20.5 h,/== 2	13.80, -4.85] -100 SCTO-basis Risk Ratio 4.56, Ratio 4.56, Ratio 4.56, Ratio 4.56, Ratio 4.56, Ratio 4.57, 0.21, 100 0.39 (0.54, 3.47) 0.57 (0.32, 1.40) 0.70 (0.44, 1.20) 0.72 (0.51, 1.60) 1.00 (0.47, 2.15)	Pisk Ratio
Total (95% CI) Heterogeneity: Tau* = Test for overall effect Test for subcroup dif Caudy as Subgroup E Catalys = CAF vs SC longheth et al. ¹⁰ Vaciantionio ¹⁰¹ Tatakis 4. Trombelli v ¹¹⁷ Tombelli et al. ¹²² Vang et al. ¹²³ Addretal (95% C) Total events Vertropeneity: Tau* = 0.0 Total events Vertropeneity: Tau* = 0.1 Total events Vertropeneity: Tau* = 0.1 Scatter overall effect z = 1.2.2 GTHres = CAF vs S laboratal (95% C)	0.00; Cl z = 4.01 Rerences 0TR + CAV vents 1 TG based 4 1 7 26 26 1.01 (P = 7 26 1.01 (P = 7 7 26 1.01 (P = 7 7 1.01 (P = 7 1.01 (P = 1	ht [#] = 0.13, c 10 ^P < 0.000 C Ch [#] = 2.5 SCTG-b stat <u>Ev</u> Iprocedure 14 9 15 12 12 12 16 15 15 15	ff = 11 (F 1) 1, df = 2 assed pro- events 105 month 4 2 9 10 5 7 38 P = 0.01% 7	100.0% ^p = 0.70]; (P = 0.28 <u>Total</u> is or minimi 14 7 15 12 16 16 16 16 16 16 16 16 16 16	-9.32 [- = 0% , / ² = 20.5 Weight 1 14.0% 14.0% 12.6% 62.4% 13.3% 13.3%	13.80, -4.85] 	Pisk Ratio
Iotal (95% CI) Heterogeneity: Tau* = Test for overall effect Fest for overall effect (audy or Subgroup E 2.1 GTRrs = CAF vs Sc longheth et al. ¹⁰⁰ 'aolantonio ¹⁰¹ 'atakis d. Trombelliu ¹¹⁷ Tombelli et al. ¹²² Vang et al. ¹²³ additet (95% CI) fest for overall effect 2 = 2.2 GTRes = CAF vs Sc interogeneity: Tau* = 0.0 isot for overall effect 2 = 2.2 GTRes = CAF vs Sc isotent of S% CI) 'otal events interogeneity: Not apple rest for overall effect 2 = (addited) (5% CI) 'otal events interogeneity: Not apple rest for overall effect 2 = (addited) (5% CI) 'otal events interogeneity: Not apple rest for overall effect 2 = (addited) (5% CI)	0.00; C z = 4.08 ferences 0.08; C = 4.08 ferences 0.08; C = 4.08 0.07 1	ht [#] = 8.13, c 10 ^P < 0.000 Chi [#] = 2.5 SCTG-b scTG-b s	8 = 11 (7 1) 1. dY = 2 assed pro- meds 0 formoral 4 2 9 10 5 7 38 P = 0.81% 7 7 7 7	100.0% ^p = 0.70); (P = 0.28 <u>Total</u> is or minin 14 7 15 12 12 16 16 16 16 16 16 15 15 15 15 15 15 15 15 15 15	-9.32 [- = 0% Mesget 1 Mesget 20.5 1.6% 1.5% 1.5	13.80, -4.85] -100 SCTO-bass Risk Ratio 4.16, Random, 1956 CI biol 1.00 (0.31, 3.23) 0.39 (0.64, 3.47) 0.47 (0.32, 1.40) 0.70 (0.44, 3.20) 0.70 (0.44, 3.20) 0.70 (0.44, 3.20) 0.70 (0.44, 3.20) 0.70 (0.44, 3.20) 1.00 (0.47, 2.15) 1.00 (0.47, 2.15)	Pick Ratio
Iodal (95% CI) Heterogeneity: Tau* = Test for overall effect Test for suberoup dif Caudy or Subgroup E 12.1 6 CIPrs = CAF vs SC Jorghett et al. ⁴⁰ voctors et al. ⁴⁰ voctors et al. ⁴⁰ voctors et al. ⁴⁰ votors et al. ⁴⁰ (otal events referogeneity: Tau* = 0.1 (et for overall effect .2 = 1.2.2 CIPrers = CAF vs S instantial (95% CI) (otal events referogeneity: Nut applie (et for overall effect .2 = 0.3 coverall effect .2 =	0.00; Ci z = 4.08 ferences 0TR + CAF vests Tr TG based 4 1 8 7 7 28 00; ChF = 1.81 0F 7 28 00; ChF = 1.81 0F 7 7 cable 9 0.00 0F =	ht [#] = 8.13, c (P < 0.000 (Chi [#] = 2.5 sctG-b dal <u>Ev</u> procedures 15 12 16 78 3.60, dr = 5 (0.07) nd procedure 15 15	8" = 11 (/ 1) 1, dt' = 2 assed pro- weds 0 fill monet 4 2 9 10 5 7 38 P = 0.61% 7 38 7 38 7 38 7 38 7 38 7 38 7 7 7	100.0% ^p = 0.70); (P ⁰ = 0.28 <u>Total</u> 14 7 12 16 76 76 76 15 15	-9.32 [- = 0% 1, i ^a = 0% 1, i ^a = 20.5 1, i ^a = 20.5 14.0% 26.5% 26.5% 26.5% 12.6% 12.6% 12.6% 12.6% 12.6% 12.6% 12.3% 13.3%	13.80, -4.85] i-100 SCTO-basis Risk Ratio d.H., Radoux, 16%, CI 0.00 (0.31, 3.23) 0.39 (0.64, 3.147) 0.39 (0.64, 3.147) 0.37 (0.64, 3.147) 0.37 (0.64, 3.147) 0.37 (0.64, 5.110) 0.72 (0.65, 1.803) 1.00 (0.47, 2.15) 1.00 (0.47, 2.15)	Risk Ratio
Total (95% CI) Heterogeneity: Tau" = Test for overall effect Test for suberoup dif Catady or Suberoup dif Catady or Suberoup dif Catado Suberoup dif Pactantonio Total events deterogeneity: Tau" = 0.1 Test for overall effect 2 = 1.2.2 GTRes CAF vs S Interopeneity: CAF vs S Interopene	0.00; Ci z = 4.01 ferences 0TR + CAV wests 1s TG based 4 7 7 26 0.00 (P = 0.00 (P = 500 (P	ht [#] = 8.13, c) (P < 0.000 Chi [#] = 2.5 SCTG-b tat <u>Ev</u> Iprocedures 14 9 15 12 12 15 15 16 78 3.00, dr = 5 (0.07) ed procedure 15 15 15	8 = 11 (7 1) 1, dY = 2 assed pro- reads 10 monet 4 2 9 10 6 7 38 P = 0.01); 7 7 7	100.0% ^p = 0.70); (0 ^p = 0.28 <u>Total</u> is or million 14 7 12 12 12 16 76 19 15 15 15 15	-9.32 [- *= 0% h,i*= 20.5 h,i*= 2	13.80, -4.85] -100 SCTO-basis Risk Ratio 4.80, Random, 95% CI 0.40 (0.31, 3.23) 0.39 (0.64, 3.24) 0.47 (0.32, 1.40) 0.70 (0.41, 1.20) 0.70 (0.41, 1.20) 0.72 (0.51, 1.03) 1.00 (0.47, 2.15) 1.00 (0.47, 2.15)	Pisk Ratio
Total (95% CI) Heterogeneity: Tau* = Test for overall effect Test for subcroup dif Cauty or Subgroup E C.2.1 GTRs = CAF vs SC borghett et al. ¹⁰⁰ 'actartionio ¹⁰¹ Tablois & Trombelli ^{VIT} Trombelli et al. ¹⁰² Vang et al. ¹⁰³ Subtrati (95% C) Total events referorgeneity: Tau* = 0.1 rotal revents referorgeneity: Co 'otal events referorgeneity: Not apple referorgeneity: Co 'otal events referorgeneity: Not apple referorgeneity: Co	0.00; Ci z = 4.01 ferences 0TR + CAP wests Tr based 4 5 7 7 26 00; ChP = 1.81 (P = 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 7 7 26 7 7 7 26 7 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 26 7 7 7 26 7 7 7 26 7	ht [#] = 0.13, c 10 ^P < 0.000 C DH [#] = 2.5 SCTG-b scTG-b tal <u>Fv</u> 10 12 12 12 12 12 12 12 12 12 12	8 ^r = 11 (7 1) 1, d7 = 2 assed pro- wears 10 monet 4 2 8 10 6 7 38 P = 0.61% 7 7 7 7	100.0% ^p = 0.70); (P = 0.20 codures Total is or minis 14 7 15 12 16 16 16 16 16 16 16 16 16 10 10 10 10 10 10 10 10 10 10	-9.32 [- *= 0% h,/* = 20.5 h,/* = 20.5 h,/	13.80, -4.85] 100 SCTO-basis Risk Ratio 4.58, Randows, 95% CI bley 1.00 (8.31, 3.23) 0.39 (8.64, 3.47) 0.79 (9.32, 1.47) 0.77 (9.32, 1.47) 1.00 (8.47, 2.15) 1.00 (8.47, 2.15) 1.00 (8.47, 2.15) 1.00 (8.47, 2.15) 1.00 (8.47, 2.15)	Pisk Ratio
Iodal (95% CI) Heterogeneity: Tau" = Test for overall effect Test for overall effect Test for subcroup dif Condy as Subgroup E C.2.1 GTRrs = CAF vs 50 longheth et al. ¹⁰⁰ vaciantonio ¹⁰⁰ Tatakis d. Trombelli ¹¹⁷ Tombelli et al. ¹²⁰ Vang et al. ¹²¹ Vang et al. ¹²¹ Subtotal (95% CI) Test for overall effet z = 1.2.2 GTRrss = CAF vs 50 laterogeneity: Not apple rest for overall effet. z = 1.2.3 GTRrss/GTRess vs 5 Succhell et al. ¹²⁸ Referogeneity: Not apple rest for overall effet. z = 1.2.3 GTRrss/GTRess vs 5 Succhell et al. ¹²⁸ Referogeneity: Not apple	0.00; Ci z = 4.01 ferences 0.00; Ci z = 4.01 ferences 0.01; Ci z = 4.01 ferences 1.01 ci 1.01 ci	ht [#] = 8.13, c (P < 0.000 Chi [#] = 2.5 SCTG-b stat Ex Iprocedures 14 9 15 12 12 12 12 16 16 16 16 16 16 15 15 15 15 15 15 15 15 15 15 15 15 15	8 = 11 (7 1) 1. dY = 2 assed pro- wears 10 month 4 2 9 10 5 7 38 P = 0.01); 7 7 7 12 12	100.0% ^p = 0.70); (P = 0.28 <u>Total</u> is or minim 14 7 15 12 16 16 16 16 16 15 16 15 16 15 15 15 15 15 15 15 15 15 15	-9.32 [- = 0% ./ ² = 0% ./ ² = 20.5 	13.80, -4.85] .100 SCTO-bass Risk Ratio 4.14, Randows, 95% CI biol 1.00 (8.31, 3.23) 0.39 (8.64, 3.47) 0.47 (3.32, 1.40) 0.70 (3.41, 1.20) 0.70 (3.41, 1.20) 0.50 (0.210, 0.38) 0.50 (0.200, 0.38) 0.50 (0.500, 0.50) 0.50 (0.500, 0.50) 0.50 (0.500, 0.50) 0.50 (0.500, 0.50) 0.5	Pisk Ratio M.H. Random, 95% CI
Initial (95% CI) Heterogeneity: Tau" = Test for overall effect Test for suberoup dif Caudy or Subgroup E 12.1 6 CPrs = CAF ve SC longheth et al. ⁴⁵ voctors et al. ⁴⁶ voctors et al. ⁴⁰ voctors et al. ⁴⁰ votors et al. ¹⁰⁰ Tatalois & Trombelli et al. ¹⁰⁰ Tatalois & Trombelli et al. ¹⁰⁰ Tatalois & Trombelli et al. ¹⁰⁰ Vang et al. ¹⁰¹ Tatalois & Trombelli et al. ¹⁰² Vang et al. ¹⁰² votors et al. ¹⁰⁴ isotorat (95% C) Total events referogeneity: Not apple rest for overall effect z = 1.2.2 GTRvs/GTRars ve S Subtotal (95% C) Total events isotoral (95% C) Total events isotoral (95% C) Total events isotoral (95% C)	0.00; Ci z = 4.01 ferences 0TR + CAV vents 1s TG-based 4 7 1 7 26 00; Ch ^p = 1.01 (P = 7 7 7 26 00; Ch ^p = 1.01 (P = 7 7 7 26 1.01 (P = 7	ht [#] = 8.13, c) (P < 0.000 Chi [#] = 2.5 SCTG-b tal <u>Ev</u> [procedures 14 9 15 12 12 12 12 13 16 78 3.60, dr = 5 (0.07) ml procedure 15 15 15 15 10 1.00) seaths() 26 26 26 26 26 26 26 26 26 26 26 26 26	8 = 11 (/ 1) 1, df = 2 assed pro- wears 10 monet 4 2 9 10 6 7 38 P = 0.01); 7 7 7 7 12 12	100.0% ^p = 0.70); (0 ^p = 0.28 <u>Total</u> 14 7 15 12 12 16 76 15 15 15 18 18	-9.32 [- *= 0% 1, /* = 20.5 1, /* = 20.5 2,	13.80, -4.85] 13.80, -4.85] SCTO-basis Risk Ratio 4.16, Ration, 95% CI 0.47 (0.10, 0.11, 0.21) 0.47 (0.11, 0.11, 0.11, 0.11) 0.47 (0.11, 0.11, 0.11) 1.00 (0.47, 2.15] 1.00 (0.47, 2.15] 0.50 (0.28, 0.88] 0.50 (0.28, 0.88]	Pisk Ratio
Total (SIS's CI) Heterogeneity: Tau" = Test for overall effect Test for subcroup dif East for subcroup dif East for subcroup dif East for subcroup dif Catalysis and the Paofantonio ¹⁰¹ Tatakis & Trombelli d ¹¹² Tombelli et al. ¹⁰² Wang et al. ¹⁰² Wang et al. ¹⁰² Wang et al. ¹⁰³ Reterogeneity: Tau" = 0.0 Test for overall effect 2 = 1.2.2 GTRess CAI vs Si Reterogeneity: Not applic Test for overall effect 2 = 1.2.3 GTRessGTRess vs 5 Durchell et al. ¹⁰³ Reterogeneity: Not applic Test for overall effect 2 = 1.2.3 GTRessGTRess vs 5 Durchell et al. ¹⁰³ Reterogeneity: Not applic Test for overall effect 2 = 1.2.3 GTRessGTRess vs 5 Durchell et al. ¹⁰⁴ Reterogeneity: Not applic Test for overall effect 2 = Notal (SSS CI)	0.00; Ci z = 4.08 ferences 0.08; CAP ferences 0.08; ChP = 1.09 0.00; ChP = 1.09 0.00; ChP = 0.00; ChP = 0.00; ChP = 1.09 12 12 12 12 12 12 12 12 12 12	ht [#] = 8.13, c) (P < 0.000 Chi [#] = 2.5 SCTG-b tal Ex Procedures 14 9 15 12 12 12 15 15 3.60, dr = 5 (0.07) rd procedure 15 15 1.00) seaths) 36 36 2002)	8 = 11 (/ 1) 1, dt' = 2 assed pro- weds 10 fill moret 4 2 9 10 fill 7 38 P = 0.010 7 38 7 38 7 38 7 38 7 38 7 38 7 38 7 3	100.0% ^p = 0.70); (P ⁰ = 0.28 <u>Total</u> 14 7 15 12 12 16 76 15 15 16 19 109 109	-9.32 [- *= 0% 1, i* = 20.5 1, i* = 20.5 5.7% 14.0% 26.5% 20% 12.0% 62.4% 13.3% 13.3% 13.3% 13.3%	13.80, -4.85] 13.80, -4.85] SCTO-basis SCTO-basis Risk Ratio 4.16, Random, 95% CI 0.30 (0.31, 3.23) 0.37 (0.31, 3.23) 1.00 (0.47, 2.15) 0.50 (0.28, 0.88) 0.50 (0.28, 0.88) 0.69 (0.52, 0.51)	-50 0 50 eld procedures GTR + CAF
Total (95% CI) Heterogeneity: Tau* = Test for overall effect Test for overall effect Test for suboroup dif County or Subgroup P Cat of CFRs = CAF vs SC Dorphett et al. ⁴² Victors et al. ⁴⁰ Victors et al. ⁴⁰ Victors et al. ⁴⁰ Totalexe at at ⁴⁰ Nang et al. ⁵⁰ Total events Heterogeneity: Tau* = 0.0 Total events Heterogeneity: Tau* = 0.0 Total events Heterogeneity: Not applic Test for overall effect z = 1.2.3 GTR:skGTRows vs 3 Dochail et al. ¹²⁰ Noted events Heterogeneity: Not applic Test for overall effect z = Istal (95% CI) Total events Heterogeneity: Not applic Test for overall effect z = Istal (95% CI) Total events Heterogeneity: Not applic Test for overall effect z = Istal (95% CI) Total events	0.00; Ci z = 4.01 ferences 0TR + CAP wests 1s TG based 4 7 1 7 26 0:00 (P = 0:00 (P = 0:00 (P = 12) CTG based 7 7 cable 0:00 (P = 12) 12 cable 12 14	h/# = 8.13, c) (P < 0.000 Chi# = 2.5 SCTG-b tal Ex Iprocedures 14 9 15 12 12 12 13 78 3.60, dr = 5 0.07) of procedure 15 15 15 15 15 15 15 15 15 15 15 15 15	8 = 11 (/ 1) 1, df = 2 assed pro- reads 10 monet 4 2 9 10 6 7 38 P = 0.01); 7 7 7 12 12 12	100.0% ^p = 0.70); (0 ^p = 0.28 <u>Total</u> is or mini- 14 7 12 12 12 12 16 76 15 15 15 16 18 18 109	-9.32 [- *= 0% h.*= 20.5 h.*= 20.5 h	13.80, -4.85] 13.80, -4.85] SCTO-basis Risk Ratio 4.50, Random, 95% CI 0.69 (0.31, 3.23) 0.39 (0.64, 3.47) 0.47 (0.31, 3.23) 0.39 (0.51, 3.47) 0.70 (0.41, 1.20) 0.70 (0.41, 1.20) 0.70 (0.41, 1.20) 0.72 (0.51, 1.63) 1.00 (0.47, 2.15) 1.00 (0.47, 2.15) 0.50 (0.28, 0.86) 0.50 (0.28, 0.86) 0.50 (0.28, 0.86)	Pisk Ratio

Figure 1.

Forest plots of random-effects meta-analysis comparing GTR + CAF and SCTG-based procedures. IV = inverse variance; nRS = non-resorbable membrane; M-H = Mantel-Haenszel; Tau² = Kendall τ test; z = z test. A) Difference in the percentage of recession reduction. B) Difference in the number of sites exhibiting CRC.

et al.¹³⁸, within seven Class III defects on mandibular incisors treated with SCTG + CAF, mean recession depth decreased from 5.1 to 0.8 mm (86.4%), with concomitant mean CAL and KT gains of 5 and 3 mm, respectively. CRC was achieved in three recessions (42.8%). When compared with the Class II defects included in the same study, no significant differences were observed (P > 0.05).

Additionally, three other RCTs evaluated specifically Class III defects. 1) Aroca et al.¹³⁹ evaluated 139 Class III GRs in a group of 20 patients treated with a modified tunnel/SCTG procedure with or without the addition of EMD in sites of MRTDs. Despite the significant changes within groups recorded for recession reduction and CAL at the 12-month exam, the use of EMD did not lead to significant improvements between aroups (MRC of 82% and CAL gain of 2.9 mm for the EMD group, and MRC of 83% and CAL gain of 2.8 mm for the control group). 2) Henriques et al.140 also compared the outcomes of SCTG + CAF with (test group) or without (control group) the addition of EMD, in a split-mouth study comprising 12 individuals. Twelve months after treatment, significant recession reductions of GR of 2.5 mm (70.0%) and 1.7 mm (54.8%) were found for the test and control groups, respectively (P = 0.01). CAL and KT were also improved (for test, 3.0 and 0.8 mm, respectively; and for control, 1.2 and 0.6 mm, respectively). 3) The study by Cairo et al.¹⁴¹ assessed the use of SCTG + CAF and CAF for the treatment of Class III GRs (i.e., with interdental clinical attachment loss [AL] less than or equal to the buccal AL). Of the 15 patients treated with SCTG + CAF, 57% presented CRC, whereas 64% of the 14 treated with CAF showed a similar outcome. The MRC was 2.6 mm (85.0%) for the combined approach and 2.0

mm (69.0%) for the use of flap alone, and both treatments reported similar esthetic outcomes (as measured by a visual analog scale [VAS]).¹⁴¹ According to the authors, the following could be concluded: A) SCTGs lead to an increase in the number of sites with CRC up to >80% of the sites when the baseline amount of interdental clinical AL was ≤3 mm; B) more sites treated with CAF experienced

	Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
	2.1.1 SCTG-based pr	recedures vs CAF (6	mont	hs)		
Ì	Bittencourt et al. 40,41	5.4	3.33	34.3%	5.40 [-1.13, 11.93]	-
9	Cortellini et al. 54	5.6	9.02	4.7%	5.60 [-12.08, 23.28]	
)	da Silva et al. ⁵⁶	6.5	9.72	4.0%	8.50 [-12.55, 25.55]	
1	Kuis et al. ⁸⁰	5.3	2.58	57.1%	5.30 [0.24, 10.36]	
1	Subtotal (95% CI)			100.0%	5.40[1.58, 9.22]	
1	Heterogeneity: Tau [#]	= 0.00; Ch ^p = 0.01, d	(=3)	P >0.99);/	*= 0%	
	rescior overail enect	2 = 2.17 (F = 0.000)	r .			
3	Total (95% CI)			100.0%	5.40 [1.58, 9.22]	•
	Heterogeneity: Tau [®] Test for overall effect Test for subgroup dif	= 0.00; Chi ^a = 0.01, d : <i>z</i> = 2.77 (P = 0.006) ferences: Not applic	r= 3 ()) able	P>0.99);	*= 0%	100 -50 0 50 100 CAF SCTG-based proce
					Mean Difference	Mean Difference
1	Study or Subgroup	Mean Difference	SE	Weight	N, Random, 95% CI	IV, Random, 95% CI
1	2.2.1 SCTG-based pr	rocedures vs CAF (6	mon	ites)		and the second se
2	Cortellini et al.54	5.8	9.02	8.7%	5.60 [-12:08, 23:28]	
	da Silva et al. ⁵⁶	6.5	9.72	7.5%	6.50 [-12.55, 25.55]	
1	Subtotal (95% CI)			16.1%	6.02[-6.94, 18.98]	
ł	Test for overall effect	= 0.00; ChP = 0.00; d t z = 0.91 (P = 0.36)	r=1(P= 0.95)	/* = 0%	
9	2.2.2 SCTG-based pr	rocedures vs CAF (2	4 mo	nths)		
	Kuis et al. ⁶⁰ Subtetal (SC), Ch.	8.1	3.23	67.6%	8.10 [1.77, 14.43]	
1	Hataroappoint bird -	anlicable.		07.0%	0.10[1.11, 14.43]	
1	Test for overall effect	$t = 2.51 \ (P = 0.01)$				
1	2.2.3 SCTG-based pr	rocedures vs CAF (3	10 moi	nths)		1000000
	Bittencourt et al.40.41	7.6	6.58	18.3%	7.80 [-5.30, 20.50]	1
	Subtotal (95% CI)			16.3%	7.60 [-5.30, 20.50]	-
	a second s	the second se				
1	Heterogeneity. Not a Test for overall effect	pplicable $t = 1.16$ (P = 0.25)				
ļ	Heterogeneity: Not a Test for overall effect Total (95% CI)	pplicable t z = 1.16 (P = 0.25)		100.0%	7.68 (2.48, 12.89)	
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ^a Test for overall effect Test for subgroup di	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 flerences: Chi ^a = 0.0	#=3() 8.d#=	100.0% P = 0.99) 2 (P = 0.1	7.68 (2.48, 12.89) /*= 0% (6)./*= 0%	100 -50 0 50 100 CAF SCTG-based proce
	Heterogeneity, Not a Test for overall effect Total (95% Ct) Heterogeneity, Tau ^a Test for overall effect Test for subgroup di	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.0	f = 3 () 8, df =	100.0% P = 0.99) 2 (P = 0.9	7.68 (2.48, 12.89) (*= 0% 16)./*= 0% Mean Difference	L100 -50 0 50 100 CAF SCTG-based proce
	Heterogeneity, Not a Test for overall effect Total (95% Ct) Heterogeneity, Tau ^a Test for overall effect Test for subgroup di Study or Subgroup	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ² = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ² = 0.0 Mean Difference	f = 3 () 8, df = SE	100.0% P = 0.99) 2 (P = 0.1 Weight	7.68 (2.48, 12.89) (*= 0% (6)/*= 0% Mean Difference IV, Random, 95% CI	L100 -50 0 50 100 CAF SCTG-based proce Mean Difference M, Randem, 95% CI
	Heterogeneity, Not a Test for overall effect Total (95% Cl) Heterogeneity, Tau ² - Test for overall effect Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.0 Mean Difference recedures vs CAF (6	1'= 3 () 8, dt'= <u>SE</u> mont	100.0% P = 0.99) 2 (P = 0.1 Weight hs)	7.68 (2.48, 12.89) /*= 0% 16)./*= 0% Mean Difference IV, Random, 95% CI	100 -50 0 50 100 CAF SCTG-based proce Mean Difference M, Random, 95% Cl
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ^a - Test for overall effect Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴	pplicable t z = 1.16 (P = 0.25) = 0.00; ChiP = 0.08, d t z = 2.89 (P = 0.004 ferences: ChiP = 0.0 Mean Difference recedures vs CAF (6 5.6	r = 3 () 8, dr = sat 9.02	100.0% P = 0.93) 2 (P = 0.1 Weight hs) 10.5%	7.68 (2.48, 12.89) (*= 0% (6))*= 0% Mean Difference IV, Random, 95% Cl 5.60 (-12.08, 23.28)	Mean Difference N, Random, 95% Cl
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ^a - Test for overall effect Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Sitra et al. ⁵⁶	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.0 Mean Difference rocedures vs CAF (6 5.6 6.5	f = 3 () 8. df = <u>SE</u> 9.02 9.72	100.0% P = 0.93) 2 (P = 0.1 Weight hts) 10.5% 9.0%	7.68 [2.48, 12.89] (*= 0% 160. /*= 0% Mean Difference N, Random, 95% Cl 5.60 [-12.08, 23.28] 0.50 [-12.55, 25.55]	Mean Difference M, Random, 95% Cl
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ^a - Test for overall effect Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Silva et al. ⁵⁶ Subtotal (95% CI)	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.00 Mean Difference rocedures vs CAF (6 5.6 6.5	f'= 3 () 8, df'= mont 9.02 9.72	100.0% P= 0.93) 2 (P= 0.1 Weight hs) 10.5% 9.0% 19.5%	7.68 [2.48, 12.89] (*= 0% 160. /*= 0% Mean Difference N, Random, 95% Cl 5.60 [-12.08, 23.28] 6.50 [-12.55, 25.55] 6.02 [-6.94, 18.98] 7= 0%	Mean Difference M, Random, 95% Cl
	Heberogeneity: Not a Test for overall effect Total (95% CI) Heberogeneity: Tau ^a i Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ de Sithe et al. ⁵⁶ Subtotal (95% CI) Heberogeneity: Tau ^a i Test for overall effect	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^p = 0.08, d t z = 2.89 (P = 0.004 ferences: Ch ^p = 0.0 Mean Difference toccdures vs CAF (6 5.6 5.5 = 0.00; Chi ^p = 0.00, d t z = 0.91 (P = 0.36)	f = 3 () 8, df = 502 9.02 9.72 F = 1 ()	100.0% P = 0.99) 2 (P = 0.1 Weight hs) 10.5% 9.0% 19.5% P = 0.95);	7.68 [2.48, 12.89] (*= 0% 160.1* = 0% Mean Difference IV, Random, 95% CI 5.60 [-12.08, 23.28] 6.50 [-12.55, 25.55] 6.02 [-6.94, 18.98] (*= 0%	100 -50 0 50 100 CAF SCTG-based proce Mean Difference M, Randem, 95% CI
	Heberogeneity: Not a Test for overall effect Total (95% CI) Heberogeneity: Tau ^a i Test for subgroup dil Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ ds Situe et al. ⁵⁶ Subtotal (95% CI) Heberogeneity: Tau ^a i Test for overall effect 2.3.2 SCTG-based pr	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.00 Mean Difference recedures vs CAF (6 5.6 5.5 = 0.00; Chi ^a = 0.00, d t z = 0.91 (P = 0.36) recedures vs CAF (3	fr= 3 () 8, dr= 9.02 9.72 7= 1 (0 more	100.0% P = 0.93) 2 (P = 0.1 Weight hts) 10.5% 9.0% 19.5% P = 0.95); films)	7.68 [2.48, 12.89] (* = 0% 160, J* = 0% Mean Difference N, Random, 95% Cl 5.60 [-12.00, 23.20] 6.50 [-12.55, 25.55] 6.62 [-6.94, 18.90] J* = 0%	Mean Difference M. Randem, 95% CI
	Heberogeneity: Not a Test for overall effect Total (95% CI) Heberogeneity: Tau ² i Test for overall effect Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Silva et al. ⁵⁶ Subtotal (95% CI) Heberogeneity: Tau ² : Test for overall effect 2.3.2 SCTG-based pr (littencourt et al. ^{40,41}	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ² = 0.08, d t z = 2.89 (P = 0.04 ferences: Chi ² = 0.0 Mean Difference recedures vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	Y = 3 () 8, dY = mont 9,02 9,72 Y = 1 (0 mon 6,58	100.0% P = 0.93) 2 (P = 0.9 Weight 10.5% 9.0% 19.5% P = 0.95) (fbs) 19.7%	7.68 [2.48, 12.89] (*= 0% 160.1* = 0% Mean Difference IV, Random, 95% CI 5.60 [-12.00, 23.20] 6.50 [-12.55, 25.55] 6.02 [-6.94, 18.90] /*= 0% 7.60 [-5.30, 20.50]	100 -50 0 50 100 CAF SCTG-based proce Mean Difference M, Randem, 95% CI
and the second sec	Heberogeneity: Not a Test for overall effect Total (95% CI) Heberogeneity: Tau ² i Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Silva et al. ⁵⁶ Subtotal (95% CI) Heberogeneity: Tau ² i Test for overall effect 2.3.2 SCTG-based pr Differcourt et al. ^{60,45} Subtotal (95% CI)	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ² = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ² = 0.00 Mean Difference recedures vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	Y = 3 () 8, dY = mont 9,02 9,72 Y = 1 (0 mor 6,58	100.0% P = 0.93) 2 (P = 0.1 Weight hs) 10.5% 9.0% 19.5% P = 0.95); mbs) 19.7% 19.7%	7.68 [2.48, 12.89] (*= 0% 160./* = 0% Mean Difference IV, Random, 95% CI 5.60 [-12.00, 23.20] 6.60 [-12.55, 25.55] 6.62 [-6.94, 18.90] /*= 0% 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50]	Mean Difference M, Random, 95% CI
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ²⁺ Test for overall effect Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ do Silva et al. ⁵⁶ Subtotal (95% CI) Heterogeneity: Tau ²⁺ Test for overall effect 2.3.2 SCTG-based pr Dittencourt et al. ^{40,45} Subtotal (95% CI) Heterogeneity: Not a Test for overall effect	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.00 Mean Difference recedures vs CAF (6 5.6 6.5 = 0.00; Chi ^a = 0.00, d t z = 0.91 (P = 0.36) recedures vs CAF (3 7.6 pplicable t z = 1.16 (P = 0.25)	f = 3 () 8, d' = <u>SE</u> 9.02 9.72 f = 1 (0 mee 6.58	100.0% P = 0.93) 2 (P = 0.1 Weight hs) 10.5% 9.0% 19.5% P = 0.95); films) 19.7% 19.7%	7.68 [2.48, 12.89] (*= 0% 160)*= 0% Mean Difference N, Random, 95% CI 5.60 [-12.00, 23.20] 6.50 [-12.55, 25.50] 6.52 [-6.94, 18.98] /*= 0% 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50]	Mean Difference M, Random, 95% CI
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ²⁺ Test for overall effect Test for subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ do Silva et al. ⁵⁶ Subtotal (95% CI) Heterogeneity: Tau ²⁺ Test for overall effect 2.3.2 SCTG-based pr Dittencourt et al. ^{40,45} Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.00 Mean Difference recedures vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	Y = 3 () 8, dY = 9,02 9,72 Y = 1 (0 more 6,58	100.0% P = 0.93) 2 (P = 0.1 Weight hs) 10.5% 9.0% 19.5% P = 0.95); films) 19.7% 19.7% softwal	7.68 [2.48, 12.89] (*= 0% 160)* = 0% Mean Difference N, Random, 95% CI 5.60 [-12.00, 23.20] 6.02 [-6.94, 18.90] (*= 0% 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50]	Mean Difference M, Random, 95% CI
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ²⁺ Test for overall effect Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ do Silva et al. ⁵⁶ Subtotal (95% CI) Heterogeneity: Tau ²⁺ Test for overall effect 2.3.2 SCTG-based pr Dittencourt et al. ^{40,45} Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁸⁰	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ^a = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ^a = 0.00 Mean Difference recedures vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	Y = 3 () 8, dY = 9,02 9,72 Y = 1 (0 more 6,58 3,74	100.0% P = 0.93) 2 (P = 0.1 Weight hts) 10.5% 9.0% 19.5% P = 0.95); (fbs) 19.7% 19.7% 19.7% 19.7%	7.68 [2.48, 12.89] (*= 0% 160.1*= 0% Mean Difference N, Random, 95% Cl 5.60 [-12.09, 23.28] 6.50 [-12.55, 25.55] 6.02 [-6.94, 10.98] *= 0% 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50] 9.60 [2.27, 16.93]	Mean Difference M, Random, 95% CI
	Heberogeneity: Not a Test for overall effect Total (95% CI) Heberogeneity: Tau ² i Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Sitha et al. ⁵⁶ Subtotal (95% CI) Heberogeneity: Tau ² i Test for overall effect 2.3.2 SCTG-based pr (littencourt et al. ^{40,45} Subtotal (95% CI) Heberogeneity: Not aj Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁴⁰	pplicable t $z = 1.16$ ($P = 0.25$) = 0.00; Chi ² = 0.08, d t $z = 2.89$ ($P = 0.04$ ferences: Chi ² = 0.0 Mean Difference toccdures vs CAF (6 5.6 5.5 = 0.00; Chi ² = 0.00, d t $z = 0.91$ ($P = 0.36$) toccdures vs CAF (3 7.6 pplicable t $z = 1.16$ ($P = 0.25$) tpocedures vs CAF (9 9.6	Y = 3 () 8, dY = 9.02 9.72 Y = 1 (0 mee 6.50 3,74	100.0% P = 0.93) 2 (P = 0.9 2 (P = 0.9 10.5% 19.5% 19.5% 19.7% 19.7% 19.7% 19.7% 50.9% 60.9%	7.68 [2.48, 12.89] (*= 0% 160,1*= 0% Mean Difference N, Random, 95% CI 5.60 [-12.08, 23.28] 6.50 [-12.55, 25.55] 6.02 [-6.94, 18.98] /*= 0% 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93]	Mean Difference M, Random, 95% CI
	Heberogeneity: Not a Test for overall effect Total (95% C) Heberogeneity: Tau ² i Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Silva et al. ⁵⁶ Subtotal (95% C) Heberogeneity: Tau ² : Test for overall effect 2.3.2 SCTG-based pr Dittencourt et al. ^{40,45} Subtotal (95% C) Heberogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁴⁰	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ² = 0.08, d t z = 2.89 (P = 0.04 ferences: Chi ² = 0.04 Mean Difference recedures vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	Y = 3 () 8, dY = 9.02 9.72 Y = 1 (0 more 6.50 3,74	100.0% P = 0.93) 2 (P = 0.9 10.5% 10.5% 19.5% 19.5% 19.7% 19.7% 19.7% 19.7% 19.7% 19.7% 19.7% 19.7%	7.68 [2.48, 12.89] (*= 0% 160.1*= 0% Mean Difference N, Random, 95% CI 5.60 [-12.00, 23.20] 6.50 [-12.55, 25.55] 6.02 [-6.94, 18.98] /*= 0% 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93]	Mean Difference M, Random, 95% CI
	Heterogeneity: Not a Test for overall effect Total (95% CI) Heterogeneity: Tau ² i Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Silva et al. ⁵⁶ Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 2.3.2 SCTG-based pr Bittencourt et al. ^{40,45} Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁴⁰ Subtotal (95% CI) Heterogeneity: Not a Test for overall effect	pplicable t z = 1.16 (P = 0.25) = 0.00; ChiP = 0.08, d t z = 2.89 (P = 0.04 ferences: ChiP = 0.04 ferences: ChiP = 0.04 ferences: ChiP = 0.04 ferences: vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	f'= 3 () 8, d'= 9.02 9.72 f= 1 (0 met 6.50 3.74	100.0% P = 0.93) 2 0P = 0.1 Weight hts) 10.5% 9.0% 19.5% 19.5% 19.7% 19.7% 19.7% 19.7% 19.7% 50.9% 60.9%	7.68 [2.48, 12.89] (*= 0% 160.1*= 0% Mean Difference N, Random, 95% CI 5.60 [-12.00, 23.20] 6.50 [-12.55, 25.55] 6.02 [-6.94, 18.90] 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93]	Mean Difference M, Random, 95% CI
	Heberogeneity: Not a Test for overall effect Total (95% CI) Heberogeneity: Tau ² i Test for subgroup di Study or Subgroup 2.3.1 SCTG-based pr Cortellini et al. ⁵⁴ da Silva et al. ⁵⁶ Subtotal (95% CI) Heberogeneity: Tau ² : Test for overall effect 2.3.2 SCTG-based pr Bittencourt et al. ^{40,45} Subtotal (95% CI) Heberogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁴⁰ Subtotal (95% CI) Heberogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁴⁰	pplicable t z = 1.16 (P = 0.25) = 0.00; ChiP = 0.08, d t z = 2.89 (P = 0.04 ferences: ChiP = 0.04 ferences: ChiP = 0.04 ferences: ChiP = 0.04 ferences: vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	fr= 3 () 8, dr= 9.02 9.72 f= 1 (0 met 6.50 3.74	100.0% P = 0.93) 2 0P = 0.1 Weight hts) 10.5% 19.5% P = 0.95); flbs) 19.7% 19.7% 19.7% 50.9% 60.9% 60.9%	7.68 [2.48, 12.89] (*= 0% 160.1*= 0% Mean Difference N, Random, 95% CI 5.60 [-12.00, 23.20] 6.50 [-12.55, 25.55] 6.02 [-6.94, 18.90] 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93]	Mean Difference M, Randem, 95% CI
	Heterogeneity: Not a Test for overall effect Total (95% C) Heterogeneity: Tau ² i Test for subgroup di Study or Subgroup di Study or Subgroup di Subtotal (95% C) Heterogeneity: Tau ² i Test for overall effect 2.3.2 SCTG-based pr Differicourt et al. ⁹⁰ Subtotal (95% C) Heterogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁹⁰ Subtotal (95% C) Heterogeneity: Not a Test for overall effect 2.3.3 SCTG-based pr Kuis et al. ⁹⁰	pplicable t z = 1.16 (P = 0.25) = 0.00; Chi ² = 0.08, d t z = 2.89 (P = 0.004 ferences: Chi ² = 0.00 Mean Difference recedures vs CAF (6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.	Y = 3 () 0, d' = 9,02 9,72 Y = 1 () 0 more 6,50 3,74	100.0% P = 0.93) 2 0P = 0.1 Weight hs) 10.5% 9.0% 19.5% 19.5% 19.7% 19.7% 19.7% 19.7% 50.9% 60.9% 50.0% 100.0% P = 0.97% 100.0%	7.68 [2.48, 12.89] (*= 0% 160.1* = 0% Mean Difference N, Random, 95% CI 5.60 [-12.00, 23.20] 6.02 [-6.94, 18.50] 7.60 [-5.30, 20.50] 7.60 [-5.30, 20.50] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93] 9.60 [2.27, 16.93]	Mean Difference M, Random, 95% CI

Figure 2.

Forest plots of random-effects meta-analysis comparing SCTG-based procedures and CAF. IV = inverse variance; M-H = M antel-Haenszel; Tau² = Kendall τ test; z = z test. **A through C)** Difference in the percentage of recession reduction (according to the different follow-up periods). **D through F)** Difference in the number of sites exhibiting CRC (according to the different follow-up periods).

soft tissue contraction in the early healing phase; and C) SCTG + CAF was associated with longer chair time and stronger perception of the surgical procedure, leading to greater postoperative discomfort.

Effect of treatment of Miller¹⁷ Class IV GRs. With respect to the outcomes achieved after the treatment of Class IV recession defects. six publications could be identified and included, but the entire base of evidence is formed exclusively by case reports¹⁴²⁻¹⁴⁶ or case series.¹⁴⁷ In total, the outcomes of 21 Class IV recessions treated by coronally positioned FGG + citric acid, 142 the association of CAF + SCTG, 143, 145 CAF + SCTG + autogenous bone graft,144 LPF,¹⁴⁶ and SCTG (envelope technique)¹⁴⁷ have been reported. The major amount of information is from the case series by Vergara and Caffesse,¹⁴⁷ who presented data on 12 defects ranging from 2 to 10 mm (mean recession reduction of 5.1 mm) within a group of patients aged >40 years. Six months after treatment, the authors reported a mean recession reduction of 3.2 mm (62.7%, range of 2 to 10 mm), but CRC was achieved only in 16% of the cases. Overall, all other publications reported partial RC and CAL gain similar to these findings,¹⁴²⁻¹⁴⁷ but they all also stated that the amount of RC could not be anticipated. In three case reports,¹⁴⁴⁻¹⁴⁶ additional restorative procedures were necessary to complete treatment and improve patients' esthetics.

Histologic Attachment and Re-Entry Assessment

The human histologic findings of GRs treated by ADMG, CM,

	SCTG-based proce	idures .	CAF			Risk Ratio	Risk Ratio
itudy or Subgroup	Events	Total	Events	Tetal	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
24.1 SCTG-based pro	ocedures vs CAF (6)	months)					NO DOED
Bittencourt et al. 40,41	13	17		17	7.5%	1.44 (0.86, 2.43)	1
Contellini et al. 54	25	42	16	43	9.5%	1.60 [1.01, 2.54]	
da Silva et al.**	2	11		11	0.4%	2.00 (0.21, 58.98)	-
Sublidial (195%, Cit.	53	127	45	128	100.05	1.10 [1.01, 1.37]	
Total events	92		25			over 1 mary scale	7.0
Heterogeneity Tau ^a -	0.00 Ch#+ 3.03 #	-20	1281/*-	1%			
Test for overall effect.	r = 2.88 (P = 0.004)		100				
Report and the second	MANDORAL STOL			-	100.00		
Total (95% CB		127	1	128	100.0%	1,23 [1,47, 1,42]	20 C
Total events	10 100 Chill 107 -		18				house and the second second
Test for subgroup diff	2 = 2.88 (P = 0.004) erences: Not applica	itie	138,7*8	278			0.05 012 4 5 20 CAF SCTG-based proce
	SC1G-based proce	dures	CN			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M.R. Random, 95% CI	M-H, Random, 95% CI
2.5.1 SCTG-based pro	ocedures vs CAF (6)	months)	4				
Corbellini et al. ⁵⁴	25	42	16	43	12.7%	1.00 [1.01, 2.54]	
da Silva et al. ¹⁶	2	11	· 3	11	0.6%	2.00 (0.21, 18.90)	
Sublictal (95% CI)	12	53		54	14.3%	1.01[1.03, 2.54]	
rosal events Heterogeneity: Tau# = Test för overall effect	27 0.00; Chi#= 0.04; df 2 = 2.00 (P= 0.04)	= 1 () ^p = 0	17	0%			
2.5.2 SCTG-based pro	ecedures vs CAF (24	months	E				
Kuis et al. ⁸⁰	51	67	38	- 57	70.2%	1.34(1.09, 1.69)	
Subtotal (95% CI)		57		57	78.2%	1,34 [1.09, 1.65]	•
Total events	51		38				
Heterogeneity: Not ap	plicable						
Test for overall effect	r = 2.83 (P = 0.005)						
2.5.3 SCTG based are	coduces in CAL IN	monther	12				
Differences of all all 40.47	LA LA	47		1.7	10.00	1 53 40 47 - 2 241	
Subtotal (95% CD		17	10	17	15.5%	1.50 (0.97, 2.34)	
Total events	15	62	10	- 10		and the second second	
Heterogeneity: Not ap	plicable		- 25				
Test for overall effect	2=1.83 (P=0.07)						
							122
Total (95% CI)	- m ₁₁ 10	127	1 5	128	100.0%	1.40 [1.18, 1.66]	•
Total (95% CI) Total events	83	127	65	128	100.0%	1.40 [1.18, 1.66]	· ·
Total (195% CI) Total events Hotorogeneity: Tau ^a = Test for overall effect. Test for subgroup diff	93 0.00, ChiP = 0.77, af 2 = 3.87 (P < 0.001) brences: ChiP = 0.64	127 = 3 (P = 0 .df = 2 (P	65 186),/*+ = 0.735./	128 0% *= 0%	100.0%	1.40 [1.18, 1.66]	A DS 8/2 CAF SCTG-based proce
Total (95% CI) Total events Historogeneity: Tau ^e = Test for overall effect. Test for subgroup diff	93 0.00, Chi ^p = 0.77, aff 2 = 3.87 (P < 0.001) Intences: Chi ^p = 0.84 SCTG based proce	127 = 3 (P = 0 .df = 2 (P educes	65 1860/** = 0.731/	128 0% *= 0%	100.0%	1.40 (1.18, 1.66) Fisk Ratio	CAF SCTG-based proce
Total (HS% CE) Total events Heterogenetity Tau* = Test for overall effect Test for subgroup diff Study or Subgroup	93 0.00, ChiP = 0.77, df 2 = 3.87 (P < 0.001) erences: ChiP = 0.64 SCTG-based proce Events	127 = 3 (P = 0 .df = 2 (P educes Total	65 186);/*+ = 0.73);/ CAI Events	128 0% *= 0% Total	100.0%	1.40 (1.18, 1.66) Risk Ratio M.H. Randers, 95% Cl	CAF SCTG-based proce Risk Ratie M-H, Randem, 55% CI
Total (195% Ct) Total events Heterogenetity: Tao# + Test for overall effect. Test for subgroup diff Study or Subgroup 2.6.1 SCTG based pro	93 0.00, ChiP = 0.77, df 2 = 3.87 (P < 0.001) brences: ChP = 0.64 SCTG-based proce Events ccedures vs CM (61	127 = 3 (P = 0 .dt = 2 (P educes Total months)	65 188()*= = 0.73)./ CAI Events	128 0% *= 0% Total	100.0%	1.40 [1.18, 1.66] Risk Ratio M.H. Randoes, 95% CI	CAF SCTG-based proce
Total (95% CI) Total events Historogeneity: Tau ² = Test for subarous diff Shudy or Subgroup 2.6.1 SCTG-based pri Cotalitini et al. ⁵⁴	93 0.00, ChP = 0.77, df 2 = 3.87 (P < 0.001) irrences: ChP = 0.64 SCTG-based proce Events occelures vs. CAP (65 25	127 = 3 (P = 0 .dt = 2 (P educes <u>Total</u> months) 42	65 186),/*= = 0.72),/ CAU Events 16	128 0% *= 0% Total 43	100.0% Weight	1.40 [1.18, 1.66] Risk Ratio M.H. Randees, 95% CI 1.60 [1.01, 2.54]	CAF SCTG-based proce Risk Ratio M-H, Random, 55% CI
Total (95% CI) Total events Heateropeneity: Tau ^p = Test for overall effect Test for overall effect Study or Subgroup 2.8.1 SCTG-based pro Continie et al. ¹⁶	93 0.00, ChiP = 0.77, df 2 = 3.87 (P < 0.001) trences: ChiP = 0.84 SCTG-based proce Events ccedures vic CMI (6) 25 2	127 = 3 (P = 0 .df = 2 (P educes Total months) 42 11	65 1882/*= = 0.732/ Events 16 1	128 0% *= 0% Total 43 11	100.0% Weight 17.5% 0.7%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% CI 1.80 [1.01, 2.54] 2.00 [0.21, 18.98]	CAF SCTG-based proce
Tetal (195% CI) Total events Hotorogeneity: Tau ² + Test for overall effect. Test for ovboroup diff Study or Subgroup 2.6.1 SCTG-based pri Contelline et al. ¹⁶ Go Silva et al. ¹⁶ Subtotal (195% CI)	83 0.00, Chil* = 0.77, df 2 = 3.87 (P < 0.001) terences: Chil* = 0.84 SCTG-based proce Events to codures vs CAV (6 25 2	127 = 3 (P = 0 . d' = 2 (P edur-es <u>Total</u> months) 42 11 53	65 1882/** = 0.738./ Events 16 1	128 0% *= 0% Total 43 11 54	100.0% Weight 17.5% 18.2%	1.40 [1.18, 1.96] Risk Ratio M.H. Random, 95% Cl 1.60 [1.01, 2.54] 1.61 [1.03, 2.54]	B 05 8 ¹ 2 CAF SCTG-based proce Risk Ratie M-H, Randsen, 95% CI
Total (95% CD) Total events Hestorogeneith: Tau? + Test for evenal effect Test for subgroup diff Shudy or Subgroup 2.6.1 SCTG-based pr Codellini et al. ⁵⁶ da Silva et al. ⁵⁶ Subdotal (95% CD) Total events	83 0.00, Chi* = 0.77, df 2 = 3.87 (P < 0.001) erences: Chi* = 0.64 SCTG-based proce Events ccedures vc. Chi (S 25 2 27	127 = 3 (P = 0 .df = 2 (P edures <u>Total</u> months) 42 11 53	65 1882/** = 0.738./ Events 16 1 17	128 0% Total 11 54	100.0% Weight 17.5% 0.7% 10.2%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% Cl 1.60 [1.01, 2.54] 1.61 [1.03, 2.54]	B 05 82 5 20 CAF SCTG-based proce Risk Ratie M.H. Randem, 95% CI
Total (195% CD) Total events restrogrammity: Tau® = Test for overall offect Test for subgroup diff Study or Subgroup 2.6.4 SCTO-based pr Codellini et al. ⁵⁶ dis Silvo et al. ⁵⁶ Subtotal (195% CD) Total events Heterogeneity: Tau® = Test for overall effect	83 0.00, Chi ^p = 0.77, df <i>z</i> = 3.67 (P < 0.001) brences: Chi ^p = 0.64 <u>SCTG based proce</u> <u>Events</u> 25 25 2 27 0.00; Chi ^p = 0.64, df <i>z</i> = 2.08 (P = 0.04)	127 = 3 (P = 0 .df = 2 (P edures <u>Total</u> months) 42 11 53 = 1 (P = 0	65 1982/*= = 0.738./ Events 16 1 17 1952./*=	128 0% Total 43 11 54 0%	100.0% Weight 17.5% 0.7% 18.2%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% CI 1.60 [1.01, 2.54] 2.00 (0.21, 18.98) 1.61 [1.03, 2.54]	B 05 82 5 20 CAF SCTG-based proce Risk Ratie M.H. Randem, 95N CI
Total (95% C) Total events Hedoropenith: Tau ² + Test for overall effect Test for subgroup 26.4 SCTG based pri Cotaline et al. ⁵⁶ do Silos et al. ⁵⁶ Subtotal (95% C) Total events Heteropenith; Tau ² + Test for overall effect 2.6.2 SCTG-based pri	93 0.00, Chil ² = 0.77, df 2 = 3.87 (P < 0.001) tencos:: Chil ² = 0.64 SCTG-based proce <u>Events</u> condures vs. CAF (S 25 2 2 2 2 0.00, Chil ² = 0.64, df 2 = 2.08 (P = 0.04) condures vs. CAF (S	127 = 3 (P = 0 .df = 2 (P edures <u>Total</u> months) 42 11 53 = 1 (P = 0) months)	65 1882/*= = 0.731/ Events 16 1 17 1.852/*=	128 0% Total 43 11 54 0%	100.0% Weight 17.5% 0.7% 10.2%	1.40 [1.18, 1.66] Risk Ratio M.H. Randon, 95% CI 1.60 [1.01, 2.54] 2.00 (9.21, 18.98) 1.61 [1.03, 2.54]	B 05 82 5 20 CAF SCTG-based proce Risk Ratie M-H, Randem, 55% CI
Total (95% CI) Total events Heterogeneity: Tau ² + Test for overall effect Test for overall effect Study or Subgroup 2.6.1 SCTG-based pri Contelline et al. ⁵⁶ Subtetal (95% CI) Total events Heterogeneity: Tau ² o Test for overall effect 2.6.2 SCTG-based pri Bittencourt et al. ^{40,er}	83 0.00, Chil* 0.77, df 2 3.87 (P < 0.001) trences: Chil* 0.64 SCTG-based proce Development 25 2 2 2 0.00; Chil* 0.64, df 2 2 0.00; Chil* 0.64, df 2 2 2.00 (P = 0.04) 5 5	127 = 3 (P = 0 off = 2 (P oduries Total months) 42 11 53 = 1 (P = 0 0 sconths) 17	85 1882/*= = 0.731/ CAU Events 16 1 17 1.852/*= 10	128 0% Total 43 11 54 0%	198.0% Weight 17.5% 18.2%	1.40 [1.18, 1.96] Risk Ratio M.H. Random, 95% Cl 1.60 [0.07, 21, 18.98] 1.61 [1.03, 2.54] 1.61 [1.03, 2.54]	B 05 8 ¹ 2 CAF SCTG-based proce Risk Ratie M-H, Randsen, 95% CI
Total (95% CI) Total events Hestorogeneth: Tau? + Test for evenal effect Test for evenal effect Contains et al. ⁵⁶ Contains et al. ⁵⁶ Contains et al. ⁵⁶ Contains et al. ⁵⁶ Subtotal (95% CI) Total events Heterogeneth; Tau? + Test Stor evenal effect 2.8.2 SCTG-based prin Subtotal (95% CI)	83 0.00, Chil* 0.77, df 2 = 3.87 (P < 0.001) erences: Chil* 0.64 SCIG-based proct- Events ccedures vs CM (6) 25 27 0.00; Chil* 0.64, df 2 = 2.08 (P + 0.04) 55 1000 Chil* 0.04, df 1000 Chil* 0.04 (30) 1000 C	127 = 3 (P = 0 . df = 2 (P edures <u>Total</u> months) 42 11 53 = 1 (P = 0 0 months) 17 17	85 1882/*= = 0.735/ CAJ Events 16 1 1052/*= 10	128 0% Total 43 11 54 0%	198.0% Weight 17.5% 0.7% 18.2%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% Cl 1.80 [1.01, 2.54] 2.00 [0.21, 18.98] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31]	B 05 02 5 20 CAF SCTG-based proof Bisk Ratio M-H, Random, 55% CI
Total (195% CD) Total events Hederogeneith: Tau [®] + Test for evenal effect Test for subgroup 2.6.4 SCTG-based pri Codatini et al. ⁵⁶ dis Sibas et al. ⁵⁶ Statestal (195% CD) Total events Hederogeneith: Tau [®] + Test for overall effect 2.6.2 SCTG-based pri Bithencourt et al. ^{40,47} Subtotal (195% CD) Total events	83 0.00, Chi ⁴ = 0.17, df 2 = 3.67 (P < 0.001) brences: Chi ² = 0.64 SCTG-based proce Events 25 2 2 0.00; Chi ² = 0.64, df 2 = 2.00 (P = 0.04) ccodures vs. CAF (N 15 15	127 = 3 (P = 0 , df = 2 (P edures <u>Total</u> months) 42 11 53 = 1 (P = 0) months) 53 = 1 (P = 0) months) 17 17	85 1882/*= = 0.735/ CAJ Events 16 1 10 10 10 10	128 *= 0% Total 43 11 54 0%	198.0% Weight 17.5% 18.2% 19.7%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% CI 1.60 [1.01, 2.54] 2.00 [0.21, 18, 90] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	B 05 82 5 20 CAF SCTG-based proce Risk Ratie M.H. Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau ² + Test for evenal effect Test for evenal effect Study or Subgroup 2.6.1 SCTG based pri Contelline et al. ⁵⁶ costelline et al. ⁵⁶ costelline et al. ⁵⁶ Subtetal (95% CI) Total events Heterogeneity: Tau ² e Test for evenal effect Stotat events Bittencourt et al. ^{40,ers} Subtetal effect.	83 0.00, Chil [™] = 0.77, at <i>y</i> = 3.87 (<i>p</i> [®] < 0.001) terences:: Chil [®] = 0.84 SCTG-based proce <u>Eventures vs</u> CAF (55 25 27 0.00; Chi [™] = 0.64, at <i>y</i> = 2.00 (<i>p</i> [®] = 0.04) 15 15 15 15 15 15	127 = 3 (P = 0 .df = 2 (P indures <u>Total</u> months) 42 11 53 = 1 (P = 0) esonths) 17 17	65 1862/** = 0.735./ Dvents 16 1 17 1852/** 10 10 10	128 *= 0% Total 43 11 54 0% 17 17	198.0% Weight 17.5% 0.7% 18.2% 18.2%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% Cl 1.60 [0.07, 21.98] 1.61 [1.03, 2.54] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31]	B 05 8 ¹ 2 5 20 CAF SCTG-based proce Bisk Ratie M-H, Random, 95% CI
Testal (195% CD) Total events Heterogeneith: Tau® + Test for evenal effect Test for evenal effect Contains et al. ⁵⁶ do Silva et al. ⁵⁶ do Silva et al. ⁵⁶ do Silva et al. ⁵⁶ Subtotal (195% CD) Total events Heterogeneith: Tau® et Subtotal (195% CD) Total events Heterogeneith: Not ap Test for evental effect 2.8.3 SCTG-based prin Test for overall effect	83 0.00, Chil* 0.77, df 2 = 3.87 (P < 0.001) terences: Chil* 0.64 SCTG-based proce- Events codures vs CM (6) 25 27 0.00, Chil* 0.04, df 2 × 2.08 (P* + 0.04) occedures vs CMF (3) 15 pticable 2 = 1.83 (P = 0.07) occedures vs CAF (40)	127 = 3 (P = 0 off = 2 (P reduces <u>Total</u> months) 42 53 = 1 (P = 0 1 months) 17 17 10 10 10 10 10 10 10 10 10 10	65 1862/*= = 0.726/ CAF 10 18 17 1.052/*= 10 10	128 0% Total 43 11 54 0%	198.0% Weight 17.5% 18.2% 18.2%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% Cl 1.60 [1.01, 2.54] 2.00 [0.21, 18.98] 1.61 [1.03, 2.54] 1.60 [0.97, 2.31] 1.50 [0.97, 2.31]	B 05 02 5 20 CAF SCTG-based proce Bisk Ratie M.H. Random, 55% CI
Total (95% CD) Total events Heaterogeneith: Tau? + Test for evenal effect Test for evenal effect Test for subgroup 2.6.1 SCT6-based pri- Codalini et al. ⁵⁶ Sabtotal (95% CD) Total events Heterogeneith: Tau? + Test for events Heterogeneith: SCD Total events Heterogeneith: Not ap Total revents Heterogeneith: Not ap Total events Heterogeneith: Not ap Total for events Heterogeneith: Not ap Total events Heterogeneith: Not ap	83 0.00, Chi* = 0.77, df 2 = 3.87 (P < 0.001) trences: Chi* = 0.64 SCIG based proce 25 27 0.00; Chi* = 0.64, df 2 = 2.00 (P = 0.04) ocedures vs CAF (M 15 15 pticable 2 = 1.83 (P = 0.07) ocedures vs CAF (M 47	127 = 3 (P = 0 .df = 2 (P odures <u>Total</u> months) 42 11 53 = 1 (P = 0 0 esonths) 17 17 17 57	65 1862/** = 6.73h/ CAU Events 16 1 1 10 10 10 10	128 0% Total 43 11 54 0%	100.0% Weight 17.5% 0.7% 18.2% 19.7% 19.7%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% CI 1.60 [0.07, 2.54] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	B DS B2 5 20 CAF SCTG-based proce Risk Ratie M.H. Randem, SSN CI
Total (95% CI) Total events Heteropanelly, Tau ⁹ + Test for overall effect. Test for overall effect. Test for overall effect. Study or Subgroup 2.6.1 SCTG hased pri Cotaline et al. ¹⁶ Subtotal (95% CI) Total events Heteropanelly, Tau ⁹ + Test for overall effect. 2.6.2 SCTG-based pri Natheropanelly, Not ap Test for overall effect. 2.6.3 SCTG-based pri Natheropanelly. Not ap Test for overall effect. 2.6.3 SCTG-based pri Natheropanelly. Not ap	53 0.00, ChiP = 0.77, df 2 = 3,87 (P < 0.001) tences:: ChiP = 0.84 5CTG based proce 25 2 27 0.00; ChiP = 0.64, df 2 = 2.00 (P = 0.04) 5 000; ChiP = 0.64, df 15 15 15 01; 15 15 01; 15 01; 15 15 01; 15 15 01; 15 15 01; 15 15 01; 15 15 15 01; 15 15 15 15 15 15 15 15 15 15 15 15 15	127 = 3 (P = 0 .df = 2 (P edures <u>Total</u> months) 42 11 53 = 1 (P = 0 0 months) 17 17 17 17	65 1882/** = 6.773// 18 1 1 10 10 10 10 10 10	128 7*= 0% 7*= 0% 43 11 54 55 17 17 17 57	100.0% Weight 17.5% 19.2% 19.2% 19.7% 82.1%	1.40 [1.18, 1.96] Risk Ratio M.R. Randon, 95% CI 1.60 [0.07, 2.54] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	B 05 82 5 20 CAF SCTG-based proce Bisk Ratie M.H. Random, 55% CI
Total (95% CD) Total events Heterogeneity: Tau ² + Test for evenal effect Test for evenal effect Continue et al. ¹⁶⁴ Subtetal (95% CD) Total events Heterogeneity: Tau ² of Subtetal (95% CD) Total servers Heterogeneity: Total ap Total (95% CD) Total servers Heterogeneity: Not ap Test for evental effect 2.6.3 SCTG-based per Kais et al. ¹⁰⁵ Subtetal (95% CD) Total events	83 0.00, Chil* 0.77, df 2 3.87 (P < 0.001) trences: Chil* 0.044 SCTG-based proce 25 27 0.00; Chil* 0.04, df 2 2 200 (P = 0.04) scedures vs CAF (St 15 15 15 15 15 15 15 15 15 15	127 = 3 (P = 0 off = 2 (P edures Total months) 42 15 53 = 1 (P = 0 1 months) 17 17 17 17 17 57 57	85 1802/*= CAW Touris 18 1 1 1 10 10 10 10 10 10 10 10 10 10 10	128 7************************************	100.0% Weight 17.5% 18.2% 19.7% 19.7%	1.40 [1.18, 1.06] Risk Ratio M.H. Random, 95% CI 1.60 [0.07, 21, 18.98] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	Risk Ratie
Total (95% CD) Total events Test for events offect Test for evenal offect Test for subgroup diff Study or Subgroup 2.6.1 SCTG-based pro Contains et al. ⁵⁶ Subtotal (95% CD) Total events Neterogeneity: Tau" # Test for evenal effect 2.6.2 SCTG-based pro Subtotal (95% CD) Total events Heterogeneity: Not ap Test for overail effect 2.6.3 SCTG-based pro Kuis et al. ⁵⁰ Subtotal (95% CD) Total events Neterogeneity: Not ap Test for overail effect	83 0.00, Chil* 0.77, df 2 = 3.87 (P < 0.001) trences: Chil* 0.64, SCT6-based proce- Events ccedures of CMI (6) 25 27 0.00; Chil* 0.04, df 2 = 2.08 (P + 0.04) ocedures vs CAF (8) 15 officiatie 2 = 1.83 (P = 0.07) ecedures vs CAF (8) 47 47 plicable 2 = 2.59 (P + 0.010)	127 = 3 (P = 0 .df = 2 (P totares <u>Totat</u> months) 42 153 = 1 (P = 0 1 months) 17 17 57	85 1882/*= = 0.73k/ CAM 10 10 10 10 10 10 10 10 10 10 10 10 10	128 0% Total 43 11 54 0% 17 17 57 57	102.0% Weight 17.5% 19.7% 19.7% 19.7%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% Cl 1.60 [1.01, 2.54] 2.00 [0.21, 18.98] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.38 [1.08, 1.77]	B 05 B2 5 20 CAF SCTG-based proof Bisk Ratio M.H, Random, 55% CI
Total (95% CI) Total events Hotoropanelly, Tau ⁹ + Test for overall effect. Test for overall effect. Test for overall effect. Shady or Subgroup 2.6.1 SCTG based pri Cotalini et al. ⁵⁶ Galdeni et al. ⁵⁶ Subtotal (95% CI) Total events Hotoropanelly, Tau ⁹ + Test for overall effect. 2.6.2 SCTG-based pri Bithercourt et al. ^{40,er} Subtotal (95% CI) Test for overall effect. 2.6.3 SCTG-based pri Subtotal (95% CI) Total events Hotoropanelly. Not ap Test for overall effect. 2.6.3 SCTG-based pri Subtotal (95% CI) Total events Hotoropanelly. Not ap Test for overall effect. Total (95% CI)	53 0.00, CMP = 0.77, at 2 = 3.87 (P < 0.001) trences: CMP = 0.64 SCTG based proce Events 25 27 0.00, CMP = 0.04, at 2 = 2.00 (P = 0.04) conduces vs CMF (M 15 15 pticable 2 = 1.83 (P = 0.07) ocedures vs CAF (M 47 47 pticable 2 = 2.59 (P = 0.010)	127 = 3 (P = 0 .df = 2 (P odurves Total months) 42 11 53 = 1 (P = 0 0 months) 17 17 17 17 0 months) 57	65 1882/*= = 0.731/ CAM 10 10 10 10 10 10 10 10 10 10 10 10 10	128 7 = 0% 7 otal 43 11 54 0% 17 17 57 57 57	100.0% Weight 17.5% 18.2% 19.7% 19.7% 19.7%	1.40 [1.18, 1.06] Risk Ratio M.R. Random, 95% CJ 1.60 [0.07, 2.54] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	B 05 82 5 20 CAF SCTG-based proce Bisk Ratie MH, Random, 55% CI
Total (95% CI) Total events Hotorogeneity: Tau? + Test for evenal effect Test for evenal effect Contains et al. ¹⁶ do Silva et al. ¹⁶ do Silva et al. ¹⁶ do Silva et al. ¹⁶ Subtotal (95% CI) Total events Hotorogeneity: Tau? + Test for evenal effect Distorements Not ap Test for evenal effect Distorageneity: Not ap Test for events Hotorogeneity: Not ap Test for events	33 0.00, CMP = 0.77, at 2 = 3.87 (P < 0.001) trences: ChP = 0.84 SCTG based proce 125 2 2 2 2 2 2 2 3 7 0.00, CMP = 0.64, at 2 = 2.00 (P = 0.04) 15 15 15 pticable 2 = 1.83 (P = 0.07) ecodures vs CAF (M 47 47 pticable 2 = 2.59 (P = 0.010) 8	127 = 3 (P = 0 .df = 2 (P edures <u>Total</u> months) 42 53 = 1 (P = 0 1 months) 17 17 17 17 1 2 months) 57 57 57	85 1882/*= CAW Towns: 18 17 10 10 10 10 10 10 10 10 10 10 10 10 10	128 *= 0% Total 43 11 54 0% 17 17 57 128	100.0% Weight 17.5% 10.7% 10.7% 10.7% 10.7% 102.1%	1.40 [1.18, 1.66] Risk Ratio M.H. Random, 95% CI 1.60 [0.07, 2.84] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	B 05 8 ¹ 2 5 20 CAF SCTG-based proce Bisk Ratio M-H, Random, 95% CI
Total (195% CI) Total events Hotorogeneth: Tau® + Test for overall effect Test for overall effect Test for subgroup 2.6.1 SCTG-based pri Contains et al. ¹⁶ do Silva et al. ¹⁶ Sabtotal (195% CI) Total events Heterogeneth: Tau® + Sabtotal (195% CI) Total events Heterogeneth: Not ap Test for overall effect 2.6.3 SCTG-based pri Note et al. ¹⁰⁵ Sabtotal (195% CI) Total events Heterogeneth: Not ap Test for overall effect Total events Heterogeneth: Not ap Test for overall effect Total events Heterogeneth: Not ap Test for overall effect Test events Heterogeneth: Not ap Test for overall effect Test (195% CI) Total events Heterogeneth: Not ap	83 0.00, Chil* 0.77, df 2 = 3.87 (P < 0.001) terences: Chil* 0.044 SCTG-based proce- Events codures vs CAF (80 2 2 27 0.00, Chil* 0.04, df 2 = 2.00 (P = 0.04) 05 pticable 2 = 1.83 (P = 0.01) ocedures vs CAF (80 47 47 pticable 2 = 2.59 (P = 0.010) 88 0.00, Chil* = 0.45, df	127 = 3 (P = 0 .df = 2 (P edures <u>Total</u> months) 42 53 = 1 (P = 0 1 months) 17 17 17 17 17 17 17 17 127 12	85 1882,**= 6728,/ 188 17 1852,**= 10 10 10 10 10 10 10 10 10 10 10 10 10	128 *= 0% Total 43 11 54 0% 17 17 57 57 128 0%	100.0% Weight 17.5% 19.2% 19.2% 19.2% 19.2% 10.2%	1.40 [1.18, 1.06] Risk Ratio M.H. Random, 95% CI 1.60 [1.01, 2.54] 2.00 (0.27, 18.90] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	B D5 B ² CAF SCTG-based proce Risk Ratie M-H, Random, 95% CI
Total (195% CD) Total events Test for events offect Test for evenal offect Test for subgroup diff Shady or Subgroup 2.6.1 SCTG-based pro Contains et al. ⁵⁶ da Silva et al. ⁵⁶ da Silva et al. ⁵⁶ Subtotal (95% CD) Total events Subtotal (195% CD) Total events Test for events Heterogeneity: Not ap Test for events Heterogeneity: Test ap	83 0.00, Chil* 0.77, df 2 = 3.87 (P < 0.001) terences: Chil* 0.64, SCT6-based process Eccedures of CMI (6) 25 27 0.00; Chil* 0.04, df 2 = 2.08 (P* 0.04) 000; Chil* 0.04, df 15 opticable 2 = 1.83 (P = 0.07) eccedures vs. CAF (6) 47 47 opticable 2 = 2.59 (P = 0.010) 86 0.00; Chil* 0.45, df 2 = 3.74 (P < 0.001)	127 = 3 (P = 0 .df = 2 (P induces Total months) 41 53 = 1 (P = 0 0 essenths) 17 17 17 57 0 essenths; 57 127 = 3 (P = 0	85 1882/*= CAN 16 1 10 10 10 10 10 10 10 10 10 10 10 10 1	128 *= 0% Total 41 54 0% 57 57 128 0%	100.0% Weight 12.5% 15.7% 15.7% 15.7% 100.0%	1.40 [1.18, 1.06] Risk Ratio M.R. Random, 95% CJ 1.60 [0.07, 2.54] 1.61 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [1.08, 1.77] 1.38 [1.08, 1.77]	B 05 82 CAF SCTG-based prov
Total (95% C) Total events instorogeneity: Tau ⁹ + Test for overall effect. Test for overall effect. Test for overall effect. Cotallini et al. ¹⁶ Cotallini et al. ¹⁶ Cotallini et al. ¹⁶ Subtotal (95% C) Total events instorogeneity: Tau ⁹ + Test for overall effect. 26.3 STG-based priv Subtotal (95% C) Total events instorogeneity: Not ap Test for overall effect. 26.3 STG-based priv Subtotal (95% C) Total events instorogeneity: Not ap Test for overall effect. Test for overall effect. Test (95% C) Total events instorogeneity: Not ap Test for overall effect. Test for overall effect.	33 0.00, CMP = 0.77, at 2 = 3.87 (P < 0.70) 1 = 0.64 SCTG-based proce Events 25 2 27 0.00, CMP = 0.64, at 2 = 2.00 (P = 0.04) scedures vs CAF (30 15 15 pticable 2 = 1.83 (P = 0.07) ecedures vs CAF (40 47 47 pticable 2 = 2.59 (P = 0.010) 80 0.00, CMP = 0.45, at 2 = 3.74 (P < 0.001) 80 0.00, CMP = 0.45, at 2 = 3.74 (P < 0.001) 10	127 = 3 (P = 0 .df = 2 (P redures Total months) 42 13 53 = 1 (P = 0 0 months) 17 17 17 0 months) 57 57 127 57 57 57 57	85 1882/*= = 8.731/* CAM 10 10 10 10 10 10 10 10 10 10 10 10 10 1	128 *= 0% Total 43 154 0% 17 17 57 57 128 0% *= 0%	100.0% Weight 17.5% 18.2% 19.7% 19.7% 102.1%	1.40 [1.18, 1.06] Risk Ratio M.R. Randors, 95% CI 1.60 [0.07, 2.54] 1.01 [1.03, 2.54] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31] 1.50 [0.97, 2.31]	B 05 02 CAF SCTG-based proce

When GTR with non-resorbable membranes (non-RS) is performed, new CT attachment with newly formed cementum and crestal bone may be formed at least 180 days after treatment.155,156 Conversely, the use of GTR with RS has shown contrasting results. Whereas Harris¹⁶¹ described the formation of a long junctional epithelium without regeneration of periodontal tissues, Vicenzi et al.¹⁵¹ showed that the use of RS can promote periodontal regeneration by forming "a coronal area of CT attachment and an apical area of bone fibers and cementum." Regarding reentry assessments, data on 11 GRs treated with RS showed a mean gain of 2.0 mm (range of 1.5 to 2.5 mm) or \approx 44% of the mean baseline CAL.¹⁶⁴ For non-RS, 3.1 mm of newly formed tissue over the root surfaces could be seen (i.e., 57.7% of the baseline mean recession depth).¹⁰⁷

Despite not being published in an English-language journal, a PhD thesis by Chambrone¹⁵⁷ assessed the histologic healing of six molar teeth presenting GR (to the apex of the mesial root) treated with LPF. Three months after surgery, long junctional epithelium and CT attachment with collagen fibers running parallel to the root surface covering the major part of the root surface were found. Sharpey fibers inserted into new cellular cementum could also be found in the most apical area of the previously exposed root surface (close to the original periodontal ligament [PDL]). Regarding the use of CAF alone, Cummings

EMD, FGG, GTR, LPF, SCTG, and growth factors have been described by a group of case publications.^{51,93,148-163} These are mainly derived from teeth already scheduled for extraction for orthodontic,^{51,93,148-156} periodontal,^{157,158} or prosthetic reasons.¹⁵⁹⁻¹⁶² et al.¹⁶³ also described the presence of a long junctional epithelium with the underlying gingival CT presenting collagen fibers in a parallel arrangement with the root 6 months after surgery. For the treatment of deep recessions with thick FGGs, it has been reported that a long junctional epithelium,

as well as the development of new CT attachment, new cementum with perpendicular inserting CT fibers (deposited on old cementum), and new bone growth, may occur at deep portions of the previously denuded root surfaces.¹⁴⁸

Some authors described different types of attachment after the use of SCTGs. Histologic data retrieved ≥ 5 months after surgery showed the following: 1) some degree of periodontal regeneration at the base of the recession defect (i.e., formation of new bone, 149,153,159,163 cementum, 149,150,153,159,163 and PDL;^{149,159}) and 2) major portions of the root covered by CT attachment (mostly parallel to the root surface)^{149,150,153,154,158-160,163} and/or long junctional epithelium.^{149,153,154,158-160} It has also been suggested that the formation of new attachment may be associated with the use of SCTGs, including the palatal periosteum, and its potential "barrier effect" when the graft is placed with periosteum facing the root surface.¹⁵⁰ A similar assumption was already proposed by another case report.¹⁵⁹ Histologic evidence of RC above the original free gingival margin was found associated with the use of SCTG.¹⁵⁸

Regarding the use of CM, histologic and microcomputed tomography analysis showed the formation of a long junctional epithelium attachment and CT adhesion without areas of regeneration 120 days after surgery.¹⁵² For ADMG,¹⁶³ there was an evident disposition of dense collagen arranged parallel to the root surface, the presence of some CT fibers inserted perpendicularly into the root surface (in 25% of the sample), and some bone/cement apposition (in 50% of the sample). Harris¹⁶⁵ used 2-mm punch biopsies removed from interproximal areas (including soft tissue only) of GRs treated with ADMG and SCTG and showed that both grafts were incorporated by the tissues into the surgical sites and presented similar structures (i.e., cellular components) 3 to 7 months after surgery, respectively, but elastin fibers may also be present at ADMG sites.

Additionally, the healing response of biologic mediators associated with CAF procedures was evaluated as well. Histologic evaluation of CAF + EMD indicates the formation of new cementum, organizing PDL fiber running parallel between cementum and areas of condensing bone.^{51,158} When an SCTG was added to the CAF + EMD procedure, a longer junctional epithelium (\approx 1.2 mm) and a zone of CT with fibers running parallel to the root surface could be seen at the coronal half of the recession defect, whereas partial regeneration of periodontal supporting tissues was observed at the apical half of the recession area.¹⁶²

Likewise, it has been found that the treatment of GR with CAF + collagen dressing saturated with recombinantly produced PDGF-BB placed on β -tricalcium phosphate (β -TCP) and collagen wound dressing matrices can promote alveolar bone, cellular cementum, and PDL (inserted into bone and cementum) regeneration.^{93,154}

Recipient- and Donor-Site Anatomic and Surgical Characteristics

The importance of flap thickness was studied in a case series of 19 patients treated by CAF, in which it was suggested that flap thickness >0.8 mm is associated with the achievement of CRC of shallow GRs.¹⁶⁶ Berlucchi et al.¹⁶⁷ found that the baseline recession depth and flap thickness were associated with the degree of success achieved by EMD + CAF. It was shown that 19 patients presenting recession depth <4 mm achieved significant (P =0.009) MRC of 94.7% (CRC = 89.5%) when compared with 11 patients with recession depth ≥ 4 mm, which reached 85.8% MRC (CRC = 36.4%). Also, this study demonstrated that the higher the distance between the cemento-enamel junction (CEJ) and bone crest and the thinner the flap thickness (≤ 1 mm for $GR \ge 4$ mm), the smaller the chance of achieving CRC at 12-month follow-up. Another prospective study containing 21 Class I GRs submitted to CAF found that an initial gingival thickness (GT) >1.1 mm was related to 100% RC 6 months after treatment.¹⁶⁸ An RCT on CAF (not included in part II because of its 3-month follow-up period) showed that the higher the flap tension, the lower the recession reduction (i.e., flap tension of 6.5 g led to 78% MRC and 18% CRC, whereas flaps sutured almost without flap tension [0.4 g] achieved 87% MRC and 45% CRC).¹⁶⁹ Moreover, comparisons between conventional CAF versus semilunar-design CAF showed that these procedures may reach MRC ranging from 57.8%³⁶ to 93.0%⁵⁹ and CRC ranging from 9.0%⁵⁶ to 78.9%⁸⁰ and MRC varying from 41.8%¹¹² to 90.0%⁴⁰ and CRC varying from 9.0%¹¹² to 52.9%⁴⁰ 6 months after surgery, respectively.

The practice-based study by Pini Prato et al.¹⁷⁰ reported that, among a group of 60 patients, each with one localized Class I recession treated with CAF, 33 (55%) presented with hypersensitivity, and of them, in 11 (33.3% of those with hypersensitivity or 18.3% of the total number of patients) this condition was still present at the 6-month follow-up. Besides sites in which the gingival margin was sutured at the level of the CEJ that did not reach 100% coverage at the final evaluation, other factors, such as baseline recession depth (i.e., deeper defects) and the amount of flap displacement over the CEJ (i.e., greater coronal displacements), were allied with greater recession decrease.¹⁷⁰ Authors of the same Italian research group¹⁷¹ using a Bayesian network analysis with data from the same GRs found that the accomplishment of CRC may be prejudiced by the post-surgical position of the gingival margin (the more apical the gingival margin after surgery, the smaller the chance of CRC) and, secondarily, by the baseline recession depth (i.e., deeper defects were associated with a more apical location of the gingival margin after surgery). In addition, the influence of baseline recession outcomes are in line with data from the individual patient data meta-analysis of 602 Miller Class I and II recession defects described by Chambrone et al.,⁷ who showed that the greater the baseline recession depth, the smaller the chance of achieving CRC.

Some specific factors related to SCTGs have also been studied, such as the cellular composition of these grafts, the use of grafts with epithelial collar, the maximum graft dimensions that could be safely taken from the palatal vault, clinical predictability of teeth treated with grafts removed from a donor area used previously (i.e., removed from the same donor site at different time periods), and change in tissue thickness (i.e., biotype change) after treatment. For instance, in the case series by Harris,¹⁷² trimmed samples of 30 SCTGs removed from the palate with the parallel incision method (using a scalpel with parallel blades designed by the author) were histologically assessed. It could be found that epithelium remained in 80% of the specimens and that two thirds of the graft were composed of the lamina propria and one third by submucosa. Despite these features, it was reported that all grafts (placed in 28 localized and two multiple GRs) functioned well clinically.¹⁷²

Two studies have compared the outcomes of SCTGs with or without an epithelial collar. In the study by Bouchard et al.,44 a mean GR decrease of 2.9 mm for both types of grafts (P > 0.05) and a significant gain of KT for grafts with an epithelial collar (comparison between groups, P < 0.005) were reported. Similarly, Byun et al.⁴⁷ did not find significant differences between groups in terms of MRC, CRC, or KT gain. Regarding the maximum available tissue graft obtained from the palatal vault, Monnet-Corti et al.,¹⁷³ after examining 198 maxillary plaster models of periodontally healthy individuals using a Boley gauge, reported a mean length of the harvesting area of 31.7 mm (31.1 mm [range of 24 to 45 mm] for females and 33.0 mm [range of 26 to 46 mm] for males) and a mean height ranging from 12.1 mm (midpalatal aspect of the canine) to 16.2 mm (interproximal palatal area between the second premolar and the first molar). The authors considered that the palatal vault has adequate dimensions to allow safe and adequate SCTG removal.¹⁷³

Another practice-based case series¹⁷⁴ described the clinical outcomes of SCTGs removed from the

same donor site at different times from 60 consecutively treated patients. A total of 176 GR defects were evaluated (85 were treated by the first graft removed and 91 by the second), and both groups presented similar clinical improvements in recession depth, CAL, and KT.¹⁷⁴ The MRC obtained with the second SCTG (98.2%) was statistically significantly better than with the first (95.4%). but no additional donor-site postoperative problems were observed related to the second graft than those related to the first.¹⁷⁴ The authors also described that a minimum timeframe of 2 months seems to be enough to allow tissue restructuring between the removal of first and the second grafts.¹⁷⁴ Concerning the change in tissue thickness after various procedures, a mean increase of 0.45 mm^{41,56} was described when SCTGs of 1.0-41 to 1.3-mm⁵⁶ thickness were combined with CAF. For CAF alone, there were no changes in the periodontal biotype.^{41,56}

In addition, no significant differences were observed whether the SCTG was obtained via conventional graft harvesting techniques (e.g., trap door, parallel incision method) or by epithelialized gingival graft harvesting technique (i.e., deepithelialized FGG) in terms of SCTG dimensions, postoperative pain, or bleeding.¹³⁰ Conversely, conventional harvesting techniques were associated with increased surgical chair time and better outcomes on "postoperative inability to chew- and stress-related visual analog scale values."¹³⁰

Smoking-Related Outcomes

In addition to the data reported by the included SR² that compared the clinical outcomes of smokers and non-smokers, additional information on the role of tobacco smoking on the short- and long-term clinical parameters, gingival crevicular fluid (GCF) markers, graft vascularization, and comparisons between different procedures among smokers could be retrieved from three recent studies¹⁷⁵⁻¹⁷⁷ and one paper assessed previously.¹⁷⁸

The long-term stability of GRs treated with SCTG + CAF was assessed within a sample of 30 nonsmoking and 25 smoking patients followed for 36 months.¹⁷⁵ At the 12-month evaluation, the authors reported MRC of 92.6% for non-smokers and 89.0% for smokers; however, after 36 months, these rates decreased to 81.5% and 68%, respectively (P < 0.05). For CRC, a similar pattern of recession increase was equally observed at 12 and 36 months for both smokers (62.1% and 12.5%, respectively) and non-smokers (72.5% and 42.5%, respectively). It could be also observed that smoking patients testing positive for interleukin-1 gene polymorphism were at an increased risk of periodontal breakdown after RC procedures.¹⁷⁵ Regarding the influence of smoking and GCF markers on CAF results, Kaval et al.,¹⁷⁶ after treating 30 patients (15 smokers and 15 non-smokers, each group composed of 18 GRs) separated according to the baseline cotinine levels, did not detect significant differences between these patients in terms of clinical variables or biochemical content in GCF markers 6 months after surgery. Conversely, GRs with GT \geq 0.95 mm were 100% covered in non-smokers, whereas for some smokers it did not happen.¹⁷⁶

The unique RCT available in the literature tested the association of EMD + ADMG + CAF versus ADMG + CAF in a group of 19 heavy smokers (\geq 10 cigarettes/d >5 years) with bilateral Miller Class I or II GRs of \geq 3 mm depth.¹⁷⁷ After a 6month follow-up period, it could be found that both groups benefited from these therapies, but defects also treated with EMD presented better clinical outcomes.¹⁷⁷

A final important characteristic not evaluated by the smoking SR^2 but reported by a previous study¹⁷⁸ relates to the histologic and histomorphometric assessment of SCTGs. Trimmed specimens from 30 grafts (half from smokers) used to treat localized GRs showed that donor sites of smokers present less vascularization (i.e., blood vessels) than the palatal vault of non-smokers.¹⁷⁸

Furthermore, updated meta-analyses including the data from recent studies^{175,176} in addition to those used originially^{2,170,178-181} showed that nonsmokers may be benefiting from an additional mean coverage of 17.49% (P = 0.01; $l^2 = 74\%$) and a superior number of sites achieving CRC (RR = 0.36; P = 0.04; $\hat{P} = 61\%$) when compared with smokers when SCTG was the treatment of choice (Fig. 3). The significant heterogeneity (P) found for these comparisons was directly associated with the data of the late study,175 because the original analysis reported 0% of heterogeneity.² Also, based on the significant difference of sites with CRC, the RD and NNT calculated were -0.35 (95% CI = -0.50 to -0.20; P < 0.001) and 3, respectively. For CAF, the lack of significance between groups in terms of sites exhibiting CRC (RR = 0.87; 95% CI= 0.50 to 1.51; $P = 0.62; l^2 = 42\%$ and MRC (-8.87%; 95% CI = -21.65 to 3.91; P = 0.07; $l^2 = 62\%$) remained at 6 months after surgery (see supplementary Fig. 13 in online Journal of Periodontology).

Root Surface Conditioning

Three RCTs¹⁸²⁻¹⁸⁶ that investigated the role of combined restorative–surgical approaches in the treatment of GR associated with NCCLs and their detailed outcomes have been explored by a recent publication in *Clinical Advances in Periodontics*.¹⁸⁷ In this best-evidence topic paper, these trials as-

sessed the combination of restorative procedures + CAF¹⁸²⁻¹⁸⁴ or SCTG + CAF^{185,186} procedures. Two of them reported not only short-term outcomes (6 months) but long-term results (24 months) as well.¹⁸³⁻¹⁸⁶ Overall, the included studies showed that both procedures provided significant recession reduction and CAL gain, independently of whether the NCCL was restored or not (i.e., combined restorative–surgical approaches were as safe, predictable, and effective as the single use of the surgical procedures).¹⁸²⁻¹⁸⁷ None of these included RCTs have evaluated the esthetic outcomes by a standardized scale.¹⁸²⁻¹⁸⁶

With respect to the long-term stability of results achieved with RC procedures, there was an increase in recession depth between short- and long-term assessments for GRs treated with CAF (independently of whether cervical lesions were restored or not).^{183,184} Although not significant and ranging from 65% to 67% MRC, recession recurrence was doubled when CAF was used alone.^{183,184} For SCTGs, restored and nonrestored cervical lesions were equally favored by soft tissue RC as expressed by a minimum MRC of 90% after 24 months, but half of the sites presenting 100% coverage at the 6-month evaluation were no longer completely covered by soft tissue.^{185,186} Regarding color alterations of the restorative materials, seven of 16 (43.7%)¹⁸⁴ and eight of 18 (44.4%)¹⁸⁶ of the restorations treated with CAF and SCTG, respectively, presented a color that did not match the tooth color at the 24-month evaluation. For probing depth (PD), there was a significant increase for both restored and nonrestored sites after 2 years,¹⁸⁶ but no significant bleeding on probing was found regardless of the follow-up period.182-186

Within the included RCTs, maxillary Class I recession defects with NCCLs were restored 2 weeks before¹⁸² or during¹⁸³⁻¹⁸⁶ the surgical procedures. Two RCTs¹⁸³⁻¹⁸⁶ evaluated only 1- to 2-mm cervical lesions, whereas the third study¹⁸² did not report the depth of defects. Apart from these features, there were no clinical differences between restored and non-restored cervical lesions 6 months after treatment (in terms of GR, CAL change, and esthetics), but SCTG showed a trend of better outcomes than CAF.¹⁸⁵ It was also verified by one of these RCTs¹⁸⁵ (in an additional report)¹⁸⁸ that cervical lesion restoration with resin-modified glass ionomer did not lead to detrimental effects on the subgingival microflora/biofilm or the inflammatory markers present at the GCF after a 6-month period.

Additionally, the authors of two of these RCTs¹⁸³⁻¹⁸⁶ performed a stepwise multivariate linear regression of the 78 NCCLs included in their previous publications to assess whether the shape of the



Figure 3.

Forest plot of random-effects meta-analysis comparing SCTG-based procedures in non-smokers versus smokers. IV = inverse variance; M-H = Mantel-Haenszel; $\tau au^2 =$ Kendall τ test; z = z test. **A**) Difference in the percentage of recession reduction. **B**) Difference in the number of sites exhibiting CRC.

lesions (height and width), KT (width and thickness), papillae anatomy (height and width), bone level, and the post-surgical level of the gingival margin could modify GR and CAL short-term changes (i.e., 6 months after surgery).¹⁸⁷ It could be demonstrated that the depth of the cervical lesion may influence the amount of RC when CAF is used (i.e., the deeper the cervical lesions, the greater the coverage).¹⁸⁹ Also, the vertical extension (height) of the cervical lesion was found to influence GR change independently of surgical treatment, i.e., whether the defect was treated with CAF or SCTG.¹⁸⁹ Although larger defects lead to greater changes in baseline recession depth, it was observed that CRC of the defect might not be achieved.¹⁸⁹

A similar non-randomized study¹⁹⁰ assessed the predictability of treating NCCLs based on the maxi-

mum RC level (i.e., "a line [line of root coverage] that should coincide with the anatomic cementoenamel junction when it was not clinically detectable on the tooth with Miller Class I or II gingival recession"). Through the use of five different treatment procedures to attain RC within a sample of 94 patients (26 Class I, 20 Class II, 38 Class III, and 10 Class IV recessions), it could be demonstrated that the predetermination of the maximum RC level of cervical lesion associated with GR may be considered a useful tool during selection of treatment options because it can provide satisfactory esthetic outcomes and correct emergence profiles.¹⁹⁰ Moreover and as suggested by the authors, the selection of procedures should be based on the following types of treatment: 1) Types I and II (radicular cervical lesions plus Class I or II GR): RC alone; 2) Type III (crown-radicular cervical lesion plus Class I, II, or III GR): coronal and radicular odontoplasty + restoration + RC; 3)Type IV (radicular cervical lesion plus Class III or crownradicular cervical lesion plus Class I or II with the deepest point of the cervical lesion localized at the level of the

anatomic crown): coronal and radicular odontoplasty + restoration + RC; and 4) Type V (radicular cervical lesion plus Class III or IV GR when the cervical lesion was located "on that portion of the root surface that was not coverable with soft tissues"): restoration alone.¹⁹⁰

A novel technique to identify and reconstruct the CEJ level of teeth with NCCLs using a combination restorative-periodontal approach for the treatment of localized or multiple GR was proposed in a recent prospective study.¹⁹¹ Based on the contralateral homologous tooth or adjacent teeth used to identify the level of lost CEJ, the crown length, and the shape of the gingival margin at each one of the 25 teeth with Class I or II GR (15 treated with CAF and 10 with SCTG + CAF), these authors considered this a useful technique based on the reported MRC (91%) and CRC (80%) found 24 months after therapy. 191

Regarding the treatment of carious or restored roots requiring RC, Fourel, 192 Miller, 193 Prato et al., 194 Corsair,¹⁹⁵ and Goldstein et al.¹⁹⁶ described their outcomes using different treatment approaches. The first author reported the 4-year results of caries lesions on two maxillary teeth (#11 and #12) treated with thorough scaling ("until all softened dentin was removed and only rock-solid dentin was present") and CAF.¹⁹² Soft tissue coverage of 3.6 and 4.0 mm were observed 4 years after surgery comprising previously carious and non-carious exposed root surfaces of teeth #11 and #12.¹⁹² The second treated five localized, deep GRs (range of 4 to 7 mm) based on caries removal, vigorous scaling and root planing (SRP), citric acid application, and FGG, with 100% success (i.e., CRC).¹⁹³ The third presented two cases of previously restored roots in which the treatment consisted of the following: 1) removal of restoration; 2) SRP; 3) GTR with non-RS + CAF; 4) membrane removal 30 days after surgery; and 5) additional flap advancement over the remaining exposed cervical lesion/recession.¹⁹⁴ The authors reported that the satisfactory clinical results achieved with therapy (i.e., CRC of 4 and 5 mm in previously restored areas) could be maintained for ≥18 months.¹⁹⁴ The fourth reported the removal of a composite Class V restoration at tooth #11, the subsequent use of an SCTG to cover the 4-mm GR present on the buccal surface, and the 7-year follow-up showing CRC of the defect.¹⁹⁵ The last study provided a direct comparison between 27 teeth with restored (n = 9) and non-restored (n = 18) carious roots and 33 intact teeth with GR (Class I or II GR ranging from 2 to 6 mm for both groups) treated with SCTG + CAF.¹⁹⁶ Carious dentin and restorations were removed before the surgical procedures when indicated, and all recession defects were thoroughly planed and covered without the use of RMAs or restorative treatment.¹⁹⁶ Eighteen (66.6%) of 27 carious roots and 26 (78.8%) of 33 intact roots achieved CRC, with MRC of 97.7% and 99.1%, respectively.¹⁹⁶ Given the lack of statistical differences between groups and the absence of recession/caries recurrence through the follow-up period (12 to 72) months), it was concluded that "the treatment of GR on previously carious roots using SCTG is highly effective and predictable."196

The influence of the type of mechanical rootsurface preparation/instrumentation was reported in two RCTs.^{104,129,197} The first one compared root-surface polishing at slow speed with a rubber cup for 60 seconds against SRP with curets before flap elevation at 3 months (10 GRs per group) and 14 years (nine GRs per group) after treatment (Table 2).^{104,197} It was found that at neither the short- nor long-term examinations were there significant differences between groups when CAF was the procedure of choice of GR ≥ 2 mm, except for KT width.^{104,197} Based on the initial band of KT, the authors suggested that root polishing may be more indicated than SRP when the amount of KT is >3 mm (and vice versa for KT \leq 3 mm).¹⁹⁷ The second study compared the effect of hand and ultrasonic instrumentation on the outcomes of 22 Class I defects (11 per group) treated with CAF and similarly did not find significant differences between groups in terms of MRC (95.4% and 84.2%, respectively) or CRC (82% and 55%, respectively).¹²⁹ In addition, two recent RCTs evaluated root-surface biomodification with neodymium:yttrium-aluminum-garnet (Nd:YAG)⁶⁰ or erbium:yttrium-aluminum-garnet (Er:YAG)⁶¹ lasers before the use of SCTG + CAF (Table 2), but none of these root-modification methods enhanced the outcomes of treatment.

Tooth Type and Location

As mentioned previously, most of the RCTs described the treatment of maxillary canines and premolars.^{1-11,21-27} Specifically to other tooth types, the effect of treatment on mandibular incisors/posterior teeth and lingual defects have been studied also.

Data of 50 consecutively treated patients presenting with one molar tooth with Class I or II GR \geq 3 mm (and without furcation involvement greater than Class I) treated with SCTG + CAF (39 defects) or SCTG + double papilla flap (11 cases) support that these teeth may be effectively treated based on the significant gains in clinical parameters (i.e., MRC of 91.1%, CRC of 58%, and CAL and KT gains of 4.6 and 2.2 mm, respectively).¹⁹⁸ Recently, de Sanctis et al., 199 after treating 10 patients presenting sites of multiple GR (26 Class I or II GR) in posterior mandibular teeth with SCTG + CAF, reported significant recession reduction (mean coverage of 91.2% and 50% CRC) and CAL and KT gain 12 months after surgery. Regarding results of efficacy trials, the unique RCT on the treatment of Class I or II GRs on molar teeth compared the 12month results of a modification of the LPF (i.e., laterally moved CAF) to SCTG + CAF¹³¹ (Table 2). Of the 25 patients/defects treated per group, 12 (48%) in SCTG + CAF and one (4%) in the LPF achieved CRC, and logistic regression analysis showed that 100% RC was significantly higher for the first group (odds ratio = 22.1; 95% CI = 2.4to 200.6).¹³¹ Furthermore, significantly less postoperative pain/discomfort and better masticatory ability for the modified LPF group were identified. Conversely, no significant differences in MRC (88.8% for SCTG + CAF and 74.2% for modified LPF) or in patient/professional esthetics evaluation were identified. $^{131} \end{tabular}$

A couple of case series tested the role of RC procedures on mandibular incisors. Within the 100 defects treated by Miller in 1985 (already mentioned under "Effect of treatment of Miller¹⁷ Class III GRs"), 77 were incisors (76 located in the mandible).¹³² All the 10 Class I defects reached 100% RC, whereas among the 51 Class II defects (recession depth ranging from 3 to 7 mm), CRC was achieved in 47 (92.1% CRC and 95.7% MRC).¹³² For the 15 Class III defects, 14 reached 100% CRC, and one reached 80% CRC (98.6% MRC and 93.3% CRC; recession depth range of 4 to 8 mm).¹³² When SCTG-based procedures were used, overall MRC of 88.8% (80.2% SCTG + CAF, 90.5% SCTG + tunnel + laterally positioned pedicle, and 95.9% SCTG + double papilla flap; P = 0.009) and CRC of 62.7% (20 of 41 defects for SCTG + CAF, 24 of 38 for SCTG + tunnel + laterally positioned pedicle, and 30 of 39 for SCTG + double papilla flap) were found.200

When maxillary and mandibular sites were considered, it was reported that significantly greater improvements of recession depth and width of KT were observed for maxillary multiple recession defects treated with SCTG + CAF compared with alike mandibular defects.²⁰¹ For single defects treated with LPF, only KT change was significantly greater for maxillary teeth.²⁰²

With respect to the treatment of palatal/lingual defects, the case reports by Harris²⁰³ (a 6.5-mm palatal recession on a molar teeth), Wilcko et al.²⁰⁴ (two Class II, one Class II, and two Class III lingual GRs), and Soileau²⁰⁵ (one Class II GR at the mandibular incisal area) suggested promising results of treatment linked to the use of SCTG (i.e., 84.6%, 100%, 100%, and 70.8%, respectively).

Long-Term Effectiveness Outcomes and Unusual Conditions That May Be Reported During Conventional Daily Practice

The outcomes of 17 practice-based and/or non-randomized studies with a minimum follow-up period of 24 months have been described in 19 papers,²⁰⁶⁻²²³ comprising a total of 563 patients (one study did not report the number of patients treated²¹⁹) and 904 defects (Table 3). Within these studies, a minimum mean GR reduction of 70% was recorded, and CRC ranged from 25% to 92.5%.²⁰⁶⁻²²³ Of these studies, Pini Prato et al.²¹⁵ found that "a coronal displacement of the gingival margin was observed in the SCTG + CAF treated sites, while an apical relapse of the gingival margin was noted in the CAF-treated sites between the 6-month and 5-year follow-ups."

With regard to the recent RCTs (Table 2), three recent publications that described very long results $(\geq 10 \text{ years})$ deserve special attention as well. The data regarding a 14-year RCT on CAF showed that KT width and CRC were guite stable during this period.¹⁰⁴ Of the nine GRs available for analysis in each of the root preparation procedures tested, five in the polishing group and three in the SRP group showed CRC.¹⁰⁴ Creeping attachment was observed in two GRs (one per group) that were not completely covered 3 months after surgery, and one GR (SRP) 100% covered at 3 months developed a new recession at the final examination (overall, recession relapse was found in 39% of the 18 GRs treated).¹⁰⁴ Nickles et al.⁹⁶ described significant loss of RC for teeth treated with GTR or SCTG at the 10-year examination; however, sites treated with GTR lost significantly more soft tissue than those receiving SCTG (P = 0.002). McGuire et al.⁹¹ reported that, within the remaining sample of nine individuals (of the 19 examined at 12 months) reexamined 10 years after treatment, there was some loss of RC, but at both 12 and 120 months, MRC and CRC were similar for teeth treated with EMD + CAF or SCTG + CAF.

Additionally, other unusual outcomes that have not been explored by the included SRs were evaluated. For instance, there have been reports on the development of cyst-like areas,^{224,225} root resorption,^{226,227} bone exostosis,²²⁸ or epithelial cell discharge²²⁹ secondarily to the use of SCTG-based procedures, described 4²²⁹ to 24²²⁷ months after the procedure. Likewise, foreign body reaction was reported when combined with a bioabsorbable GTR device.²³⁰

Similar to the data by Pini Prato et al.,²¹⁵ certain clinical trials and case reports have explored the potentially relevant factors associated with the occurrence of postoperative migration of the gingival margin in a coronal direction, covering areas of previously partially or totally denuded root surfaces (i.e., creeping attachment).²³¹ The amount of creeping attachment within each publication related to the type of RC procedure, percentage and amount of RC, and follow-up years are described in supplementary Table 1 in online *Journal of Periodontology*. Overall, long-term data showed that 0.3 to 9 mm of creeping attachment may occur.^{146,202,212,232-240}

PATIENTS' PREFERENCES (PATIENT-CENTERED OUTCOMES)

Within the included SRs, the use of CAF alone or combined with biomaterials was described as being less painful and more comfortable, whereas use of SCTG and non-RS has been associated with increased morbidity (i.e., postoperative pain, bleeding, and swelling during the early phase of healing) and some complications (i.e., membrane exposure/contamination), respectively.^{1,4,5,7,10,11} Conversely, because of the lack of information on esthetics change reported by the patient, decrease in root hypersensitivity, and postoperative pain, the key patient-centered outcomes could not be adequately assessed by the body of SRs. For instance, findings from one SR on cervical dentin hypersensitivity²⁹ showed that there is not enough evidence to support or refute the assumption that RC may decrease hypersensitivity. Overall, the base of SRs suggests that patients were satisfied with the final esthetics achieved, despite the potential postoperative discomfort and complications during the early phase of healing related to autogenous graft procedures.

Despite not being considered eligible for inclusion in the included SRs, two large sample case series reporting data on 728 patients were retrieved for analysis.^{241,242} In one prospective study, the frequency of occurrence of three postoperative complications (i.e., pain, swelling, and bleeding) and the potential predictors related to these adverse effects were assessed within a sample of 228 patients submitted to the 331 surgical procedures performed to treat Class I or II GRs using FGG, SCTG + double papilla flap, or ADMG.²⁴¹ FGGs were used in 70 cases, SCTG + double papilla flap in 172, and ADMGs in 89 (84 ADMG + double papilla flap and five ADMG as FGGs), and within them, moderate to severe pain (27% to 40%) and swelling (19% to 60%) were the most significant adverse events (<6% of the sample experienced moderate or severe bleeding, but all of them were associated with the use of autogenous grafts).²⁴¹ The use of a double papilla flap was less associated with pain than FGG (27% versus 38.7%), whereas FGG presented less swelling (21.3% versus 31.6%), and SCTG was the unique procedure in which moderate or severe discomfort 1 week after surgery was reported (7.6%).²⁴³ These authors demonstrated that long surgical procedures (P = 0.001) and smoking status (P = 0.01) were directly linked to pain and/or swelling post-surgically, that procedures involving FGG increased pain (P = 0.002) or bleeding (P = 0.03; compared with SCTG), and that the use of ADMGs significantly reduced swelling (P = 0.02) or bleeding (P = 0.001).²⁴³

In a practice-based evaluation of 500 consecutively treated patients treated with SCTGs (479 involving RC and 21 augmentation procedures), the incidence of infection (0.8%), bleeding (3.0%), swelling (5.4%), and pain (18.6%) was considered very low, and none of the potential predictor factors included in the statistical model (i.e., age, sex, smoking, purpose of the graft, recipient site size, or defect location) were directly associated with such complications.²⁴⁴

In one RCT reporting outcomes on SCTGs and growth factor-based procedures, patients "rated mild or no discomfort due to bleeding, swelling, sensitivity, clinical rating of color/texture of the tissues" as similar for sites treated with SCTGs or growth factor-based procedures.⁹³ Also, 25 (78.1%) patients experienced mild or moderate adverse events, such as mild contusion, followed by face swelling.⁹³

Regarding the effect of RC on cervical dentin hypersensitivity and quality of life of patients, a recent paper describing the outcomes of 25 Class I GRs (in 22 patients) treated with SCTG + CAF showed that cervical dentin hypersensitivity (by thermal [cold] and evaporative [air blast] stimuli) was significantly reduced (P < 0.001) 3 months after surgery.²⁴³ Also, it was concluded by the authors that RC procedures positively influenced patients' oral health-related quality of life independently of the amount of RC achieved.²⁴³ Another long-term study evaluating CAF-treated sites (and already presented in Table 3) showed that, at baseline, 33 (55%) of 60 patients presented cervical dentin hypersensitivity, whereas after 8 years of follow-up, 10 (18%) of 57 did not.²¹⁶ For GTR-based procedures, no significant changes in cervical dentin hypersensitivity were seen 12 months after treatment.⁸²

Recent data provided additional information on patients' perceptions on the presence of GR, requests for treatment, and post-surgical satisfaction.^{218,244} For instance, cross-checking data of questionnaires and clinical examination of 120 consecutively treated patients indicated that perception of buccal defects by patients should be taken into consideration during decision-making (i.e., their individual and spontaneous requests for treatment), because only a small percentage of GRs were perceived by them (218 of 783 [28%]), and most of them were asymptomatic in nature or considered of no esthetic or functional importance (73%).²⁴⁴ Rossberg et al.²¹⁷ described that 80% of a group of patients followed for a period of 11.4 years had requested surgical correction of the defects for esthetics and 20% for cervical dentin hypersensitivity, but all of them were satisfied with the improvements achieved.

Among patients submitted to treatment, the results of VASs have been described for ADMG, CAF, laterally moved CAF, GTR, SCTG, and CM. McGuire et al. did not find statistically significant differences in "the clinical rating of color/texture of the tissues" between the SCTG + CAF and bone

substitutes + growth factors + CAF,⁹³ nor between CM + CAF and SCTG + CAF.⁹² Wessel and Tatakis,²⁴⁵ after treating 12 individuals with SCTGs and 11 with FGGs found that, 3 days after surgery, 91.6% of the individuals submitted to SCTG and all submitted to FGG complained of some postoperative pain since the surgery, with VAS scores of 3.5 and 4.8, respectively. Despite the lack of significant difference between procedures, the proportion of patients reporting pain in the palate was significantly greater for FGGs (P = 0.045). Eighteen days later, approximately half of the patients treated with SCTGs or FGGs were still experiencing pain but with lesser VAS values than those recorded earlier and without significant differences between groups (1.6 and 1.4, respectively).²⁴⁵ Overall, withingroup comparisons for the FGG group showed a significant reduction of the VAS pain score between 3 and 21 days (P = 0.005) and no changes for the SCTG aroup (P = 0.07).²⁴⁵

Information on 15 Class I or II GRs treated with ADMG indicates high and better scores related to patient opinion (8.1 of 10) than those recorded by an independent periodontist (6.7 of 10) at 12-month follow-up.²⁴⁶ Zucchelli et al.¹³¹ showed the following: 1) RC involving only pedicle grafts (laterally moved CAF) presented better postoperative course and chewing ability (P < 0.01) than SCTG + CAF; 2) the use of autogenous graft led to significantly (P < 0.01) better postoperative sensitivity; and 3) the lack of significant differences between groups in terms of esthetics (P > 0.05).¹³¹

For CAF-based procedures in multiple GRs, similar outcomes concerning 6-month esthetics and 1-week postoperative pain were reported when vertical releasing incisions were performed.⁹⁸ When CAF with and without vertical incisions were compared in such defects (multiple GRs), similar patient satisfaction outcomes (overall satisfaction, color match, RC) were reported, but flaps without vertical incisions provided significantly better (F = 8.9; P < 0.01) postoperative course during the first week of healing.¹²⁸

In addition, of the nine patients re-examined by McGuire et al.⁹¹ 10 years after treatment, 66.6 (n = 6) favored EMD + CAF instead of SCTG + CAF, one favored SCTG, and two had no preference. In terms of esthetic satisfaction, six patients had no preference for a particular type of treatment, two favored esthetic results with the EMD, and one favored results with SCTG.⁹¹

DISCUSSION

As reported within the base of SRs included in this review, the treatment of GR with RC procedures plays an important role in contemporary periodontology.

Since the first SR published in 2002,⁹ there has been a continuously increasing interest in the systematic evaluation of clinically relevant scientific evidence regarding the esthetic and functional effects of treatment gingival defects. The interest is not only focused on the clinician's knowledge but includes patient-centered outcomes (e.g., esthetic assessment, functional limitations, discomfort, root sensitivity, and preferences) as well.^{6,7}

With respect to the effect of treatment of Class I and II recession defects, an accurate review of SRs showed that SCTG-based procedures led to the most significant gains in defect coverage and KT width, increases in the number of sites with CRC, and greater long-term stability of outcomes. These results could be confirmed by some of the metaanalyses presented in part II (Figs. 1 and 2), as well as by the outcomes of the 94 RCTs presented in Table 2. It could also be confirmed that the combination of CAF with soft tissue graft substitutes, such as CM and EMD, led to more positive outcomes compared with CAF alone; these combined treatments could be viable alternatives to SCTGs (with clinical outcomes close to those reported for SCTGs). Overall, all the soft tissue RC procedures described in the literature for localized and MRTDs can significantly improve RD and CAL in the short term (i.e., 6 months after treatment).

The outcomes of the 12 sets of meta-analysis, combining data of pairwise comparisons in nonsmoking individuals, on the mean percentage RC showed the following: 1) ADMG + CAF provided 15.6% more RC than CAF alone; 2) EMD + CAF led to 12% to 15% additional improvements when compared with CAF alone when follow-ups >6 months were included in the pooled estimates; 3) SCTG-based procedures performed 5% to 8% better than CAF, 8.9% better than CM + CAF, 9.3% better than GTR + CAF, and 32.5% better than FGG, and SCTG provided slightly (5.3%) but significantly superior outcomes than EMD + CAF when the longer-term outcomes were used in the analysis; and 4) SCTG-based microsurgical procedures improved outcomes by 9.0% when compared with macrosurgical (conventional) techniques. Regarding the number of sites exhibiting CRC after therapy, SCTG-based procedures were superior to CAF, FGG, and GTR, whereas EMD was superior to CAF alone. Additionally, SCTG-based microsurgical approaches increase the number of sites exhibiting CRC. Based on these significant differences in terms of CRC, the NNT was calculated to determine how many defects would need to be treated with a respective procedure to result in one more defect achieving CRC than would have occurred using another RC procedure. As a result, three defects with FGGs, five to seven with CAF, and six with

Study	Participants (n)/ Age (y)	Interventions (GR)	Follow-Up	∆GR (mm)	A CAL (mm)	ΔKTW (mm)	SCRC (%)	MRC (%)	RMA
Caffesse and Guinard ²⁰⁶ and Guinard and Caffesse ²⁰⁷	21/19 to 68	LPF	36 mo	3.2	3.7	3.1	NR/14	82.3	°Z
		FGG and CAF		3.0	3.3	3.5	NR/12	71.4	°N N
Chambrone and Chambrone ²⁰²	32 (NS)/18 to 55 Class I or Class II GR	LPF (max GR) LPF (mand GR)	24 mo	4.3 5.4	4.8 5.4	3.7 3.2	6/16 (62.5) 5/16 (68.7)	94.5 93.2	Yes Yes
de Sanctis and	40/20 to 38	CAF	36 mo	3.6	3.6	1.8	34/40 (85)	96.7	оХ
Zacciell	Eight smokers Class I or II GR								
Griffin and Chaina ²⁰⁹	06/18 to 60	PCG + CAF	36 mo	2.4	3.8	0.9	21/37 (56.7)	85.8	No
	One smoker Class I or II GR								
Gunay et al. ²¹⁰	20 (NS)/16 to 58 Class 1 or	SCTG + EMD + CAF	24 mo	4.0	4.6	2.6	25/36 (69.4)	92.1	Yes
	Class II GR	EMD + CAF		3.0	3.8	2.2	31/37 (83.7)	94.3	Yes
Harris ²¹¹	100/18 to 70 Seven smokers Class 1 or 11 GR	scTG	27.5 mo	3.7	4.4	3.0	135/146 (92.5)	98.4	Yes
Lee et al. ²¹²	15 (NS)/22 to 44 20 GR Class I or Class II and One Class III	SCTG + CAF	36 mo	с. Е	т. т.	6:	11/21 (52.4)	91.3	°Z
Moses et al. ²¹³	65/17 to 59 Class I or II GR	SCTG + DPF EMD + CAF	24 mo	4.5 3.3	3.8 3.6	2.4 1.2	NR/37 NR/28	84.3 76.9	No Yes
Pini Prato et al. ²¹⁴	50/15 to 40	GTR with non-RS + CAF FGG and CAF	48 mo	4.2 3.8	5.0 3.1	1.8 5.1	NR/25 NR/25	73.I 72.3	°Z °Z

Characteristic:	s and Outco	mes of Long-Term	(≥24 Months)	Practice-	Based and	/or Non-Rai	ndomized St	tudies	
Study	Participants (n)/ Age (y)	Interventions (GR)	Follow-Up	Δ GR (mm)	Δ CAL (mm)	ΔKTVV (mm)	SCRC (%)	MRC (%)	RMA
Pini Prato et al ²¹⁵	13/24 to 51 Three smokers 79 GR Class I or Class II and 14 Class II	sctg + caf caf	60 mo	3.2 2.2	Х Х	NR	23/44 (52.3) 17/49 (34.7)	88.8 75.9	°Z Z
Pini Prato et al. ²¹⁶	57/29.7 (mean) 11 smokers	CAF	96 mo	2.3	2.6	-0.5	20/57 (35.1)	71.8	No
Rossberg et al. ²¹⁷	20/22 to 57 36 GR Class I or Class II and three Class II or IV	SCTG (envelope)	11.4 y (6 to 22 y)	2.7	ж Z	4.7	32/39 (82.0)	89.7	Ž
Scabbia and Trombelli ²¹⁸ andTrombelli et al. ²¹⁹	20/23 to 35	GTR with non-RS + CAF	48 mo	3.5	3.9	1.2	5/20 (25.0)	77.7	°Z
1	Nine smokers Class I or II		10 y	3.2	3.3	1:2		72.7	
Tözüm ²²⁰	NR/NR Class II GR	SCTG (tunnel)	36 mo	3.1	3.8	NR	NR/14	92.2	No
Wennström and Zucchelli ²²¹	67/19 to 38	SCTG + CAF	24 mo	3.9	3.7	2.8	51/58 (87.9)	98.9	No
	Class I GR	CAF		3.9	3.6		36/45 (80.0)	97.1	
Zahedi et al. ²²²	15 (NS)/25 to 60 Class I GR	GTR with RS + CAF	24 mo	2.9	3.5	0.4	9/15 (60.0)	82.2	°N N
Zucchelli and De Sanctis ²²³	22/18 to 34 Five smokers Class I or II GR	CAF	60 mo	2.5	2.5	1.4	62/73 (85.0)	94	No
DPF = double papilla fla _f baseline.	p; KTW = KT width; n	nand = mandibular; max = maxilla	ry; NR = not reported; ¹	YS = non-smokir	ig; PCG = platelet o	concentrate graft; SC	CRC = sites with CRC	c; Δ = mean ch	ange from

GTR need to be treated so that one can reach this benefit over defects treated with SCTG. For CAF, four defects need to be treated to accomplish CRC over sites treated with EMD + CAF, and four defects should be treated with SCTG-based macrosurgical approaches to obtain one more site exhibiting CRC than SCTG-based microsurgical approaches.

Despite the strong evidence on RC outcomes and the strong relationship between root-surface exposure and cervical dentin hypersensitivity, one of the included SRs suggested that there is not enough evidence to support or refute the use of RC procedures for treating such types of hypersensitivity.²⁹ This result is certainly associated with the lack of adequate assessments within RCTs given that cervical dentin hypersensitivity usually has not been considered among RCT outcomes. The lack of strong supportive evidence does not mean that there is no evidence; it seems reasonable to consider that successful coverage of recessions on teeth presenting with cervical dentin hypersensitivity can (from a clinical point of view) also decrease hypersensitivity. In fact, among the restricted group of studies that investigated cervical dentin hypersensitivity, 216,243 it was demonstrated clearly that CAF²¹⁶ alone or SCTG²⁴³ provided significant improvements in thermal and evaporative hypersensitivity. Nevertheless, cervical dentin hypersensitivity outcomes merit additional investigation and should be part of future research studies on RC.

Considering the use of RMA, there is clear support from the literature on the lack of additional benefits provided by the use of chemical agents (i.e., citric acid, EDTA, or tetracycline hydrochloride solution)^{4-7,9,28} or biomodification therapies (i.e., Er:YAG⁶¹ or Nd:YAG lasers⁶⁰). In general terms, such agents and therapies did not lead to any detrimental effect on the expected final clinical outcomes, and they were not able to improve the results of treatment. In addition, the type of mechanical method used for root debridement (i.e., rubber cup, manual curets, or ultrasonic devices) does not appear to modify RC outcomes.^{104,129,198}

With respect to the assumptions explored in parts II and III, the lack of information on Class III and mainly Class IV recession defects was evident. For Class III defects, the use of RC procedures provided rates of MRC that ranged from 54.8%¹⁴⁰ to 85.0%¹⁴¹ within the included RCTs specially designed to evaluate these defects. Within other studies that included Class I or II GR defects as well, an MRC ranging from 51.5%¹³⁵ to 98.1%¹³² was found for Class III defects. For both groups of studies, SCTGs provided the best results. CRC varied between 42.8%^{136,138} and 90.5%¹³² for Class III defects within studies that also included Class I and/or II defects and between

57% (SCTG + CAF)¹⁴¹ and 64% (CAF)¹⁴¹ for trials evaluating exclusively Class III recessions. These results indicated that Class III defects treated with RC may achieve good and predictable clinical results. Concerning Class IV recessions, there were only a few case reports published, and some degree of RC could be achieved, whereas the final esthetic results could be improved by combined restorative approaches performed subsequent to the healing period.¹⁴⁴⁻¹⁴⁶ However, such limited information does not allow at this point definitive conclusions or the establishment of some degree of predictability for these defects.

Regarding the histologic attachment formed during the RC wound-healing process. ADMG, CAF. CM, FGG, LPF, and SCTG led mainly to the development of long junctional epithelium and CT attachment with collagen fibers running parallel to the root surface, 148, 149, 152-154, 157-160, 163, 165 whereas procedures involving GTR, EMD, and growth factors led to partial regeneration of the lost tissues.^{51,93,151,154-} ^{156,158,162} Moreover, it was described that SCTGs are mostly formed by components of the lamina propria;¹⁷³ regardless of whether trimmed from FGG or harvested directly from the palate, SCTGs result in the same graft dimensions and postoperative pain/ bleeding,¹³⁰ and the palatal vault provides suitable dimensions to allow harmless graft removal¹⁷⁴ even when harvesting more than once from the same location.175

Some recipient- and donor-site anatomic characteristics that were evaluated by the included studies indicated that reduced flap thickness,¹⁶⁶⁻¹⁶⁸ deep baseline recession depth,^{7,167,171,172} and flaps positioned and sutured apical to the CEJ (i.e., the more apical the gingival margin after surgery)¹⁷¹ may negatively influence achievement of CRC. Moreover, it should be noted that some trials included in this study^{34,84,96,224} focused their interest in improvements to the flap design (i.e., procedures not involving the use of vertical releasing incisions). However, at this point in time, there are not enough outcomes to support or refute the superiority of these procedures (i.e., the outcomes of these studies did not provide superior outcomes to those achieved by "conventional" procedures, and there is a lack of short- and long-term data on SCTG + tunnel approaches/flap without vertical incisions versus conventional CAF technique + SCTG). Consequently, it seems a little premature to conclude, based on the available base of RCTs, any significant clinical difference between flaps advocating or not the use of vertical releasing incisions.

Another important issue linked to the prognosis of soft tissue RC is tobacco smoking.² Evidence is clear that smokers may benefit from soft tissue RC; however, the use of an SCTG does not provide the same effect of treatment as that achieved in non-smokers.² By updating the meta-analysis by Chambrone et al.² and reporting the difference in mean percentage RC, it could be demonstrated that non-smokers may obtain 17.5% additional RC than smokers when patients were treated with an SCTG. Likewise, non-smokers had greater benefit regarding the number of sites with CRC, indicating that at least three defects in smokers need to be treated with an SCTG to result in one more defect reaching CRC than in the non-smokers. These outcomes may be explained by the characteristics of the donor (i.e., less vascularized palatal vault¹⁷⁷) and recipient (i.e., less vascularized flap)² sites of smokers, characteristics that might influence revascularization and incorporation of the SCTG and overall wound healing.² Conversely, when CAF was used alone, significant differences could not be noted; however, limited evidence is available for analysis, and, independently of the surgical procedure tested, it should be noted that smoking status was confirmed biochemically in only two trials.^{176,179} For the re-maining trials,^{170,175,177,178,180,181} the investigators used the number of cigarettes smoked per day as the threshold for the patient inclusion.

It has been argued that root-surface conditions may influence final RC procedure outcomes. Some RCTs¹⁸²⁻¹⁸⁵ assessed the use of combined restorative/ surgical approaches when treating GRs. The combined use of restorative materials (i.e., resin-modified glass ionomer or microfilled resin composite) did not lead to negative effects on bleeding scores¹⁸²⁻¹⁸⁵ or subgingival microflora.¹⁸⁸ However, these studies showed no significant differences in MRC between restored and non-restored groups, although it was noted that almost 45% of the cervical restorations presented a color that did not match the tooth color 24 months after treatment. Furthermore, because the color of the restorations may change over time, it should be evaluated how these can be removed. It may be suggested that teeth with NCCLs could be first treated, for instance, by SCTG + CAF and then, after healing, receive a supplementary restorative procedure. For carious root surfaces, the outcomes of the few studies available indicate that, when the carious dentin and existing root restorations are properly removed before the surgical procedures and the root surfaces are thoroughly planed, RC procedures may be greatly effective and predictable.193-197

As reported previously,^{1-7,9} the majority of defects treated in most studies were located in the maxilla (canines and premolars). For other groups of teeth, such as incisors and molars specifically, similar high rates of success might be achieved as well.^{131,132,199-201} Two practice-based case series

studies suggested that procedures involving CAF procedures may perform better in the maxilla than in the mandible.^{206,207} Additionally, data from the few case reports on the treatment of lingual/palatal defects suggest that these type of defects may be safely and successfully treated.²⁰⁴⁻²⁰⁶

With respect to the long-term outcomes that may be expected in private practice, it seems possible to anticipate a mean 70% RC ≥2 years after treatment.²⁰⁷⁻²²⁵ There is a marked variation on the amount of RC achieved in different studies (25% to 92.5%), but SCTG-based procedures provided the best and more stable outcomes, whereas CAF alone may be associated with the greatest amount of apical relapse of gingival margin position over time (Table 3).²⁰⁷⁻²²⁵ This is in line with the data from the three RCTs included in this study.^{91,96,104} It is also important to highlight that, despite the possible occurrence of some adverse events related to the treatment with SCTGs (i.e., development of cyst-like areas, 226, 227 root resorption, 228, 229 or bone exostosis²³⁰), these were restricted to a very limited number of cases and cannot per se undermine the safety/ success of autogenous grafts. Overall, all RC procedures can be considered safe. Likewise, the results of some graft procedures (i.e., FGGs and SCTGs) may be improved over time by the coronal displacement of the gingival margin (creeping attachment). However, neither the "favorable" (creeping attachment) nor the "unfavorable" (adverse events) outcomes can be anticipated.

In addition to the data presented by the included SRs,^{1-10,21-27} information on diverse patient-centered outcomes could be obtained by two large studies, one university based²⁴¹ and another practice based.²⁴² It could be verified that some patients may experience some degree of pain and swelling during the early phases of healing, but only a very few of them experience bleeding.^{241,242} In fact, these early postoperative adverse effects may not interfere with the final result or even amount to contraindications for treatment.

It is clear that less traumatic procedures, with less chair time and involving only one surgical site, are preferred by most patients.^{1-10,21-27} Independent of such preferences, most of the treated patients considered esthetics as their main concern, and in the great majority, the final outcomes of the performed surgical procedure (irrespective of inclusion of one or more surgical sites) fulfilled their personal expectations.^{1-10,21-27,30-246} However, differences among studies in terms of procedures, analysis (i.e., patient based or site based), sample size, follow-up period, experience of operators, lack of baseline, and final recession characteristics prevent additional conclusions on this topic.

In addition, it should be clear that effectiveness is a very significant question, which has not been explored to the same extent that efficacy has. In this study, publications from private offices are regarded as evidence of effectiveness (for instance, the publication from Pini Prato et al.¹⁰⁴). Publications like this one may not be considered as examples of the average private practice setting. The idea of effectiveness is based on outcome of therapy by average clinicians in the community and not by "experts." Conversely, it should be noted most clinicians are not used to design research protocols or conducting/running clinical studies, and in the great majority may sometime present the results of their work as case reports. These issues are important and deserve distinction, because often there is a gap between protocols investigated by experts and those implemented in clinical practice.

CONCLUDING REMARKS

A comprehensive assessment of the relevant literature, performed as part of the 2014 American Academy of Periodontology *Workshop on Periodontal Regeneration and Tissue Engineering*, revealed a sizable volume of publications for most RC procedures. This comprehensive assessment of the RC literature, the "decision tree" generated from it (Fig. 4), and the ensuing consensus report should help clinicians in their daily practice as they try to make the best possible choice of treatment modality to satisfy their patients' needs. Regarding the focused questions addressed in this review, the following can be concluded.

What Is the Efficacy/Effectiveness of RC Procedures by the Degree of Recession?

The vast majority of the published RC studies consist of RCTs and SRs on Miller Class I and II single recession defects. Because of the lack of data from "efficacy trials" on other important conditions of interest, such as treatment of Miller Class III and IV defects or treatment of palatal/lingual defects, controlled clinical trials, case series, and case reports were included in the assessment of the literature in an effort to provide fundamental outcome information for such other conditions.

Miller¹⁷ Class I and II GR. All RC procedures can provide significant reduction in recession depth and CAL gain without alteration of PD for Miller Class I and II localized recession-type defects, but MRTDs seems to be benefit as well despite the reduced quantity of information available. SCTG-based procedures provided the best outcomes for clinical practice because of their superior percentages of MRC and CRC and the significant increase of KT when compared with most of the other procedures. The use of CAF with ADMG, EMD, and CM also provided gains, many of them similar to SCTG-based procedures, and thus these may be considered as adequate substitute treatment approaches. Defects treated at the mandible and at posterior sites (i.e., molars) can be safely and satisfactorily treated as well. The final outcomes achieved seem to benefit from the use of magnification during the surgical procedures, but little evidence was available for analysis. Conversely, smoking may decrease the expected results of SCTG.

Miller Class III and IV GR. Class III defects may significantly benefit from the use of RC procedures (in the short term) when SCTG-based procedures are used. Alternatively, EMD + CAF, ADMG + CAF, and GTR + CAF can be used as graft substitutes. Overall, the marginal level of the gingival tissue of teeth adjacent to the GR seems to be the clinical reference point when planning and predicting the expected results of Class III defects. Concerning Class IV recessions, the data from the limited number of case reports suggest that these defects may be improved after treatment, but the amount of RC cannot be anticipated, and restorative procedures may be necessary to reach the final expected esthetic outcomes.

Which Factors May Influence the Outcomes (i.e., Smoking Status and Root Surface Conditions)?

For instance, is it possible to accomplish RC for teeth with NCCLs, root caries, or cervical root resorption? It was clearly demonstrated that smoking may significantly decrease the effect of therapy, especially when SCTG-based procedures had been used. With respect to the surface conditions and from the limited number of studies available, it could be seen that NCCLs, whether restored with composites/ionomer materials or not, may be safely treated by SCTG + CAF and CAF. Moreover, there is no evidence on the optimal timing for NCCL restoration (before/ during RC procedure or after wound healing). For teeth restored previously or presenting caries, there is some evidence indicating the positive effects of treatment of these areas by RC procedures, but for both conditions, there is a need for removal of old restorations/caries before the surgical therapy (i.e., the need for a "clean/ disease-free root surface").

What Is the Anticipated Success and Attachment Apparatus of RC Enhancements With Autogenous Grafts Compared With Alternative Methods and Materials?

As mentioned previously, SCTG-based procedures seem to be the best option in terms of clinical outcomes and cost-to-benefit ratio. Conversely, the use of matrix grafts (ADMG and CM) and EMD may be used as safe substitutes for autogenous grafts in patients with great demand for donor tissue (e.g., patients with MRTDs) or patients who do not



Figure 4.

Decision tree for the treatment of Miller¹⁷ recession-type defects (the thicker the "branch," the stronger the base of evidence). Wound healing consisting of long junctional epithelium and CT attachment (with fibers parallel to the root surface) is expected, but some degree of tissue regeneration may occur (mainly for EMD- and GTR-based procedures). Because the majority of the publications included in the study evaluated single-tooth recession sites, the decision tree seems better designed for determining appropriate treatment for single-tooth sites, but it may guide the treatment of MRTDs as well. The use of RMAs does not promote positive or negative clinical modifications. XCM = xenogenic CM.

want to be submitted to a secondary surgical procedure at the palatal vault. Histologically, most of the techniques may result in the formation of a long junctional epithelium (over the previously exposed root surface) and CT attachment with fibers parallel to the root surface. GTR and EMD procedures can lead to partial periodontal regeneration (i.e., formation of new cementum, alveolar bone, and PDL inserted in the newly formed cementum).

What Are the Long-Term and Short-Term Advantages of Root-Surface Biomodification?

The long-term outcomes (\geq 24 months) presented in the literature indicate that SCTG-based procedures

and EMD + CAF may provide superior outcomes than CAF and more stable results. Overall, a large part of the RC achieved in the short term may be maintained long term. The use of RMAs or other surface biomodification procedures did not provide superior gains in clinical outcomes, either short or long term, than those expected for procedures performed without such agents.

What Are the Relative Risks From a Patient's Viewpoint With the Different Approaches to RC Procedures?

Regarding patient-centered outcomes, all RC procedures were considered safe and effective for attaining RC and satisfactory esthetics. Data on root hypersensitivity is still scant, but recent data suggest the positive influence of RC treatment on such an outcome. Moreover, a small percentage of patients may experience postoperative bleeding, swelling, and pain. It could be considered that patients seem to prefer procedures that involve only one surgical site when considering these early postoperative adverse effects, but these were not associated with the final esthetic/functional outcomes.

Should CT Grafts Contain Epithelium and/or Periosteum?

The use of SCTGs containing epithelium and/or periosteum does not provide additional gains than SCTG without epithelium or periosteum, but the existing evidence is very limited.

Is There Evidence for Innovation When Treating Thin and Thick Biotypes With Existing Treatment Modalities?

SCTG, ADMG, and CM can positively change thin periodontal biotypes of recession sites to thick periodontal biotypes. As reported within long-term studies, patients treated with graft procedures (and their consequent biotype improvement) benefited from more stable outcomes and less recession recurrence. Also, the topic of biotype (thin versus thick) is covered more specifically in the review by Kim and Neiva²⁴⁷ included in this supplement. Overall, it seems reasonable to suggest that biotype modification (i.e., thin to thick biotypes) should be considered when planning and treating recession-type defects because of the positive, more stable long-term outcomes reported.

ACKNOWLEDGMENTS

The authors thank Drs. John C. Gunsolley and Luiz A. Chambrone for their assistance during the initial and final preparation of this review, respectively. The authors also thank all the participants of the 2014 American Academy of Periodontology Workshop on "Enhancing Periodontal Health Through Regenerative Approaches" for the comments on this review paper, especially the Periodontal Soft Tissue Root Coverage Procedures group members (Drs. Edward P. Allen, Burton Langer, Michael K. McGuire, Christopher R. Richardson, Ion Zabalegui, and Homayoun H. Zadeh). Dr. Tatakis has received research funding from Guidor USA/Sunstar Americas (Chicago, Illinois), Colgate-Palmolive (New York, New York), GABA International (Basel, Switzerland), and OraPharma (Horsham, Pennsylvania). Dr. Chambrone reports no conflicts of interest related to this review. The 2014 Regeneration Workshop was hosted by the American Academy of Periodontology (AAP) and supported in part by the AAP Foundation, Geistlich Pharma North America, Colgate-Palmolive, and the Osteology Foundation.

REFERENCES

- 1. Chambrone L, Chambrone D, Pustiglioni FE, Chambrone LA, Lima LA. Can subepithelial connective tissue grafts be considered the gold standard procedure in the treatment of Miller Class I and II recession-type defects? *J Dent* 2008;36:659-671.
- Chambrone L, Chambrone D, Pustiglioni FE, Chambrone LA, Lima LA. The influence of tobacco smoking on the outcomes achieved by root-coverage procedures: A systematic review. J Am Dent Assoc 2009;140:294-306.
- 3. Chambrone L, Lima LA, Pustiglioni FE, Chambrone LA. Systematic review of periodontal plastic surgery in the treatment of multiple recession-type defects. *J Can Dent Assoc* 2009;75:203a-203f.
- 4. Chambrone L, Sukekava F, Araújo MG, Pustiglioni FE, Chambrone LA, Lima LA. Root coverage procedures for the treatment of localised recession-type defects. *Cochrane Database Syst Rev* 2009;(2):CD007161.
- Chambrone L, Sukekava F, Araújo MG, Pustiglioni FE, Chambrone LA, Lima LA. Root-coverage procedures for the treatment of localized recession-type defects: A Cochrane systematic review. *J Periodontol* 2010;81:452-478.
- 6. Chambrone L, Faggion CM Jr, Pannuti CM, Chambrone LA. Evidence-based periodontal plastic surgery: An assessment of quality of systematic reviews in the treatment of recession-type defects. *J Clin Periodontol* 2010;37:1110-1118.

- Chambrone L, Pannuti CM, Tu YK, Chambrone LA. Evidence-based periodontal plastic surgery. II. An individual data meta-analysis for evaluating factors in achieving complete root coverage. *J Periodontol* 2012;83:477-490.
- Oates TW, Robinson M, Gunsolley JC. Surgical therapies for the treatment of gingival recession. A systematic review. *Ann Periodontol* 2003;8:303-320.
- Roccuzzo M, Bunino M, Needleman I, Sanz M. Periodontal plastic surgery for treatment of localized gingival recessions: A systematic review. *J Clin Peri*odontol 2002;29(Suppl. 3):178-194, discussion 195-196.
- Cairo F, Pagliaro U, Nieri M. Treatment of gingival recession with coronally advanced flap procedures: A systematic review. J Clin Periodontol 2008; 35(Suppl. 8):136-162.
- Buti J, Baccini M, Nieri M, La Marca M, Pini-Prato GP. Bayesian network meta-analysis of root coverage procedures: Ranking efficacy and identification of best treatment. *J Clin Periodontol* 2013;40:372-386.
- 12. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.0.1 [updated September 2008]. *The Cochrane Collaboration* 2008. Available at: www.cochrane-handbook.org (accessed and downloaded November 15, 2008).
- McGuire MK, Newman MG. Evidence-based periodontal treatment. I. A strategy for clinical decisions. Int J Periodontics Restorative Dent 1995;15:70-83.
- 14. Needleman IG. A guide to systematic reviews. *J Clin Periodontol* 2002;29(Suppl. 3):6-9, discussion 37-38.
- 15. Miller PD Jr. Regenerative and reconstructive periodontal plastic surgery. Mucogingival surgery. *Dent Clin North Am* 1988;32:287-306.
- 16. Pihlstrom BL, Curran AE, Voelker HT, Kingman A. Randomized controlled trials: What are they and who needs them? *Periodontol 2000* 2012;59:14-31.
- 17. Miller PD Jr. A classification of marginal tissue recession. Int J Periodontics Restorative Dent 1985;5:8-13.
- Lavis JN, Robertson D, Woodside JM, McLeod CB, Abelson J; Knowledge Transfer Study Group. How can research organizations more effectively transfer research knowledge to decision makers? *Milbank Q* 2003;81:221-248, 171-172.
- 19. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *J Clin Epidemiol* 2009;62:1006-1012.
- 20. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. *J Clin Epidemiol* 1992;45:769-773.
- Al-Hamdan K, Eber R, Sarment D, Kowalski C, Wang HL. Guided tissue regeneration-based root coverage: Meta-analysis. *J Periodontol* 2003;74:1520-1533.
- 22. Gapski R, Parks CA, Wang HL. Acellular dermal matrix for mucogingival surgery: A meta-analysis. *J Periodontol* 2005;76:1814-1822.
- Hwang D, Wang HL. Flap thickness as a predictor of root coverage: A systematic review. J Periodontol 2006;77:1625-1634.
- 24. Cheng YF, Chen JW, Lin SJ, Lu HK. Is coronally positioned flap procedure adjunct with enamel matrix derivative or root conditioning a relevant predictor for achieving root coverage? A systemic review. *J Periodontal Res* 2007;42:474-485.
- 25. Clauser C, Nieri M, Franceschi D, Pagliaro U, Pini-Prato G. Evidence-based mucogingival therapy. Part

2: Ordinary and individual patient data meta-analyses of surgical treatment of recession using complete root coverage as the outcome variable. *J Periodontol* 2003;74:741-756.

- Pagliaro U, Nieri M, Franceschi D, Clauser C, Pini-Prato G. Evidence-based mucogingival therapy. Part 1: A critical review of the literature on root coverage procedures. *J Periodontol* 2003;74:709-740.
- 27. Hofmänner P, Alessandri R, Laugisch O, et al. Predictability of surgical techniques used for coverage of multiple adjacent gingival recessions — A systematic review. *Quintessence Int* 2012;43:545-554.
- 28. Oliveira GH, Muncinelli EA. Efficacy of root surface biomodification in root coverage: A systematic review. *J Can Dent Assoc* 2012;78:c122.
- 29. Douglas de Oliveira DW, Oliveira-Ferreira F, Flecha OD, Gonçalves PF. Is surgical root coverage effective for the treatment of cervical dentin hypersensitivity? A systematic review. *J Periodontol* 2013;84:295-306.
- Abolfazli N, Saleh-Saber F, Eskandari A, Lafzi A. A comparative study of the long term results of root coverage with connective tissue graft or enamel matrix protein: 24-month results. *Med Oral Patol Oral Cir Bucal* 2009;14:E304-E309.
- 31. Aichelmann-Reidy ME, Yukna RA, Evans GH, Nasr HF, Mayer ET. Clinical evaluation of acellular allograft dermis for the treatment of human gingival recession. *J Periodontol* 2001;72:998-1005.
- 32. Alkan EA, Parlar A. EMD or subepithelial connective tissue graft for the treatment of single gingival recessions: A pilot study. *J Periodontal Res* 2011;46:637-642.
- 33. Aroca S, Keglevich T, Barbieri B, Gera I, Etienne D. Clinical evaluation of a modified coronally advanced flap alone or in combination with a platelet-rich fibrin membrane for the treatment of adjacent multiple gingival recessions: A 6-month study. *J Periodontol* 2009;80:244-252.
- 34. Aroca S, Molnár B, Windisch P, et al. Treatment of multiple adjacent Miller class I and II gingival recessions with a Modified Coronally Advanced Tunnel (MCAT) technique and a collagen matrix or palatal connective tissue graft: A randomized, controlled clinical trial. *J Clin Periodontol* 2013;40:713-720.
- 35. Babu HM, Gujjari SK, Prasad D, Sehgal PK, Srinivasan A. Comparative evaluation of a bioabsorbable collagen membrane and connective tissue graft in the treatment of localized gingival recession: A clinical study. *J Indian Soc Periodontol* 2011;15:353-358.
- Banihashemrad A, Aghassizadeh E, Radvar M. Treatment of gingival recessions by guided tissue regeneration and coronally advanced flap. N Y State Dent J 2009;75:54-58.
- 37. Barros RR, Novaes AB Jr, Grisi MF, Souza SL, Taba MJ, Palioto DB. A 6-month comparative clinical study of a conventional and a new surgical approach for root coverage with acellular dermal matrix. *J Periodontol* 2004;75:1350-1356.
- 38. Barros RR, Novaes AB Jr, Grisi MF, Souza SL, Taba M Jr, Palioto DB. New surgical approach for root coverage of localized gingival recession with acellular dermal matrix: A 12-month comparative clinical study. *J Esthet Restor Dent* 2005;17:156-164, discussion 164.
- 39. Berlucchi I, Francetti L, Del Fabbro M, Testori T, Weinstein RL. Enamel matrix proteins (Emdogain) in combination with coronally advanced flap or subepithelial connective tissue graft in the treatment of

shallow gingival recessions. Int J Periodontics Restorative Dent 2002;22:583-593.

- 40. Bittencourt S, Del Peloso Ribeiro E, Sallum EA, Sallum AW, Nociti FH Jr, Casati MZ. Comparative 6-month clinical study of a semilunar coronally positioned flap and subepithelial connective tissue graft for the treatment of gingival recession. *J Periodontol* 2006;77:174-181.
- 41. Bittencourt S, Ribeiro Edel P, Sallum EA, Sallum AW, Nociti FH Jr, Casati MZ. Semilunar coronally positioned flap or subepithelial connective tissue graft for the treatment of gingival recession: A 30-month follow-up study. *J Periodontol* 2009;80:1076-1082.
- 42. Bittencourt S, Del Peloso Ribeiro E, Sallum EA, Nociti FH Jr, Casati MZ. Surgical microscope may enhance root coverage with subepithelial connective tissue graft: A randomized-controlled clinical trial. *J Periodontol* 2012;83:721-730.
- 43. Borghetti A, Glise JM, Monnet-Corti V, Dejou J. Comparative clinical study of a bioabsorbable membrane and subepithelial connective tissue graft in the treatment of human gingival recession. *J Periodontol* 1999;70:123-130.
- 44. Bouchard P, Etienne D, Ouhayoun JP, Nilvéus R. Subepithelial connective tissue grafts in the treatment of gingival recessions. A comparative study of 2 procedures. J Periodontol 1994;65:929-936.
- 45. Bouchard P, Nilveus R, Etienne D. Clinical evaluation of tetracycline HCl conditioning in the treatment of gingival recessions. A comparative study. *J Periodontol* 1997;68:262-269.
- Burkhardt R, Lang NP. Coverage of localized gingival recessions: Comparison of micro- and macrosurgical techniques. J Clin Periodontol 2005;32:287-293.
- 47. Byun HY, Oh TJ, Abuhussein HM, Yamashita J, Soehren SE, Wang HL. Significance of the epithelial collar on the subepithelial connective tissue graft. *J Periodontol* 2009;80:924-932.
- 48. Caffesse RG, De LaRosa M, Garza M, Munne-Travers A, Mondragon JC, Weltman R. Citric acid demineralization and subepithelial connective tissue grafts. *J Periodontol* 2000;71:568-572.
- 49. Cardaropoli D, Cardaropoli G. Healing of gingival recessions using a collagen membrane with a hemineralized xenograft: A randomized controlled clinical trial. *Int J Periodontics Restorative Dent* 2009;29:59-67.
- 50. Cardaropoli D, Tamagnone L, Roffredo A, Gaveglio L. Treatment of gingival recession defects using coronally advanced flap with a porcine collagen matrix compared to coronally advanced flap with connective tissue graft: A randomized controlled clinical trial. *J Periodontol* 2012;83:321-328.
- 51. Castellanos A, de la Rosa M, de la Garza M, Caffesse RG. Enamel matrix derivative and coronal flaps to cover marginal tissue recessions. *J Periodontol* 2006; 77:7-14.
- 52. Cheung WS, Griffin TJ. A comparative study of root coverage with connective tissue and platelet concentrate grafts: 8-month results. *J Periodontol* 2004;75: 1678-1687.
- 53. Cordaro L, di Torresanto VM, Torsello F. Split-mouth comparison of a coronally advanced flap with or without enamel matrix derivative for coverage of multiple gingival recession defects: 6- and 24-month follow-up. *Int J Periodontics Restorative Dent* 2012; 32:e10-e20.

- 54. Cortellini P, Tonetti M, Baldi C, et al. Does placement of a connective tissue graft improve the outcomes of coronally advanced flap for coverage of single gingival recessions in upper anterior teeth? A multi-centre, randomized, double-blind, clinical trial. *J Clin Periodontol* 2009;36:68-79.
- 55. Cetiner D, Parlar A, Baloş K, Alpar R. Comparative clinical study of connective tissue graft and two types of bioabsorbable barriers in the treatment of localized gingival recessions. *J Periodontol* 2003;74:1196-1205.
- 56. da Silva RC, Joly JC, de Lima AF, Tatakis DN. Root coverage using the coronally positioned flap with or without a subepithelial connective tissue graft. J Periodontol 2004;75:413-419.
- 57. de Queiroz Côrtes A, Martins AG, Nociti FH Jr, Sallum AW, Casati MZ, Sallum EA. Coronally positioned flap with or without acellular dermal matrix graft in the treatment of Class I gingival recessions: A randomized controlled clinical study. *J Periodontol* 2004;75: 1137-1144.
- de Queiroz Côrtes A, Sallum AW, Casati MZ, Nociti FH Jr, Sallum EA. A two-year prospective study of coronally positioned flap with or without acellular dermal matrix graft. J Clin Periodontol 2006;33:683-689.
- 59. Del Pizzo M, Zucchelli G, Modica F, Villa R, Debernardi C. Coronally advanced flap with or without enamel matrix derivative for root coverage: A 2-year study. *J Clin Periodontol* 2005;32:1181-1187.
- 60. Dilsiz A, Aydin T, Canakci V, Cicek Y. Root surface biomodification with Nd:YAG laser for the treatment of gingival recession with subepithelial connective tissue grafts. *Photomed Laser Surg* 2010;28:337-343.
- 61. Dilsiz A, Aydin T, Yavuz MŠ. Root surface biomodification with an Er:YAG laser for the treatment of gingival recession with subepithelial connective tissue grafts. *Photomed Laser Surg* 2010;28:511-517.
- 62. Dodge JR, Greenwell H, Drisko C, Wittwer JW, Yancey J, Rebitski G. Improved bone regeneration and root coverage using a resorbable membrane with physically assisted cell migration and DFDBA. *Int J Periodontics Restorative Dent* 2000;20:398-411.
- 63. Duval BT, Maynard JG, Gunsolley JC, Waldrop TC. Treatment of human mucogingival defects utilizing a bioabsorbable membrane with and without a demineralized freeze-dried bone allograft. *J Periodontol* 2000;71:1687-1692.
- 64. Felipe ME, Andrade PF, Grisi MF, et al. Comparison of two surgical procedures for use of the acellular dermal matrix graft in the treatment of gingival recessions: A randomized controlled clinical study. *J Periodontol* 2007;78:1209-1217.
- 65. Haghighati F, Mousavi M, Moslemi N, Kebria MM, Golestan B. A comparative study of two root-coverage techniques with regard to interdental papilla dimension as a prognostic factor. *Int J Periodontics Restorative Dent* 2009;29:179-189.
- 66. Moslemi N, Mousavi Jazi M, Haghighati F, Morovati SP, Jamali R. Acellular dermal matrix allograft versus subepithelial connective tissue graft in treatment of gingival recessions: A 5-year randomized clinical study. *J Clin Periodontol* 2011;38:1122-1129.
- 67. Henderson RD, Greenwell H, Drisko C, et al. Predictable multiple site root coverage using an acellular dermal matrix allograft. *J Periodontol* 2001;72:571-582.
- 68. Huang LH, Neiva RE, Soehren SE, Giannobile WV, Wang HL. The effect of platelet-rich plasma on the

coronally advanced flap root coverage procedure: A pilot human trial. *J Periodontol* 2005;76:1768-1777.

- 69. Ito K, Oshio K, Shiomi N, Murai S. A preliminary comparative study of the guided tissue regeneration and free gingival graft procedures for adjacent facial root coverage. *Quintessence Int* 2000;31:319-326.
- Jahnke PV, Sandifer JB, Gher ME, Gray JL, Richardson AC. Thick free gingival and connective tissue autografts for root coverage. *J Periodontol* 1993;64: 315-322.
- 71. Jaiswal GR, Kumar R, Khatri PM, Jaiswal SG, Bhongade ML. The effectiveness of enamel matrix protein (Emdogain(®)) in combination with coronally advanced flap in the treatment of multiple marginal tissue recession: A clinical study. *J Indian Soc Periodontol* 2012;16:224-230.
- Jankovic S, Aleksic Z, Klokkevold P, et al. Use of platelet-rich fibrin membrane following treatment of gingival recession: A randomized clinical trial. *Int J Periodontics Restorative Dent* 2012;32:e41-e50.
- 73. Jankovic S, Aleksic Z, Milinkovic I, Dimitrijevic B. The coronally advanced flap in combination with plateletrich fibrin (PRF) and enamel matrix derivative in the treatment of gingival recession: A comparative study. *Eur J Esthet Dent* 2010;5:260-273.
- 74. Jepsen K, Heinz B, Halben JH, Jepsen S. Treatment of gingival recession with titanium reinforced barrier membranes versus connective tissue grafts. *J Periodontol* 1998;69:383-391.
- 75. Jepsen K, Jepsen S, Zucchelli G, et al. Treatment of gingival recession defects with a coronally advanced flap and a xenogeneic collagen matrix: A multicenter randomized clinical trial. *J Clin Periodontol* 2013;40:82-89.
- 76. Joly JC, Carvalho AM, da Silva RC, Ciotti DL, Cury PR. Root coverage in isolated gingival recessions using autograft versus allograft: A pilot study. *J Periodontol* 2007;78:1017-1022.
- 77. Keceli HG, Sengun D, Berberoğlu A, Karabulut E. Use of platelet gel with connective tissue grafts for root coverage: A randomized-controlled trial. *J Clin Periodontol* 2008;35:255-262.
- 78. Kimble KM, Eber RM, Soehren S, Shyr Y, Wang HL. Treatment of gingival recession using a collagen membrane with or without the use of demineralized freeze-dried bone allograft for space maintenance. *J Periodontol* 2004;75:210-220.
- 79. Koudale SB, Charde PA, Bhongade ML. A comparative clinical evaluation of acellular dermal matrix allograft and sub-epithelial connective tissue graft for the treatment of multiple gingival recessions. *J Indian Soc Periodontol* 2012;16:411-416.
- 80. Kuis D, Sciran I, Lajnert V, et al. Coronally advanced flap alone or with connective tissue graft in the treatment of single gingival recession defects: A long-term randomized clinical trial. *J Periodontol* 2013;84:1576-1585.
- 81. Kuru B, Yıldırım S. Treatment of localized gingival recessions using gingival unit grafts: A randomized controlled clinical trial. *J Periodontol* 2013;84:41-50.
- 82. Köseoğlu S, Duran İ, Sağlam M, Bozkurt SB, Kırtıloğlu OS, Hakkı SS. Efficacy of collagen membrane seeded with autologous gingival fibroblasts in gingival recession treatment: A randomized, controlled pilot study. *J Periodontol* 2013;84:1416-1424.
- 83. Leknes KN, Amarante ES, Price DE, Bøe OE, Skavland RJ, Lie T. Coronally positioned flap procedures with or without a biodegradable membrane in the treatment of

human gingival recession. A 6-year follow-up study. *J Clin Periodontol* 2005;32:518-529.

- Amarante ES, Leknes KN, Skavland J, Lie T. Coronally positioned flap procedures with or without a bioabsorbable membrane in the treatment of human gingival recession. *J Periodontol* 2000;71:989-998.
- 85. Lins LH, de Lima AF, Sallum AW. Root coverage: Comparison of coronally positioned flap with and without titanium-reinforced barrier membrane. *J Periodontol* 2003;74:168-174.
- 86. Mahajan A, Dixit J, Verma UP. A patient-centered clinical evaluation of acellular dermal matrix graft in the treatment of gingival recession defects. *J Periodontol* 2007;78:2348-2355.
- 87. Mahajan A, Bharadwaj A, Mahajan P. Comparison of periosteal pedicle graft and subepithelial connective tissue graft for the treatment of gingival recession defects. *Aust Dent J* 2012;57:51-57.
- 88. Matarasso S, Cafiero C, Coraggio F, Vaia E, de Paoli S. Guided tissue regeneration versus coronally repositioned flap in the treatment of recession with double papillae. *Int J Periodontics Restorative Dent* 1998;18:444-453.
- Mazzocco F, Comuzzi L, Stefani R, Milan Y, Favero G, Stellini E. Coronally advanced flap combined with a subepithelial connective tissue graft using full- or partial-thickness flap reflection. *J Periodontol* 2011; 82:1524-1529.
- 90. McGuire MK, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue. Part 1: Comparison of clinical parameters. *J Peri*odontol 2003;74:1110-1125.
- 91. McGuire MK, Scheyer ET, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue: Comparison of clinical parameters at 10 years. *J Periodontol* 2012;83:1353-1362.
- 92. McGuire MK, Scheyer ET. Xenogeneic collagen matrix with coronally advanced flap compared to connective tissue with coronally advanced flap for the treatment of dehiscence-type recession defects. *J Periodontol* 2010;81:1108-1117.
- 93. McGuire MK, Scheyer ET, Schupbach P. Growth factor-mediated treatment of recession defects: A randomized controlled trial and histologic and micro-computed tomography examination. *J Periodontol* 2009;80:550-564.
- 94. Modica F, Del Pizzo M, Roccuzzo M, Romagnoli R. Coronally advanced flap for the treatment of buccal gingival recessions with and without enamel matrix derivative. A split-mouth study. *J Periodontol* 2000; 71:1693-1698.
- 95. Nazareth CA, Cury PR. Use of anorganic bovinederived hydroxyapatite matrix/cell-binding peptide (P-15) in the treatment isolated Class I gingival recession of defects: A pilot study. *J Periodontol* 2011;82:700-707.
- Nickles K, Ratka-Krüger P, Neukranz E, Raetzke P, Eickholz P. Ten-year results after connective tissue grafts and guided tissue regeneration for root coverage. *J Periodontol* 2010;81:827-836.
- 97. Novaes AB Jr, Grisi DC, Molina GO, Souza SL, Taba M Jr, Grisi MF. Comparative 6-month clinical study of a subepithelial connective tissue graft and acellular dermal matrix graft for the treatment of gingival recession. *J Periodontol* 2001;72:1477-1484.

- 98. Ozcelik O, Haytac MC, Seydaoglu G. Treatment of multiple gingival recessions using a coronally advanced flap procedure combined with button application. *J Clin Periodontol* 2011;38:572-580.
- 99. Ozturan S, Durukan SA, Ozcelik O, Seydaoglu G, Haytac MC. Coronally advanced flap adjunct with low intensity laser therapy: A randomized controlled clinical pilot study. *J Clin Periodontol* 2011;38: 1055-1062.
- 100. Paolantonio M, di Murro C, Cattabriga A, Cattabriga M. Subpedicle connective tissue graft versus free gingival graft in the coverage of exposed root surfaces. A 5-year clinical study. *J Clin Periodontol* 1997;24:51-56.
- 101. Paolantonio M. Treatment of gingival recessions by combined periodontal regenerative technique, guided tissue regeneration, and subpedicle connective tissue graft. A comparative clinical study. *J Periodontol* 2002;73:53-62.
- 102. Paolantonio M, Dolci M, Esposito P, et al. Subpedicle acellular dermal matrix graft and autogenous connective tissue graft in the treatment of gingival recessions: A comparative 1-year clinical study. *J Periodontol* 2002;73:1299-1307.
- 103. Pilloni A, Paolantonio M, Camargo PM. Root coverage with a coronally positioned flap used in combination with enamel matrix derivative: 18-month clinical evaluation. *J Periodontol* 2006;77:2031-2039.
- 104. Pini Prato G, Rotundo R, Franceschi D, Cairo F, Cortellini P, Nieri M. Fourteen-year outcomes of coronally advanced flap for root coverage: Followup from a randomized trial. *J Clin Periodontol* 2011; 38:715-720.
- 105. Pourabbas R, Chitsazi MT, Kosarieh E, Olyaee P. Coronally advanced flap in combination with acellular dermal matrix with or without enamel matrix derivatives for root coverage. *Indian J Dent Res* 2009;20: 320-325.
- 106. Rasperini G, Roccuzzo M, Francetti L, Acunzo R, Consonni D, Silvestri M. Subepithelial connective tissue graft for treatment of gingival recessions with and without enamel matrix derivative: A multicenter, randomized controlled clinical trial. *Int J Periodontics Restorative Dent* 2011;31:133-139.
- 107. Ricci G, Silvestri M, Tinti C, Rasperini G. A clinical/ statistical comparison between the subpedicle connective tissue graft method and the guided tissue regeneration technique in root coverage. *Int J Periodontics Restorative Dent* 1996;16:538-545.
- 108. Roccuzzo M, Lungo M, Corrente G, Gandolfo S. Comparative study of a bioresorbable and a nonresorbable membrane in the treatment of human buccal gingival recessions. *J Periodontol* 1996;67: 7-14.
- 109. Romagna-Genon C. Comparative clinical study of guided tissue regeneration with a bioabsorbable bilayer collagen membrane and subepithelial connective tissue graft. *J Periodontol* 2001;72:1258-1264.
- 110. Rosetti EP, Marcantonio RA, Rossa C Jr, Chaves ES, Goissis G, Marcantonio E Jr. Treatment of gingival recession: comparative study between subepithelial connective tissue graft and guided tissue regeneration. *J Periodontol* 2000;71:1441-1447.
- 111. Rosetti EP, Marcantonio E Jr, Zuza EP, Marcantonio RA. Root coverage stability of the subepithelial connective tissue graft and guided tissue regeneration: A 30-month follow-up clinical trial. *J Dent* 2013;41: 114-120.

- 112. Santana RB, Mattos CML, Dibart S. A clinical comparison of two flap designs for coronal advancement of the gingival margin: Semilunar versus coronally advanced flap. *J Clin Periodontol* 2010;37:651-658.
- 113. Santana RB, Furtado MB, Mattos CML, de Mello Fonseca E, Dibart S. Clinical evaluation of singlestage advanced versus rotated flaps in the treatment of gingival recessions. *J Periodontol* 2010;81:485-492.
- 114. Shori T, Kolte A, Kher V, Dharamthok S, Shrirao T. A comparative evaluation of the effectiveness of subpedicle acellular dermal matrix allograft with subepithelial connective tissue graft in the treatment of isolated marginal tissue recession: A clinical study. *J Indian Soc Periodontol* 2013;17:78-81.
- 115. Spahr A, Haegewald S, Tsoulfidou F, et al. Coverage of Miller class I and II recession defects using enamel matrix proteins versus coronally advanced flap technique: A 2-year report. *J Periodontol* 2005;76:1871-1880.
- 116. Hägewald S, Spahr A, Rompola E, Haller B, Heijl L, Bernimoulin JP. Comparative study of Emdogain and coronally advanced flap technique in the treatment of human gingival recessions. A prospective controlled clinical study. *J Clin Periodontol* 2002;29:35-41.
- 117. Tatakis DN, Trombelli L. Gingival recession treatment: Guided tissue regeneration with bioabsorbable membrane versus connective tissue graft. *J Periodontol* 2000;71:299-307.
- 118. Trabulsi M, Oh TJ, Eber R, Weber D, Wang HL. Effect of enamel matrix derivative on collagen guided tissue regeneration-based root coverage procedure. *J Periodontol* 2004;75:1446-1457.
- 119. Tözüm TF, Keçeli HG, Güncü GN, Hatipoğlu H, Sengün D. Treatment of gingival recession: Comparison of two techniques of subepithelial connective tissue graft. *J Periodontol* 2005;76:1842-1848.
- 120. Trombelli L, Scabbia A, Wikesjö UM, Calura G. Fibrin glue application in conjunction with tetracycline root conditioning and coronally positioned flap procedure in the treatment of human gingival recession defects. *J Clin Periodontol* 1996;23:861-867.
- 121. Trombelli L, Schincaglia GP, Zangari F, Griselli A, Scabbia A, Calura G. Effects of tetracycline HCl conditioning and fibrin-fibronectin system application in the treatment of buccal gingival recession with guided tissue regeneration. *J Periodontol* 1995;66: 313-320.
- 122. Trombelli L, Scabbia A, Tatakis DN, Calura G. Subpedicle connective tissue graft versus guided tissue regeneration with bioabsorbable membrane in the treatment of human gingival recession defects. *J Periodontol* 1998;69:1271-1277.
- 123. Wang HL, Bunyaratavej P, Labadie M, Shyr Y, MacNeil RL. Comparison of 2 clinical techniques for treatment of gingival recession. *J Periodontol* 2001;72:1301-1311.
- 124. Wilson TG Jr., McGuire MK, Nunn ME. Evaluation of the safety and efficacy of periodontal applications of a living tissue-engineered human fibroblast-derived dermal substitute. II. Comparison to the subepithelial connective tissue graft: A randomized controlled feasibility study. *J Periodontol* 2005;76:881-889.
- 125. Woodyard JG, Greenwell H, Hill M, Drisko C, Iasella JM, Scheetz J. The clinical effect of acellular dermal matrix on gingival thickness and root coverage compared to coronally positioned flap alone. *J Periodontol* 2004;75:44-56.

- 126. Zucchelli G, Clauser C, De Sanctis M, Calandriello M. Mucogingival versus guided tissue regeneration procedures in the treatment of deep recession type defects. *J Periodontol* 1998;69:138-145.
- 127. Zucchelli G, Amore C, Sforza NM, Montebugnoli L, De Sanctis M. Bilaminar techniques for the treatment of recession-type defects. A comparative clinical study. *J Clin Periodontol* 2003;30:862-870.
- 128. Zucchelli G, Mele M, Mazzotti C, Marzadori M, Montebugnoli L, De Sanctis M. Coronally advanced flap with and without vertical releasing incisions for the treatment of multiple gingival recessions: A comparative controlled randomized clinical trial. *J Periodontol* 2009;80:1083-1094.
- 129. Zucchelli G, Mounssif I, Stefanini M, Mele M, Montebugnoli L, Sforza NM. Hand and ultrasonic instrumentation in combination with root-coverage surgery: A comparative controlled randomized clinical trial. *J Periodontol* 2009;80:577-585.
- 130. Zucchelli G, Mele M, Stefanini M, et al. Patient morbidity and root coverage outcome after subepithelial connective tissue and de-epithelialized grafts: A comparative randomized-controlled clinical trial. *J Clin Periodontol* 2010;37:728-738.
- 131. Zucchelli G, Marzadori M, Mele M, Stefanini M, Montebugnoli L. Root coverage in molar teeth: A comparative controlled randomized clinical trial. *J Clin Periodontol* 2012;39:1082-1088.
- 132. Miller PD Jr. Root coverage using the free soft tissue autograft following citric acid application. III. A successful and predictable procedure in areas of deep-wide recession. *Int J Periodontics Restorative Dent* 1985;5:14-37.
- 133. Barker TS, Cueva MA, Rivera-Hidalgo F, et al. A comparative study of root coverage using two different acellular dermal matrix products. *J Periodontol* 2010;81:1596-1603.
- 134. Boltchi FE, Allen EP, Hallmon WW. The use of a bioabsorbable barrier for regenerative management of marginal tissue recession. I. Report of 100 consecutively treated teeth. *J Periodontol* 2000;71:1641-1653.
- 135. Carney CM, Rossmann JA, Kerns DG, et al. A comparative study of root defect coverage using an acellular dermal matrix with and without a recombinant human platelet-derived growth factor. *J Periodontol* 2012;83:893-901.
- 136. Cueva MA, Boltchi FE, Hallmon WW, Nunn ME, Rivera-Hidalgo F, Rees T. A comparative study of coronally advanced flaps with and without the addition of enamel matrix derivative in the treatment of marginal tissue recession. *J Periodontol* 2004;75: 949-956.
- 137. Jepsen S, Heinz B, Kermanie MA, Jepsen K. Evaluation of a new bioabsorbable barrier for recession therapy: A feasibility study. *J Periodontol* 2000;71: 1433-1440.
- 138. Nart J, Valles C, Mareque S, Santos A, Sanz-Moliner J, Pascual A. Subepithelial connective tissue graft in combination with a coronally advanced flap for the treatment of Miller Class II and III gingival recessions in mandibular incisors: A case series. *Int J Periodontics Restorative Dent* 2012;32:647-654.
- 139. Aroca S, Keglevich T, Nikolidakis D, et al. Treatment of class III multiple gingival recessions: A randomizedclinical trial. *J Clin Periodontol* 2010;37:88-97.
- 140. Henriques PSG, Pelegrine AA, Nogueira AA, Borghi MM. Application of subepithelial connective tissue graft with or without enamel matrix derivative for root

coverage: A split-mouth randomized study. *J Oral Sci* 2010;52:463-471.

- 141. Cairo F, Cortellini P, Tonetti M, et al. Coronally advanced flap with and without connective tissue graft for the treatment of single maxillary gingival recession with loss of inter-dental attachment. A randomized controlled clinical trial. *J Clin Periodontol* 2012;39:760-768.
- 142. Miller PD Jr, Binkley LH Jr. Root coverage and ridge augmentation in Class IV recession using a coronally positioned free gingival graft. *J Periodontol* 1986;57: 360-363.
- 143. Azzi R, Takei HH, Etienne D, Carranza FA. Root coverage and papilla reconstruction using autogenous osseous and connective tissue grafts. *Int J Periodontics Restorative Dent* 2001;21:141-147.
- 144. Azzi R, Etienne D, Sauvan JL, Miller PD. Root coverage and papilla reconstruction in Class IV recession: A case report. *Int J Periodontics Restorative Dent* 1999;19:449-455.
- 145. De Castro Pinto RC, Colombini BL, Ishikiriama SK, Chambrone L, Pustiglioni FE, Romito GA. The subepithelial connective tissue pedicle graft combined with the coronally advanced flap for restoring missing papilla: A report of two cases. *Quintessence Int* 2010;41: 213-220.
- 146. Chambrone LA, Chambrone L. Root coverage in a class IV recession defect achieved by creeping attachment: A case report. *J Int Acad Periodontol* 2006;8:47-52.
- 147. Vergara JA, Caffesse RG. Localized gingival recessions treated with the original envelope technique: A report of 50 consecutive patients. *J Periodontol* 2004;75:1397-1403.
- 148. Pasquinelli KL. The histology of new attachment utilizing a thick autogenous soft tissue graft in an area of deep recession: A case report. *Int J Periodontics Restorative Dent* 1995;15:248-257.
- 149. Bruno JF, Bowers GM. Histology of a human biopsy section following the placement of a subepithelial connective tissue graft. *Int J Periodontics Restorative Dent* 2000;20:225-231.
- 150. Goldstein M, Boyan BD, Cochran DL, Schwartz Z. Human histology of new attachment after root coverage using subepithelial connective tissue graft. *J Clin Periodontol* 2001;28:657-662.
- 151. Vincenzi G, De Chiesa A, Trisi P. Guided tissue regeneration using a resorbable membrane in gingival recession-type defects: A histologic case report in humans. *Int J Periodontics Restorative Dent* 1998;18: 24-33.
- 152. Camelo M, Nevins M, Nevins ML, Schupbach P, Kim DM. Treatment of gingival recession defects with xenogenic collagen matrix: A histologic report. *Int J Periodontics Restorative Dent* 2012;32:167-173.
- 153. Majzoub Z, Landi L, Grusovin MG, Cordioli G. Histology of connective tissue graft. A case report. *J Periodontol* 2001;72:1607-1615.
- 154. McGuire MK, Scheyer T, Nevins M, Schupbach P. Evaluation of human recession defects treated with coronally advanced flaps and either purified recombinant human platelet-derived growth factor-BB with beta tricalcium phosphate or connective tissue: A histologic and microcomputed tomographic examination. *Int J Periodontics Restorative Dent* 2009; 29:7-21.

- 155. Cortellini P, Clauser C, Prato GP. Histologic assessment of new attachment following the treatment of a human buccal recession by means of a guided tissue regeneration procedure. *J Periodontol* 1993; 64:387-391.
- 156. Parma-Benfenati S, Tinti C. Histologic evaluation of new attachment utilizing a titanium-reinforced barrier membrane in a mucogingival recession defect. A case report. *J Periodontol* 1998;69:834-839.
- 157. Chambrone LA. Clinical study of the treatment of localized gingival recessions with laterally positioned flap associated with citric acid. [Thesis]. São Paulo, Brazil: University of São Paulo; 1991. 119 p.
- 158. McGuire MK, Cochran DL. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue. Part 2: Histological evaluation. *J Periodontol* 2003;74:1126-1135.
- 159. Harris RJ. Human histologic evaluation of root coverage obtained with a connective tissue with partial thickness double pedicle graft. A case report. *J Periodontol* 1999;70:813-821.
- 160. Harris RJ. Successful root coverage: A human histologic evaluation of a case. *Int J Periodontics Restorative Dent* 1999;19:439-447.
- 161. Harris RJ. Histologic evaluation of root coverage obtained with GTR in humans: A case report. *Int J Periodontics Restorative Dent* 2001;21:240-251.
- 162. Rasperini G, Silvestri M, Schenk RK, Nevins ML. Clinical and histologic evaluation of human gingival recession treated with a subepithelial connective tissue graft and enamel matrix derivative (Emdogain): A case report. *Int J Periodontics Restorative Dent* 2000;20:269-275.
- 163. Cummings LC, Kaldahl WB, Allen EP. Histologic evaluation of autogenous connective tissue and acellular dermal matrix grafts in humans. *J Periodontol* 2005;76:178-186.
- 164. Waterman CA. Guided tissue regeneration using a bioabsorbable membrane in the treatment of human buccal recession. A re-entry study. *J Periodontol* 1997;68:982-989.
- 165. Harris RJ. Root coverage with a connective tissue with partial thickness double pedicle graft and an acellular dermal matrix graft: A clinical and histological evaluation of a case report. *J Periodontol* 1998;69:1305-1311.
- 166. Baldi C, Pini-Prato G, Pagliaro U, et al. Coronally advanced flap procedure for root coverage. Is flap thickness a relevant predictor to achieve root coverage? A 19-case series. *J Periodontol* 1999;70:1077-1084.
- 167. Berlucchi I, Francetti L, Del Fabbro M, Basso M, Weinstein RL. The influence of anatomical features on the outcome of gingival recessions treated with coronally advanced flap and enamel matrix derivative: A 1-year prospective study. *J Periodontol* 2005; 76:899-907.
- 168. Huang LH, Neiva RE, Wang HL. Factors affecting the outcomes of coronally advanced flap root coverage procedure. *J Periodontol* 2005;76:1729-1734.
- 169. Pini Prato G, Pagliaro U, Baldi C, et al. Coronally advanced flap procedure for root coverage. Flap with tension versus flap without tension: A randomized controlled clinical study. *J Periodontol* 2000; 71:188-201.

- 170. Pini Prato GP, Baldi C, Nieri M, et al. Coronally advanced flap: The post-surgical position of the gingival margin is an important factor for achieving complete root coverage. *J Periodontol* 2005;76:713-722.
- 171. Nieri M, Rotundo R, Franceschi D, Cairo F, Cortellini P, Pini Prato G. Factors affecting the outcome of the coronally advanced flap procedure: A Bayesian network analysis. *J Periodontol* 2009;80:405-410.
- 172. Harris RJ. Histologic evaluation of connective tissue grafts in humans. *Int J Periodontics Restorative Dent* 2003;23:575-583.
- 173. Monnet-Corti V, Santini A, Glise JM, et al. Connective tissue graft for gingival recession treatment: Assessment of the maximum graft dimensions at the palatal vault as a donor site. *J Periodontol* 2006;77:899-902.
- 174. Harris RJ, Harris LE, Harris CR, Harris AJ. Evaluation of root coverage with two connective tissue grafts obtained from the same location. *Int J Periodontics Restorative Dent* 2007;27:333-339.
- 175. Jankovic S, Aleksic Z, Dimitrijevic B, Camargo P, Kenney B, Lekovic V. Impact of interleukin 1 gene polymorphism and smoking on long-term stability following gingival recession treatment. *Int J Periodontics Restorative Dent* 2013;33:e16-e23.
- 176. Kaval B, Renaud DE, Scott DA, Buduneli N. The role of smoking and gingival crevicular fluid markers on coronally advanced flap outcomes. *J Periodontol* 2014;85:395-405.
- 177. Alves LB, Costa PP, Scombatti de Souza SL, et al. Acellular dermal matrix graft with or without enamel matrix derivative for root coverage in smokers: A randomized clinical study. *J Clin Periodontol* 2012; 39:393-399.
- 178. Souza SL, Macedo GO, Tunes RS, et al. Subepithelial connective tissue graft for root coverage in smokers and non-smokers: A clinical and histologic controlled study in humans. *J Periodontol* 2008;79:1014-1021.
- 179. Erley KJ, Swiec GD, Herold R, Bisch FC, Peacock ME. Gingival recession treatment with connective tissue grafts in smokers and non-smokers. *J Periodontol* 2006;77:1148-1155.
- 180. Silva CO, de Lima AF, Sallum AW, Tatakis DN. Coronally positioned flap for root coverage in smokers and non-smokers: Stability of outcomes between 6 months and 2 years. *J Periodontol* 2007; 78:1702-1707.
- 181. Andia DC, Martins AG, Casati MZ, Sallum EA, Nociti FH. Root coverage outcome may be affected by heavy smoking: A 2-year follow-up study. *J Periodontol* 2008;79:647-653.
- 182. Lucchesi JA, Santos VR, Amaral CM, Peruzzo DC, Duarte PM. Coronally positioned flap for treatment of restored root surfaces: A 6-month clinical evaluation. *J Periodontol* 2007;78:615-623.
- 183. Santamaria MP, Suaid FF, Casati MZ, Nociti FH, Sallum AW, Sallum EA. Coronally positioned flap plus resin-modified glass ionomer restoration for the treatment of gingival recession associated with noncarious cervical lesions: A randomized controlled clinical trial. *J Periodontol* 2008;79:621-628.
- 184. Santamaria MP, da Silva Feitosa D, Nociti FH Jr, Casati MZ, Sallum AW, Sallum EA. Cervical restoration and the amount of soft tissue coverage achieved by coronally advanced flap: A 2-year follow-up

randomized-controlled clinical trial. *J Clin Periodontol* 2009;36:434-441.

- 185. Santamaria MP, Ambrosano GM, Casati MZ, Nociti Júnior FH, Sallum AW, Sallum EA. Connective tissue graft plus resin-modified glass ionomer restoration for the treatment of gingival recession associated with non-carious cervical lesion: A randomized-controlled clinical trial. *J Clin Periodontol* 2009;36:791-798.
- 186. Santamaria MP, da Silva Feitosa D, Casati MZ, Nociti FH Jr, Sallum AW, Sallum EA. Randomized controlled clinical trial evaluating connective tissue graft plus resin-modified glass ionomer restoration for the treatment of gingival recession associated with non-carious cervical lesion: 2-year follow-up. *J Periodontol* 2013;84:e1-e8.
- 187. Chambrone L, de Castro Pinto RC. Does the use of combined surgical/restorative approaches enhance the clinical outcomes of recession-type defects with non-carious cervical lesions? *Clin Adv Periodontics* 2014;4:127-132.
- 188. Santamaria MP, Casati MZ, Nociti FH Jr, et al. Connective tissue graft plus resin-modified glass ionomer restoration for the treatment of gingival recession associated with non-carious cervical lesions: Microbiological and immunological results. *Clin Oral Investig* 2013;17:67-77.
- 189. Santamaria MP, Ambrosano GM, Casati MZ, Nociti FH Jr, Sallum AW, Sallum EA. The influence of local anatomy on the outcome of treatment of gingival recession associated with non-carious cervical lesions. *J Periodontol* 2010;81:1027-1034.
- 190. Zucchelli G, Gori G, Mele M, et al. Non-carious cervical lesions associated with gingival recessions: A decision-making process. *J Periodontol* 2011;82: 1713-1724.
- 191. Cairo F, Pini-Prato GP. A technique to identify and reconstruct the cementoenamel junction level using combined periodontal and restorative treatment of gingival recession. A prospective clinical study. *Int J Periodontics Restorative Dent* 2010;30:573-581.
- 192. Fourel J. Gingival reattachment on carious tooth surfaces. A 4-year follow-up. J Clin Periodontol 1982;9:285-289.
- 193. Miller PD Jr. Root coverage using the free soft tissue autograft following citric acid application. II. Treatment of the carious root. *Int J Periodontics Restorative Dent* 1983;3:38-51.
- 194. Prato GP, Tinti C, Cortellini P, Magnani C, Clauser C. Periodontal regenerative therapy with coverage of previously restored root surfaces: Case reports. *Int J Periodontics Restorative Dent* 1992;12:450-461.
- 195. Corsair A. Root coverage of a previously restored tooth. A case report with a 7-year follow-up. *Clin Cosmet Investig Dent* 2009;1:35-38.
- 196. Goldstein M, Nasatzky E, Goultschin J, Boyan BD, Schwartz Z. Coverage of previously carious roots is as predictable a procedure as coverage of intact roots. *J Periodontol* 2002;73:1419-1426.
- 197. Pini-Prato G, Baldi C, Pagliaro U, et al. Coronally advanced flap procedure for root coverage. Treatment of root surface: Root planning versus polishing. *J Periodontol* 1999;70:1064-1076.
- 198. Harris RJ. Root coverage in molar recession: Report of 50 consecutive cases treated with subepithelial connective tissue grafts. *J Periodontol* 2003;74:703-708.

- 199. de Sanctis M, Baldini N, Goracci C, Zucchelli G. Coronally advanced flap associated with a connective tissue graft for the treatment of multiple recession defects in mandibular posterior teeth. *Int J Periodontics Restorative Dent* 2011;31:623-630.
- 200. Harris RJ, Miller LH, Harris CR, Miller RJ. A comparison of three techniques to obtain root coverage on mandibular incisors. *J Periodontol* 2005;76:1758-1767.
- 201. Chambrone LA, Chambrone L. Subepithelial connective tissue grafts in the treatment of multiple recession-type defects. *J Periodontol* 2006;77:909-916.
- 202. Chambrone LA, Chambrone L. Treatment of Miller Class I and II localized recession defects using laterally positioned flaps: A 24-month study. *Am J Dent* 2009; 22:339-344.
- 203. Harris RJ. Root coverage of a palatal recession defect: A case report. *J Periodontol* 2001;72:1103-1107.
- 204. Wilcko MT, Wilcko WM, Murphy KG, et al. Fullthickness flap/subepithelial connective tissue grafting with intramarrow penetrations: Three case reports of lingual root coverage. *Int J Periodontics Restorative Dent* 2005;25:561-569.
- 205. Soileau KM. Treatment of a mucogingival defect associated with intraoral piercing. *J Am Dent Assoc* 2005;136:490-494.
- 206. Caffesse RG, Guinard EA. Treatment of localized gingival recessions. Part IV. Results after three years. *J Periodontol* 1980;51:167-170.
- 207. Guinard EA, Caffesse RG. Treatment of localized gingival recessions. Part III. Comparison of results obtained with lateral sliding and coronally repositioned flaps. *J Periodontol* 1978;49:457-461.
- 208. de Sanctis M, Zucchelli G. Coronally advanced flap: A modified surgical approach for isolated recession-type defects: Three-year results. *J Clin Periodontol* 2007;34:262-268.
- 209. Griffin TJ, Cheung WS. Guided tissue regenerationbased root coverage with a platelet concentrate graft: A 3-year follow-up case series. *J Periodontol* 2009; 80:1192-1199.
- 210. Gunay H, Dogan S, Geurtsen W. Harvesting technique using a mucotome and modified surgical procedure for root coverage with enamel matrix derivatives with and without a connective tissue graft. *Int J Periodontics Restorative Dent* 2008;28:497-507.
- 211. Harris RJ. Root coverage with connective tissue grafts: An evaluation of short- and long-term results. *J Periodontol* 2002;73:1054-1059.
- 212. Lee YM, Kim JY, Seol YJ, et al. A 3-year longitudinal evaluation of subpedicle free connective tissue graft for gingival recession coverage. *J Periodontol* 2002; 73:1412-1418.
- 213. Moses O, Artzi Z, Sculean A, et al. Comparative study of two root coverage procedures: A 24-month followup multicenter study. *J Periodontol* 2006;77:195-202.
- 214. Pini Prato G, Clauser C, Cortellini P, Tinti C, Vincenzi G, Pagliaro U. Guided tissue regeneration versus mucogingival surgery in the treatment of human buccal recessions. A 4-year follow-up study. *J Periodontol* 1996;67:1216-1223.
- 215. Pini-Prato G, Franceschi D, Rotundo R, Cairo F, Cortellini P, Nieri M. Long-term 8-year outcomes of coronally advanced flap for root coverage. *J Periodontol* 2012;83:590-594.

- 216. Pini-Prato GP, Cairo F, Nieri M, Franceschi D, Rotundo R, Cortellini P. Coronally advanced flap versus connective tissue graft in the treatment of multiple gingival recessions: A split-mouth study with a 5-year follow-up. *J Clin Periodontol* 2010;37:644-650.
- 217. Rossberg M, Eickholz P, Raetzke P, Ratka-Krüger P. Long-term results of root coverage with connective tissue in the envelope technique: A report of 20 cases. Int J Periodontics Restorative Dent 2008;28:19-27.
- 218. Scabbia A, Trombelli L. Long-term stability of the mucogingival complex following guided tissue regeneration in gingival recession defects. *J Clin Periodontol* 1998;25:1041-1046.
- Trombelli L, Minenna L, Farina R, Scabbia A. Guided tissue regeneration in human gingival recessions. A 10-year follow-up study. *J Clin Periodontol* 2005;32: 16-20.
- 220. Tözüm TF. Root coverage with subepithelial connective tissue grafts and modified tunnel technique. An evaluation of long-term results. N Y State Dent J 2006;72:38-41.
- 221. Wennström JL, Zucchelli G. Increased gingival dimensions. A significant factor for successful outcome of root coverage procedures? A 2-year prospective clinical study. J Clin Periodontol 1996;23:770-777.
- 222. Zahedi S, Bozon C, Brunel G. A 2-year clinical evaluation of a diphenylphosphorylazide-cross-linked collagen membrane for the treatment of buccal gingival recession. *J Periodontol* 1998;69:975-981.
- 223. Zucchelli G, De Sanctis M. Long-term outcome following treatment of multiple Miller class I and II recession defects in esthetic areas of the mouth. *J Periodontol* 2005;76:2286-2292.
- 224. Breault LG, Billman MA, Lewis DM. Report of a gingival "surgical cyst" developing secondarily to a subepithelial connective tissue graft. *J Periodontol* 1997; 68:392-395.
- 225. Harris RJ. Formation of a cyst-like area after a connective tissue graft for root coverage. J Periodontol 2002;73:340-345.
- 226. Hokett SD, Peacock ME, Burns WT, Swiec GD, Cuenin MF. External root resorption following partial-thickness connective tissue graft placement: A case report. *J Periodontol* 2002;73:334-339.
- 227. Carnio J, Camargo PM, Kenney EB. Root resorption associated with a subepithelial connective tissue graft for root coverage: Clinical and histologic report of a case. Int J Periodontics Restorative Dent 2003;23: 391-398.
- 228. Corsair AJ, Iacono VJ, Moss SS. Exostosis following a subepithelial connective tissue graft. *J Int Acad Periodontol* 2001;3:38-41.
- 229. Tatakis DN, Trombelli L. Adverse effects associated with a bioabsorbable guided tissue regeneration device in the treatment of human gingival recession defects. A clinicopathologic case report. *J Periodontol* 1999;70:542-547.
- 230. Parashis AO, Tatakis DN. Subepithelial connective tissue graft for root coverage: A case report of an unusual late complication of epithelial origin. *J Periodontol* 2007;78:2051-2056.
- 231. Goldman H, Schluger S, Fox L, Cohen DW. *Periodontal Therapy*, 3rd ed. St. Louis: C. V. Mosby; 1964:569.
- 232. Bell LA, Valluzzo TA, Garnick JJ, Pennel BM. The presence of "creeping attachment" in human gingiva. *J Periodontol* 1978;49:513-517.

- 233. Dorfman HS, Kennedy JE, Bird WC. Longitudinal evaluation of free autogenous gingival grafts. A four year report. *J Periodontol* 1982;53:349-352.
- 234. Haeri A, Parsell D. Creeping attachment: Autogenous graft vs dermal matrix allograft. *Compend Contin Educ Dent* 2000;21:725-729, quiz 730.
- 235. Harris RJ. Creeping attachment associated with the connective tissue with partial-thickness double pedicle graft. *J Periodontol* 1997;68:890-899.
- 236. Matter J. Creeping attachment of free gingival grafts. A five-year follow-up study. *J Periodontol* 1980;51: 681-685.
- 237. Matter J, Cimasoni G. Creeping attachment after free gingival grafts. *J Periodontol* 1976;47:574-579.
- 238. Müller HP, Eger T, Schorb A. Alteration of gingival dimensions in a complicated case of gingival recession. Int J Periodontics Restorative Dent 1998; 18:345-353.
- 239. Otero-Cagide FJ, Otero-Cagide MF. Unique creeping attachment after autogenous gingival grafting: Case report. *J Can Dent Assoc* 2003;69:432-435.
- 240. Pollack RP. Bilateral creeping attachment using free mucosal grafts. A case report with 4-year follow-up. *J Periodontol* 1984;55:670-672.
- 241. Griffin TJ, Cheung WS, Zavras AI, Damoulis PD. Postoperative complications following gingival augmentation procedures. *J Periodontol* 2006;77:2070-2079.
- 242. Harris RJ, Miller R, Miller LH, Harris C. Complications with surgical procedures utilizing connective tissue grafts: A follow-up of 500 consecutively treated

cases. Int J Periodontics Restorative Dent 2005;25: 449-459.

- 243. Douglas de Oliveira DW, Marques DP, Aguiar-Cantuária IC, Flecha OD, Gonçalves PF. Effect of surgical defect coverage on cervical dentin hypersensitivity and quality of life. *J Periodontol* 2013; 84:768-775.
- 244. Nieri M, Pini Prato GP, Giani M, Magnani N, Pagliaro U, Rotundo R. Patient perceptions of buccal gingival recessions and requests for treatment. *J Clin Periodontol* 2013;40:707-712(erratum 2013;40:976).
- 245. Wessel JR, Tatakis DN. Patient outcomes following subepithelial connective tissue graft and free gingival graft procedures. *J Periodontol* 2008;79: 425-430.
- 246. Shanmugam M, Sivakumar V, Anitha V, Sivakumar B. Clinical evaluation of alloderm for root coverage and colour match. *J Indian Soc Periodontol* 2012; 16:218-223.
- 247. Kim DM, Neiva R. Periodontal soft tissue non-root coverage procedures: A systematic review from the AAP regeneration workshop. *J Periodontol* 2015;86 (Suppl):S56-S72.

Correspondence: Dr. Leandro Chambrone, Rua Antonio Pinto Guedes, 626, Mogi das Cruzes, São Paulo, 08820-430 Brazil. E-mail: leandro_chambrone@hotmail.com.

Submitted November 13, 2013; accepted for publication February 11, 2014.